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Gastric cancer is the fifth most common cancer and the second most common cause 
of cancer death worldwide. More than 50% of the patients have advanced disease 
at diagnosis and in this case the disease has a poor outcome. The staging of gastric 
cancers is based on endoscopic ultrasound, computed tomography, magnetic resonance 
imaging, positron emission tomography, in addition to the laparoscopic staging. 
Many improvements in the surgical techniques have been seen in the last decade. 
Laparoscopic surgery is an emerging approach which offers important advantages: 
less blood loss, reduced postoperative pain, accelerated recovery, early return to 
normal bowel function and reduced hospital stay. D1 lymphadenectomy, with a goal 
of examining 15 or greater lymph nodes is a standard. D2 dissection is considered as a 
standard in several institutions especially in eastern Asia. Perioperative chemotherapy 
and adjuvant concurrent radiochemotherapy are recognized as standards treatments. 
Palliative chemotherapy is the mainstay treatment of advanced stages of the disease 
(metastatic and non-operable tumors). Despite these treatment advances, the 
prognosis of gastric cancer remains poor with a 5-year survival ranging from 10 to 15% 





















Management of Gastric Cancer
http://dx.doi.org/10.5772/944
Edited by Nabil Ismaili
Contributors
Bulent c Yuksel, Okan Akturk, Marco Moschetta, Amato Antonio Stabile Ianora, Federico Cazzato, Arnaldo 
Scardapane, Giuseppe Angelelli, Kyo Young Song, Han Mo Yoo, Han Hong Lee, Jung Ho Shim, Hae Myung Jeon, Cho 
Hyun Park, Petar Svorcan, Jelena Djordjevic, Branko Maksimovic, Akihito Tsubota, Kenji Ina, Il Young Kim
© The Editor(s) and the Author(s) 2011
The moral rights of the and the author(s) have been asserted.
All rights to the book as a whole are reserved by INTECH. The book as a whole (compilation) cannot be reproduced, 
distributed or used for commercial or non-commercial purposes without INTECH’s written permission.  
Enquiries concerning the use of the book should be directed to INTECH rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons Attribution 3.0 
Unported License which permits commercial use, distribution and reproduction of the individual chapters, provided 
the original author(s) and source publication are appropriately acknowledged. If so indicated, certain images may not 
be included under the Creative Commons license. In such cases users will need to obtain permission from the license 
holder to reproduce the material. More details and guidelines concerning content reuse and adaptation can be 
foundat http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not necessarily those 
of the editors or publisher. No responsibility is accepted for the accuracy of information contained in the published 
chapters. The publisher assumes no responsibility for any damage or injury to persons or property arising out of the 
use of any materials, instructions, methods or ideas contained in the book.
First published in Croatia, 2011 by INTECH d.o.o.
eBook (PDF) Published by  IN TECH d.o.o.
Place and year of publication of eBook (PDF): Rijeka, 2019.
IntechOpen is the global imprint of IN TECH d.o.o.
Printed in Croatia
Legal deposit, Croatia: National and University Library in Zagreb
Additional hard and PDF copies can be obtained from orders@intechopen.com
Management of Gastric Cancer
Edited by Nabil Ismaili
p. cm.
ISBN 978-953-307-344-6
eBook (PDF) ISBN 978-953-51-6436-4
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,000+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




After five years of medical school at Mohammed V 
University, Faculty of Medicine and Pharmacy and two 
years of medical practice at the University Hospital in 
Rabat - Morocco, Dr. Nabil Ismaili joined the depart-
ment of medical oncology at the National Institute of 
Oncology in Rabat where he spent four years and the 
department of medical oncology at Léon-Bérard Cancer 
Center in France for a one year spell.
The main research areas in which he participated concerned different 
types and aspects of cancer diseases: breast cancers, urological cancers, 
and nasopharyngeal cancers. Dr. Ismaili published several scientific pa-
pers dealing with concurrent chemoradiotherapy in cancer of the breast, 
bladder cancer and nasopharyngeal cancer. He is an executive member in 
various associations in Cancer Research (MEACR: Middle East Association 
of Cancer Research; ASCAS: Association Scientifique des Cancérologues 
du Sud). In addition, he has several certificates in different fields of oncolo-
gy (short trainings in Morocco and abroad). Dr. Ismaili is presently with 












Part 1 Gastric Cancer Staging 1 
Chapter 1 The Role of Computed Tomography 
in the Imaging of Gastric Carcinoma 3 
Marco Moschetta, Amato Antonio Stabile Ianora,  
Federico Cazzato, Arnaldo Scardapane and Giuseppe Angelelli 
Chapter 2 MR Imaging of Gastric Carcinoma 19 
Il Young Kim 
Chapter 3 PET Imaging in Gastric Carcinoma 37 
Kiyohisa Kamimura and Masayuki Nakajo 
Chapter 4 Novel Biomedical Imaging Approach for 
Detection of Sentinel Nodes in an Orthotopic 
Xenograft Rat Model of Human Gastric Carcinoma 55 
Akihito Tsubota, Tomoki Koyama, 
Yoshihisa Namiki, Norio Tada and Hiroshi Takahashi 
Part 2 Surgery 71 
Chapter 5 Laparoscopic Surgery for Gastric Cancer 73 
Kyo Young Song and Jung Ho Shim 
Chapter 6 Lymph Node Dissection 87 
Bulent Cavit Yuksel, Okan Murat Akturk and Ilyas Hakan Ozel 
Part 3 Chemotherapy 117 
Chapter 7 Prospective Study of Triple Combination 
Chemotherapy Consisting of Paclitaxel, 
S-1, and 24-Hour Infusion of Cisplatin (PSC) 
for Inoperable Highly Advanced Gastric Cancer 119 
Kenji Ina, Ryuichi Furuta, Takae Kataoka, 
Satoshi Kayukawa and Hiroaki Iwase 
Contents 
Preface XI 
Part 1 Gastric Cancer Staging 1 
Chapter 1 The Role of Computed Tomography 
in the Imaging of Gastric Carcinoma 3 
Marco Moschetta, Amato Antonio Stabile Ianora,  
Federico Cazzato, Arnaldo Scardapane and Giuseppe Angelelli 
Chapter 2 MR Imaging of Gastric Carcinoma 19 
Il Young Kim 
Chapter 3 PET Imaging in Gastric Carcinoma 37 
Kiyohisa Kamimura and Masayuki Nakajo 
Chapter 4 Novel Biomedical Imaging Approach for 
Detection of Sentinel Nodes in an Orthotopic 
Xenograft Rat Model of Human Gastric Carcinoma 55 
Akihito Tsubota, Tomoki Koyama, 
Yoshihisa Namiki, Norio Tada and Hiroshi Takahashi 
Part 2 Surgery 71 
Chapter 5 Laparoscopic Surgery for Gastric Cancer 73 
Kyo Young Song and Jung Ho Shim 
Chapter 6 Lymph Node Dissection 87 
Bulent Cavit Yuksel, Okan Murat Akturk and Ilyas Hakan Ozel 
Part 3 Chemotherapy 117 
Chapter 7 Prospective Study of Triple Combination 
Chemotherapy Consisting of Paclitaxel, 
S-1, and 24-Hour Infusion of Cisplatin (PSC) 
for Inoperable Highly Advanced Gastric Cancer 119 
Kenji Ina, Ryuichi Furuta, Takae Kataoka, 
Satoshi Kayukawa and Hiroaki Iwase 
X      Contents
Part 4 A Rare Gastric Carcinoma 127 
Chapter 8 A Rare Gastric Carcinoma - Neuroendocrine Tumors 129 








and  in  this  case  the  disease  has  a  poor  outcome.  The  diagnosis  is  confirmed  by 
endoscopy and the histological examination of the biopsy specimen. Adenocarcinoma 
is  the most  common  histological  type.  The  staging  of  gastric  cancers  is  based  on 
endoscopic ultrasound, computed tomography, magnetic resonance imaging, positron 
emission tomography, in addition to the laparoscopic staging.  
In  localized disease,  the surgery  remains  the mainstay  treatment of  this malignancy. 
Many  improvements  in  the  surgical  techniques  have  been  seen  in  the  last  decade. 
Laparoscopic  surgery  is  an  emerging  approach which  offers  important  advantages: 
less  blood  loss,  reduced  postoperative  pain,  accelerated  recovery,  early  return  to 
normal bowel function and reduced hospital stay. However, laparoscopic surgery as a 
treatment  approach  to gastric  cancer  requires  further  investigations  as  the  extent of 
lymph node dissection  remains  controversial. D1  lymphadenectomy, with  a goal of 
examining 15 or greater  lymph nodes  is a standard. D2 dissection  is considered as a 
standard in several institutions especially in eastern Asia. Perioperative chemotherapy 
is  considered  as  a  therapeutic  standard  for  stage  2  disease.  Concurrent 
radiochemotherapy is also recognized as a standard after surgery for patients at high 
risk of relapse.  
Palliative chemotherapy  is  the mainstay  treatment of advanced stages of  the disease 
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The Role of Computed Tomography 
in the Imaging of Gastric Carcinoma 
Marco Moschetta, Amato Antonio Stabile Ianora, Federico Cazzato, 
Arnaldo Scardapane and Giuseppe Angelelli 




Gastric carcinoma represents the most common gastric neoplasm accounting for 95% of all 
gastric tumors (Angelelli et al, 2001; Fishman et al, 1996; JH Kim et al, 2006; Levine & 
Megibow, 1994). Besides, it is one of the most common cancer in the world and a major 
cause of morbidity and mortality. It cause 30% of the cancer deaths in high risk areas, such 
as China and Japan. The peak of incidence of gastric carcinoma is estimated from between 
50 and 70 years and its prevalence is variable in different countries. This pathological 
condition has a greater impact in certain geographical areas, such as Japan, Latin America 
and Eastern Europe. In fact, the prevalence of gastric carcinoma is very high in Japan, where 
the mortality rate is about 110 cases/100.000 inhabitants while a value of 50/100.000 has 
been estimated in Italy. Males are affected more commonly than females, with most patients 
presenting in the sixth decade. 
Gastric carcinoma represents an aggressive tumor with a 5 year survival rate less than 20% 
(Lee DH, 2000). Superficial carcinoma forms are called “early gastric cancer” and have a 
better prognosis, with a 5 year survival rate of more than 90%. In fact, the 5 year survival 
rates range from 3% in case of stage IV to 85-90% in case of stage I, depending on tumor 
stage (Ba-Ssalamah et al, 2003; JH Kim et al, 2006).  
Among etiological factors, some dietary habits have been identified, such as hot or salty 
food. Unlike the esophageal carcinoma, alcohol and smoking do not seem to influence the 
incidence of gastric carcinoma. Atrophic gastritis, gastric ulcers, intestinal metaplasia, reflux 
esophagitis, gastric polyps, Menetrier disease, partial gastrectomy, pernicious anemia, 
achlorhydria and hypochlorhydria represent risk conditions and may predispose to the 
development of adenocarcinoma of the stomach. 
In 30% of cases gastric carcinoma is located on antrum, in 30% on gastric body and in other 
30% on fundus or cardia; the remaining 10% is represented by diffuse infiltrating gastric 
lesions which affect all gastric walls at the time of diagnosis (Ba-Ssalamah et al, 2003).  
Macroscopically, superficial forms, also called early gastric cancer, and advanced forms can 
be identified. Early gastric cancer is limited to the mucosal or submucosal layers and is 
characterized by variable incidence values from between 30% in Japan and 2 - 6% in other 
countries. Early gastric cancer can be difficult to recognize and can appear as a small, 
circumscribed, sometimes ulcerated thickening of the gastric wall (Angelelli et al, 2001). 
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The advanced gastric carcinoma reaches the muscolaris propria and four different kinds can 
be identified: polypoid, ulcerating, ulcerating-infiltrating and infiltrating forms, also called 
linitis plastica. Generally, in case of advanced gastric carcinoma, wall thickening exceeds 1 
centimeter, with a variable extension, or a vegetating mass with irregular surfaces and a 
wide retracted base due to the invasion of the adjacent gastric wall can be identified.  
The Jarvi and Lauren classification usually identifies intestinal or diffuse histological forms, 
the latest representing about the 80-90% of all gastric forms.  The remaining 10-20% are 
represented by a third gastric form which collect all the other histological kinds. The 
intestinal form is usually moderately differentiated and originates from intestinal 
metaplasia areas; diffuse form represents an undifferentiated form which originated from 
gastric epithelium (Jarvi & Lauren, 1951).  
In most of the cases gastric carcinoma has a preferential diffusion towards the cardia or it 
follows a contiguity, lymphatic or haematic mechanism. Usually, the intestinal form is less 
infiltrating, rarely can have a peritoneal involvement and can give hepatic metastatic 
nodules. On the contrary, diffuse gastric carcinoma rapidly involves adjacent structures and 
peritoneum.  
However, metastatic diffusion usually depends on the extension and the depth of 
infiltration of the primary tumor. The most common metastatic sites are represented by 
lymph nodes (80% of cases), liver (40%), peritoneum (30%), lung (20%), pancreas (17%), 
retroperitoneum (12%), adrenal glands (10%), ovaries (5%) and diaphragm (5%). 
Symptoms from gastric carcinoma are often non specific and also completely absent for a 
long time and tumor can be already advanced at the time of the diagnosis. Epigastric pain 
syndrome, dyspepsia, anemia, weight loss and weakness represent the most common 
symptoms.  
Prognosis and therapy of gastric carcinoma depend on the stage of the disease at the time of 
the diagnosis and the first challenge for clinicians is to define the extent of the tumor in 
order to plan the best treatment (Kim JH et al, 2007; Moschetta et al, 2010).  
Besides, an early diagnosis and accurate staging are crucial for the choice of an accurate 
therapeutic approach and can also influence the survival rate (Habermann et al, 2004). 
Surgery remains the main therapeutic option and the choice of the most suitable treatment is 
determined by preoperative staging, which is based on diagnostic imaging.  
Radiation therapy or chemotherapy are reserved in selected cases.  
2. Diagnostic imaging  
Gastric carcinoma diagnosis usually bases on conventional barium radiological studies and 
endoscopy which often remain the first-line examination in the diagnostic approach to 
patients suspected of having gastric carcinoma. Both these techniques can identify initial 
mucosal lesions and endoscopy also allows to perform biopsies which are crucial for 
differentiating benign from malignant lesions, especially in case of ulcerative forms.  
Transparietal ultrasound is often used in order to search for liver metastases and lymph 
node metastases (Stabile Ianora et al, 2001). Usually, the use of this tool complements 
computed tomography examination and could be useful in case of thin patients with low 
representation of fat planes.   
Endoscopic ultrasound allows the identification of gastric wall stratification and the 
visualization of the different layers composing the gastric wall both in normal and 
pathological conditions. Diagnostic accuracy values from between 85% and 91% are 
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reported in literature for the evaluation of T parameter and from between 74% and 78% for 
N staging (Botet et al, 1991; Dittler & Siewert, 1993; Tunaci et al, 2002). 
However, it represents an invasive and operator-dependent technique which does not allow 
the study of gastric walls below stenosing tumors or the visualization of distant 
lymphadenopathies or metastases (Ahn et al, 2009; Kwee et al, 2007; Moschetta et al, 2010). 
The role of magnetic resonance imaging in the staging of gastric carcinoma is still unclear, 
but the use of this technique is increasing in this field, especially in case of pregnant women 
or in case of patients for whom uro-angiographic contrast agents are contraindicated. The 
reported accuracy values for magnetic resonance imaging range from 73% to 88% for T 
staging and from 55% to 65% for N staging (Arocena et al, 2006; Kim AY et al, 2000a, 2000b; 
Motohara et al, 2002; Sohn et al, 2000; Wang C-K et al, 2000). However, magnetic resonance 
imaging has some limitations, represented by longer examination time, motion artifacts and 
high cost.   
3. Computed tomography  
Computed tomography actually remains the most common and widespread tool for the 
staging of the disease and its reported accuracy values vary depending on the study 
technique and the device used (Moschetta et al, 2010; Stabile Ianora et al, 2001).  In fact, 
computed tomography represents a valuable tool in addiction to gastroscopy and 
endoscopic ultrasound in the preoperative staging of gastric cancer.  
It is the modality of choice for planning curative or palliative surgery and provides useful 
information for comparison during chemotherapy in patients with inoperable carcinomas 
(Yang et al, 2007).  
The depth evaluation of gastric carcinoma mural invasion is improved with the clinical 
application of multidetector devices and multiplanar reconstructions. Therefore, 
multidetector computed tomography currently remains the most commonly used 
examination in the preoperative gastric cancer staging, with faster examination times and 
higher spatial resolution. In fact, it allows to acquire isotropic voxels and to reduce motion 
artifacts as compared to single-detector devices and the resulting benefits are represented by 
a better image quality in axial, coronal and sagittal planes and also better quality 
reconstructions, with an overall greater diagnostic accuracy.    
Besides, the depth of tumor invasion has been shown to be a very important prognostic 
factor for these patients and the role of computed tomography is becoming stronger as 
technology improves, especially with bi-dimensional imaging (multi-planar 
reconstructions), tridimensional reconstructions (Volume Rendering) and virtual endoscopy 
(Blackshaw et al, 2005; Horton & Fishman, 2003; Moschetta et al, 2010).  
The role of computed tomography in the study of gastric carcinoma is mainly represented 
by preoperative local and distant staging; post-therapeutic control and follow-up; incidental 
detection of gastric carcinoma during CT examination performed for other pathological 
conditions. 
4. CT protocol 
CT protocol is very important because it can affect the quality of CT examination.  
First of all, before computed tomography examination, patients should be prepared by at 
least five hour fasting in order to empty the stomach.  
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Then, an adequate gastric distension is mandatory for the study of gastric walls; in fact, if 
stomach is not adequately distended, small gastric carcinomas can be misdiagnosed or 
collapsed gastric walls can simulate pathological conditions.  
The gastric study on computed tomography examination needs therefore an adequate 
distension that can be obtained by using endoluminal contrast agents in order to distinguish 
gastric lumen and walls from adjacent structures and to allow an accurate evaluation of 
gastric wall thickness.   
Gastrointestinal contrast agents can be subdivided in high density or positive and low 
density or negative agents, basing on the density values as compared with gastric walls. 
High density agents are mostly represented by diatrizoate and methyl-glucamine water 
solutions or barium solutions, the latest rarely used in this field.  
Low density contrast agents are represented by water, air or CO2. 
High density contrast agents are usually used in order to evaluate extra-gastric conditions, 
and in these cases gastric lumen and bowel loops are accurately delineated.  
On the contrary, when a detailed study of gastric walls is required, it is better to avoid high 
density contrast agents because gastric walls present an increment of density after 
intravenous injection of contrast material in the site of lesion and small parietal lesions can 
be misdiagnosed because of the high density of gastric content. Occasionally, positive oral 
contrast agents may not mix uniformly with gastric contents and pseudotumors can be 
created. 
Besides, also vascular or tridimensional studies can be difficult in case of high density 
agent’s use.  In fact, positive contrast agents can interfere with data manipulation during tri-
dimensional imaging of the abdomen and necessitate extensive editing (Kim AY et al, 2005). 
Therefore, in case of CT gastric carcinoma staging, the use of low density contrast material is 
preferred (Angelelli et al, 1987; Angelelli & Macarini, 1988; Moschetta et al, 2010; Rossi et al, 
1997; Shimizu et al, 2005).  
Among low density contrast materials, water represents a simple agent, with no cost or 
complication rate, well tolerated by patients and able to accurately distend the gastric cavity.  
Generally, a variable quantity from between 400 ml and 750 ml is ingested by patients ten 
minutes before CT examination, with a supplementary dose of 250 ml immediately before 
the scan.  
Air also represents an accurate contrast agent for gastric evaluation on computed 
tomography, especially when virtual gastric endoscopy is planned in patients suspected of 
having gastric carcinoma. It can be administered as effervescent powders of bicarbonate or 
citric acid, which allow an optimal gastric distension.  
Computed tomography examination also requires intravenous injection of iodinated 
contrast material which is mandatory to differentiate pathological tissue from normal 
mucosa and to obtain useful information for tumor characterization.  
Usually, a quantity of 100-150 ml (mean value of 1.5 ml/kg body weight)  is injected at 3-4 
ml/sec.  
The optimization of contrast material injection is essential in the era of multi-detector 
computed tomography, with higher time resolution. Although portal venous phase 
performed at 60-70 seconds from the intravenous injection is generally sufficient for a 
correct study of gastric walls, an additional arterial phase performed at 30-35 seconds from 
intravenous injection is useful for the staging of gastric primary lesions and for a better 
evaluation of the enhancement difference between gastric lesions and the adjacent normal 
tissue. Usually, the arterial phase is performed for upper abdomen while portal venous 
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phase includes thorax, abdomen and pelvis scanning, in order to perform distant staging of 
the disease.  
Actually, bolus tracking and automated triggering technologies are generally used in order 
to obtain a correct biphasic technique basing on patient’s characteristics.   
Finally, in order to induce gastric wall hypotonia and decrease peristaltic bowel movement, 
20 mg of scopolamine-N-butyl bromide can be intramuscularly or intravenously injected 
before CT examination. 
CT scans are usually acquired in supine position; in rare cases, oblique patient position is 
recommended in order to evaluate some gastric portions, such as antrum or fundus 
(Moschetta et al, 2010; Shirakawa et al, 1996).  
5. Image analysis  
Computed tomography axial images and reconstructions are usually examined for 
diagnosis. Bi-dimensional multi-planar reconstructions on coronal and sagittal planes and 
tridimensional volume rendering reconstructions can be used in order to accurately 
diagnose and stage primary lesions (D’Elia et al, 2000) (Fig. 1).  
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In case of air distension, virtual gastroscopy can be performed with  endoluminal navigation 
and a direct visualization of gastric mucosal features (Fig. 2). Virtual endoscopy represents a 
tri-dimensional endoluminal-perspective image, which simulates the endoluminal views at 
gastroscopy. The detection of gastric cancer may be improved by multi-detector computed 
tomography with virtual gastroscopy (Bhandari et al, 2004; Kim HJ et al, 2005).  
Besides, when ulcerative forms occur, virtual gastroscopy can also provide useful 
information for differentiating benign from malignant ulcers. In fact, benign ulcers usually 
present smooth and regular shapes, clearly demarcated and regular edges, with gastric fold 
tapering and converging toward the ulcer; on the contrary, in case of malignant ulcers, 
irregular shaped and asymmetric edges, disrupted appearance of peri-ulcer folds near the 
crater edge and fused folds can be identified.  
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On the other side, the use of a multiphasic technique after intravenous injection of contrast 
material allows to obtain an accurate imaging of gastric carcinoma and computed 
tomography can provide a complete dynamic visualization of the gastric walls in the site of 
carcinoma, enabling the calculation of whole-organ perfusion maps. In fact, computed 
tomography perfusion carries the potential to improve detection of gastric carcinoma due to 
the perfusion differences.   
Recently, a new computed tomography reconstruction protocol called Vessel Probe in multi-
planar mode has been shown to increase the diagnostic accuracy in T staging of gastric 
carcinoma in association with the water-filling technique for gastric distension (Moschetta et 
al, 2010).  
The arterial phase is generally used to evaluate the T staging in these cases, in order to take 
advantage of the maximum enhancement of the gastric wall, which is essential to use vessel 
probe software.  
Vessel Probe is a programme that allows vessels to be simultaneously examined in tri-
dimensional, curved reformat and cross-sectional reformat views. It can study and measure 
arteries from between 0.5 and 18 mm in diameter and calculate the degree of stenosis. It can 
display images in a variety of formats, including automatic and simultaneous orthogonal 
cross-sections, orthogonal multi-planar, oblique and curved reconstructions, tri-dimensional 
and curved reformat views.  
This fast and simple to use software can also be useful for examining the gastric wall on 
contrast-enhanced multi-detector computed tomography, clicking on the gastric wall in the 
lesion site. Starting from simple transverse images, Vessel Probe in multi-planar mode 
 
 
Fig. 2. Gastric carcinoma. A. CT transverse scan. B. CT multi-planar reconstruction on 
sagittal plane. C. Tri-dimensional virtual gastroscopy. The tumor appears as an irregular 
wall thickening protruding within gastric lumen and affecting the proximal tract of the 
stomach (arrows). Stomach has been distended by air.  
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automatically generates a reference line along the major axis of structures with the 
maximum enhancement values and displays the best views in multiple curved planes.  
It also explores the whole thickness of the gastric wall and adjacent structures, which can be 
useful for T staging. 
6. CT findings  
Gastric carcinoma usually appears as an irregular wall thickening with high density after 
intravenous injection of contrast material, as compared with the contiguous normal gastric 
walls (Fig. 3). In the arterial phase, the neoplasm features a markedly greater density than 
the adjacent gastric walls, while in the venous phase this enhancement usually fades 
(Angelelli et al, 2001). More voluminous lesions can appear inhomogeneous because of the 
presence of necrotic areas. 
 
 
Fig. 3. Gastric carcinoma located on the antro-pyloric tract. A. CT transverse scan. B. CT 
reconstruction on sagittal plane. The tumor causes a focal area of irregular wall thickening 
with ulcerative features (arrows). Stomach has been distended by water. 
Sometimes, during computed tomography examination of the abdomen performed for 
variable clinical or pathological conditions, gastric wall neoplastic thickenings can be 
incidentally detected. 
Gastric carcinoma is generally subdivided in “early gastric cancer” and “advanced gastric 
cancer”. 
Early gastric cancer could have different forms:  
Type I: lesion protruding more than 5 mm within gastric lumen; 
Type IIa: lesion protruding less than 5 mm; 
Type IIb: flat lesion; 
Type IIc: concave lesion (not reaching muscularis mucosae); 
Type III: ulcerative lesion (it reaches the muscolaris mucosae but not the muscolaris 
propria). 
Multi-detector computed tomography examination allows to identify type I initial lesions 
while type II and III lesions can be more difficult to detect (Ba-Ssalamah et al, 2003). 
Sometimes, the histological characteristics can also influence the enhancement pattern of the 
primary lesion; in fact, it has been demonstrated that when a high mucin content is present, 
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the tumor can have low enhancement values also in the arterial phase and it can be very 
difficult to identify, especially when a thickening of gastric walls is not associated (Chen et 
al, 2007; Moschetta et al, 2010; Tunaci et al, 2002).  
On the contrary, when adequate gastric distension is obtained, advanced cancer is usually 
easy to recognize at computed tomography examination and in 94% of cases it causes a 
circumscribed or diffuse wall thickening with associate ulcers or protruding lesions.  
In case of linitis plastica, wall thickening is diffuse and circumferential with absence of the 
normal gastric folding. Besides, wall thickening can be variable and in some cases it can reach 
a diameter of some centimeters (Angelelli et al, 1990; Fukuya, 1997;  Stabile Ianora et al, 2001).  
In 6% of cases, tumor appears like a polypoid mass with a large implant base, or a vegetating 
lesion within gastric lumen and contiguous gastric walls can generally be thickened. 
Neoplastic tissue usually presents low density values on computed tomography 
examination without contrast material injection as compared with normal gastric walls.  
After intravenous injection of contrast medium, an increment of density values can be 
detected in most of the cases and rarely the tumor can appear isodense. The most 
voluminous tumors are inhomogeneous because of the presence of intralesional low density 
and colliquative areas. Rarely, some intralesional calcifications can also be detected.  
Generally, a high density wall thickening should indicate gastric carcinoma; however, 
diagnosis should be always controlled by endoscopy and biopsy.  
On the contrary, an isodense wall thickening is generally unspecific, and differential 
diagnosis with lymphomas, peptic ulcers, chronic gastritis, intestinal metaplasia, Zollinger-
Ellison syndrome, amiloidosis, eosinophilic gastritis and Menetrier syndrome could be 
difficult in these cases.    
In case of gastric carcinoma diagnosis, depth of intramural infiltration, extension towards 
contiguous structures and local and distant metastasis need to be evaluated. 
Based on its appearance in the arterial phase, the gastric wall is defined as single-layered 
when only one high density layer can be visualised, or multi-layered when an inner high 
density and an outer low density layer can be identified.  
T staging performed by computed tomography is crucial for the therapeutic approach to 
these patients and its precise diagnostic accuracy remains controversial (Kadowaki et al, 
2000; Kumano S et al, 2005; Minami  et al, 1997). 
According to the TNM classification and computed tomography staging criteria, T1 tumors 
invade  lamina propria or submucosal layer and can appear as circumscribed wall 
thickening with intense focal enhancement or intense enhancement only, without wall 
thickening or circumscribed wall thickening with intense enhancement of inner layer and a 
low density streak corresponding to the non infiltrated muscolaris propria coat on 
computed tomography examination.  
T2 tumors invade the muscolaris propria or subserosa and appear as thickening of entire 
gastric wall with homogeneous or inhomogeneous enhancement, regular surface of the 
outer layer of gastric wall at the lesion site and normal appearance of perigastric fat.  
T3 gastric carcinomas invade serosa without infiltration of adjacent structures and generally 
are represented by thickening of entire gastric wall with homogeneous or inhomogeneous 
enhancement, irregular surface of the outer layer of gastric wall at the lesion site and 
presence of micronodules or dense stranding in the perigastric fat on computed tomography  
examination.  
Finally, T4 gastric tumors are characterized by the invasion of adjacent structures and the 
obliteration of the fat cleavage plane between the neoplastic lesion and adjacent organs. 
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Diagnostic accuracy values from between 41% and 98% have been reported in literature for 
the computed tomography evaluation of T parameter (Moschetta, 2010; Stabile Ianora, 2003); 
the controversy with regard to the effective role of this tool for the T staging of gastric 
cancer, especially in the evaluation of early gastric cancer, probably bases on the different 
used technique. In fact, the increasing values reported in recent studies are probably due to 
the high quality of multi-planar images produced by using a thin-slice collimation, isotropic 
voxels and better z-axis resolution.  
As already reported before, some interesting new data emerge with regard to the 
differentiation between various T stages by using the Vessel Probe reconstructions 
(Moschetta et al, 2010).  
This programme allows good detail of the gastric wall architecture to be obtained after the 
intravenous injection of contrast material and it can improve the diagnostic accuracy in the 
evaluation of the tumor invasion depth by analysing the wall enhancement in the lesion site. 
Generally, images obtained during the arterial phase are useful for the application of the 
Vessel Probe in the T staging because of the tumor hypervascularity and neovascularity (Lee 
JH et al, 2007; Moschetta et al, 2010). In fact, by using the tumor enhancement, the Vessel 
Probe algorithm permits a more accurate view of the gastric wall stratification as compared 
with the other computed tomography reconstructions. The high quality of these new 
reconstructions can also help to solve the problem of the differentiation between T2 and T3 
gastric carcinoma. In fact,  the reticular and dense stranding in the perilesional fat and the 
irregular appearance of the outer surface of the gastric walls can usually identify T3 
carcinomas, but can also be seen in inflammatory reactions without cancer infiltration (Chen 
et al, 2006; Takao et al, 1998).  
Vessel Probe reformatting images reduce partial volume artifacts and improve the 
evaluation of the gastric wall surface in orthogonal views.  
Besides, the high spatial resolution may be helpful when the fat cleavage plane between the 
tumor and the adjacent organs is oblique or parallel to the imaging direction.  
Finally, this kind of automatic post-processing can be obtained in a few minutes per patient 
and is therefore faster than tri-dimensional imaging of the gastric cancer, especially with 
regard to virtual gastroscopy; compared with simple multi-planar reconstructions, Vessel 
Probe algorithm allows the best view of gastric wall stratification to be automatically 
displayed in the lesion site, by simultaneously reconstructing images in multiplanar, 
perpendicular curved and oblique planar reformats (Fig. 4). 
Gastric tumor located on the proximal part of the stomach can involve peritoneum, left liver 
lobe, diaphragm, spleen and aorta; tumors located on the distal tract can also involve the 
pancreas.  
The main criteria for the diagnosis of tumor diffusion towards contiguous structures are 
based on the evaluation of perigastric fat tissue which can be preserved or infiltrated by 
high density stranding. However, in patients with poor nutritional conditions with a low 
representation of fat tissue, it could be difficult to evaluate the anatomical relationships of a 
tumor located on the posterior gastric surface with adjacent structures, such as pancreas. 
Besides, as reported before, the irregular extern gastric surface or the presence of dense 
tissue within the perigastric fat tissue could sometimes be determined by desmoplastic or 
inflammatory reactions. In these cases, overstaging can occur.  
Some experiences also reported that a neoplastic involvement of adjacent organs was 
present, although a clear perigastric adipose clivage was identifiable, thus determining 
understaging mistakes. 
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Fig. 4. Gastric ulcerative carcinoma. Same patient as in Fig. 3. A. CT reconstruction on 
oblique coronal plane. The tumor appears as an ulcerating wall thickening (arrow). B. Vessel 
Probe reconstructions allow to obtain a better identification of the gastric wall in the lesion 
site (empty arrows).   
Sometimes, gastric carcinoma can also involve the mesocolon or gastro-splenic, gastro-
hepatic and hepato-duodenal ligaments through the sierosa.  
The identification of peritoneal involvement could be very difficult on computed 
tomography and often it can be possible only in advanced forms. Ascites and peritoneal 
nodules, mostly located on the mesocolon, represent the most common signs in these cases.  
Lymph nodal involvement is generally recognized in 74 - 88% of patients with gastric 
carcinoma because of a wide perigastric net of lymphatic drain and its incidence can be 
related to tumor size and depth of infiltration. N staging need to involve all 16 nodal 
perigastric stations and it is recommended to distinguish between the involvement of 
perigastric nodal sites, with a distance of less then 3 cm from the organ, and extragastric 
nodal sites, for example following the left gastric artery, the common hepatic artery, the 
splenic artery or the celiac trunk, or distant nodal metastases, for example at the hepato-
duodenal ligament, retropancreatic, mesenteric or para-aortic sites (Fig. 5). In fact, all gastric 
carcinomas with involvement of perigastric lymph nodes located at less than 3 cm away 
from the primary lesion are classified as N1; those with involvement of extragastric lymph 
nodes located at more than 3 cm away from the primary lesion as N2; finally, N3 forms 
involve lymph nodes of retroperitoneum or the hepatic-duodenal ligament. 
Because of the panoramic view and anatomical detail, computed tomography represents a 
fundamental examination for recognizing locoregional, perigastric and distant 
adenopathies. 
However, computed tomography evaluation of N parameter is still actually challenging and 
still has several limitations in this field, with a reported accuracy value of 70%. In fact, 
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computed tomography is not able to identify neoplastic lymph nodes with normal size (false 
negatives) or it can not differentiate larger reactive lymph nodes (false positives).  
In order to reduce the number of false positives, number and enhancement values of lymph 
nodes could be also considered. The presence of numerous lymphadenopathies suggest a 
metastatic disease in 96% of cases while a single larger lymph node in 48% of cases. 
Metastatic lymph nodes are often characterized by different enhancement values as 
compared with normal nodes.  
Other difficulties in this field can be represented by the site of lymph nodes, the morphology 
of the tumor and the patient characteristics. In fact, in case of voluminous tumors with a 
prevalent extragastric development it can be difficult to detect lymph nodes strictly 
adherent to the gastric walls.  
Moreover, some nodal sites are more difficult to explore, such as paracardial or hepato-
duodenal sites.   
Finally, patient’s characteristics are also important because, in case of cachectic subjects with 
poor adipose representation, it can be more difficult to recognize lymphadenopaties.  
Therefore, computed tomography is relatively insensitive and also non specific for detecting 
nodal metastases because of its inability to recognize microscopic nodal invasion, which is 
common in gastric carcinoma, and the presence of reactive lymph nodes that may have 
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Fig. 6. A. CT Transverse Scan. B. CT Coronal Reconstruction. The tumoral tissue is well 
evident (arrow). Several suspected peri-gastric lymph nodes are associated (empty arrows).   
7. Post-therapy control 
In the past, traditional radiological studies were used in surgically treated patients with the 
possibility of providing morphological and functional information on the anastomosis and 
identifying mucosal lesions. These techniques are actually reserved to selected cases and 
widely replaced in clinical practice by endoscopy which allows a direct visualization of 
gastric mucosa with the possibility of performing biopsies in suspected areas. 
Computed tomography imaging also represents an accurate technique in this field, because 
it allows to evaluate the anatomical relationships after surgical treatment and also the 
presence of complications, such as  anastomosis dehiscence, hemorrhage or abscesses.  
Neoplastic relapse such as extramural tumor or gastric stump carcinoma and distant 
metastases can be easily detected at follow-up performed by computed tomography 
examinations. 
Gastric stump carcinoma is defined as primary tumor arising from the gastric stump, 
usually 15-20 years later partial gastrectomy.   
Generally, the affected patients underwent gastro-jejunumstomy (Billroth II) rather than 
gastro-duodenostomy (Billroth I). These tumors are usually located on the distal tract of 
gastric stump, close to the anastomosis (Ba-Ssalamah et al, 2003).  
A pathogenetic theory related to a biliary reflux above the anastomosis with consequent 
chronic gastritis and metaplasia has been proposed in these cases. Gastric stump carcinoma 
and neoplastic recurrences are detected on computed tomography as wall thickenings or 
small masses close to the anastomosis.  
However, not all peri-anastomotic thickenings are caused by neoplastic recurrence, because 
they can be determined by surgical folds, bowel adhesions or polypoid hypertrophic 
gastritis. 
An adequate technique and the use of multi-planar and tri-dimensional reconstructions with 
the possibility of virtual navigation within the lumen allow to increase diagnostic accuracy 
values, but in suspected cases it is mandatory an endoscopic and histological control 
(Quarticelli et al, 2004).   
The contribution of computed tomography is also reliable in case of patients subjected to 
chemo-radiotherapy in order to evaluate the response to the therapy, although when 
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residual masses are detected, it can be difficult to differentiate the neoplastic or fibrotic 
nature of these lesions.  
8. Conclusions 
Computed tomography represents an accurate tool in case of gastric carcinoma. It is 
important to associate the axial image examination with the analysis of multi-planar, Vessel 
Probe and tri-dimensional reconstructions. 
Multi-planar images are widely used; they increase diagnostic accuracy for the evaluation of 
the tumor extension, the anatomical relationships with contiguous organs and facilitate the 
identification of lymph nodal and distant metastases.  
Vessel Probe reconstructions can facilitate T staging of gastric carcinoma, especially in the 
arterial phase of computed tomography examination. 
Tri-dimensional reconstructions provide a volumetric evaluation of the gastric walls, with 
consequent diagnostic advantages in modifying the transparency levels and detecting 
vascular structures or gastric walls.  
Virtual gastroscopy is also accurate in detecting gastric lesions, with the possibility of 
information which well correlate with traditional endoscopy findings. 
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1. Introduction 
Magnetic Resonance (MR) imaging has not become popular for staging of gastric carcinoma 
because of a number of limitations, including motion artifacts, lack of a stable contrast 
medium, and the high cost. However, continuous technical improvements have been made 
in MR imaging of the abdomen, thereby reducing motion artifacts and improving image 
quality. These improvements include breath-hold fast imaging techniques, placement of 
abdominal binders, administration of antiperistaltic agents, and the use of phased array 
coils. In vitro studies using 1 - 4.7- T MR systems have shown that MRI allows the depiction 
of gastric wall layers and therefore, technically permits the evaluation of the local tumor 
stage of gastric carcinomas. However, MR study in gastric carcinoma is challenging and it 
has much possibility. Usually, the preoperative staging workup of gastric carcinoma is 
performed mainly with computed tomography (CT). CT has been a favored method for 
preoperative evaluation and staging in patients with gastric carcinoma (Goldberg & Thoeni. 
1989; Werthmuller & Margulis. 1991; Halvorsen & Thompson. 1991). Parallel advances in CT 
equipment and scanning techniques have reduced scanning time and decreased motion 
artifacts. Simultaneously, rapid IV contrast administration with an automatic power injector 
has improved contrast enhancement of the gastric wall and gastric carcinoma. Helical CT 
has advantages over conventional CT, including faster scanning time and fewer respiratory 
misregistration artifacts in a single breath-hold (Hahn, et al., as cited in Stark & Bradley. 
1992). However, CT is limited, particularly in the diagnosis of lymph node metastasis, 
peritoneal metastasis, and small hematogenous metastasis. Endoscopic sonography has 
been reported to be the most accurate technique for the T staging of gastric carcinoma 
because it can define five layers of the gastric wall (Botet, et al. 1991). But this technique 
cannot evaluate other factors such as liver metastasis and peritoneal seeding. In addition, 
endoscopic sonography is an invasive technique dependent on the operator. 
2. MR Imaging  
2.1 MR Imaging techniques 
Residual stool or foodstuff can obviate the evaluation of gastrointestinal wall structures. 
Therefore, MRI should be performed following a 6 hr fasting period to ensure a consistent 
assessment of the stomach. A reliable distension of stomach must be achieved to allow for a 
reliable evaluation of the gastric wall. Otherwise, insufficient distension may result in false-
positive or false-negative findings. Adequate distension of the stomach can be easily 
accomplished by oral administration of water or water based contrast agents. Image data 
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should be collected without any time delay after contrast administration. Fast breath-hold 
MR sequences and antiperistaltic drugs are suggested for gastric carcinoma patient. A large 
volume (1 L) of tap water is ingested to the patient for the distention and opacification of the 
stomach (Seong, et al. 1998). This large volume of water was tolerated by the patients while 
providing sufficient distention of the stomach, which made it easier to differentiate gastric 
carcinoma from normal gastric wall. Water is absolutely safe and does not cause 
susceptibility artifacts. Sohn et al. (2000) used water or effervescent granules as oral contrast 
agents. Water is biphasic and the simplest contrast agent. Effervescent granules (a negative 
contrast agent) make the lumen of the stomach dark. If the stomach is overly distended with 
air, a magnetic susceptibility artifact may occur. However, the use of effervescent granules 
still provides improved evaluation of the gastric wall and can be used to supplement or 
replace water for gastric distention (Halvorsen, et al. 1996). Furthermore, oral Gd-DTPA 
does not provide additional diagnostic information over using tap water in MRI for gastric 
carcinoma (Kim A., et al. 2000a, 2000b). Therefore, the water-filling method may be 
appropriate for MRI of advanced gastric carcinoma (AGC).  
There are various techniques for performing MR scanning. Sohn et al. (2000) used that 
imaging technique with a superconductive magnet operating at 1.5 T with a phased array 
coil. Patients fasted for 6 hr and ingested 500ml of water or effervescent granules as an oral 
contrast agent. Twenty milligrams of scopolamine (Buscopan; Boehringer International, 
Ingelheim, Germany) were administered intramuscularly 5 min before the examination for 
decrease of bowel peristalsis. Patients can be placed on the MR gantry in the supine or prone 
position to allow the lesion to contact the ingested water or air. When water was used as the 
oral contrast agent, the patients in whom the lesion was at the gastric cardia or fundus were 
imaged in the supine position, and the other patients were imaged in the prone position. 
The positions were reversed when effervescent granules were used as or patients were 
examined with a breath-hold T1-weighted 2D FLASH technique in the axial, coronal, and 
sagittal planes. The scanning parameters for T1-weighted axial images were TR/TE, 
146.1/4.1 msec; flip angle, 80°; and one excitation. The bandwidth was 260 Hz; field of view, 
33 cm; matrix size, 128× 256; and the slice thickness was 8 mm with a 1.6-mm gap. The scan 
time was 18 sec. The parameters for the T1-weighted coronal and sagittal images were the 
same as those for T1-weighted axial images, except for the TR (100 for coronal and sagittal 
images) and field of view (45 cm for coronal images). The scan times of coronal and sagittal 
images were 14 and 12 sec, respectively. T2-weighted axial turbo spin-echo images were 
obtained with a TR/TE of 3200/138, an echo spacing of 9.2 msec, an echo train length of 29, 
a flip angle of 18°, one excitation, a bandwidth of 260 Hz, a field of view of 33 cm, a matrix 
size of 116 × 256, an 8-mm slice thickness with a gap of 1.6 mm, and a scan time of 17 sec. 
Sixty seconds after an IV bolus injection of 15–20 mg of gadopentetate dimeglumine 
(Magnevist; Schering, Berlin, Germany) at a rate of approximately 1 ml/sec through an 
antecubital vein, axial T1-weighted FLASH images with fat suppression were obtained 
(157.6/4.1; flip angle, 80°; one excitation; bandwidth, 260 Hz; field of view, 33 cm; matrix 
size, 128× 256; slice thickness, 8 mm; gap, 1.6 mm) with a scan time of 19 sec. All sequences 
were performed in a single breath-hold. Nineteen slices were obtained for unenhanced and 
contrast-enhanced T1-weighted axial images, and 11 slices were obtained for coronal and 
sagittal T1- and T2-weighted images. For fast MR imaging, Sohn et al. (2000) performed 
breathhold T1-weighted 2D FLASH, T2-weighted turbo spin-echo, and contrast-enhanced 
T1- weighted FLASH sequences with fat suppression. In most cases, Sohn et al. (2000) 
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staged the tumor with two or three planes (axial, coronal, and sagittal) of unenhanced T1-
weighted images only. Sohn et al. (2000) used the fat suppression technique in contrast- 
enhanced MR imaging to make the contrast between enhanced gastric tumor and perigastric 
fat more conspicuous. However, contrast-enhanced T1-weighted images showed more 
artifacts and lower visual contrast than unenhanced T1-weighted images. The T2- weighted 
images showed little difference in signal intensity between tumor and normal gastric wall 
and did not show an advantage for tissue characterization. Coronal and sagittal images 
were useful for evaluation of extraluminal outgrowth and omental infiltration by tumor. MR 
images, even with breath-hold fast MR imaging, were not completely free from motion 
artifacts, and sometimes a ghost artifact from aortic pulsation hid a lesion at the gastric 
angle. 
On the other study, Kim A et al. (2000) used a 1.0 T scanner with a body phased array coil. 
Axial, coronal, and sagittal images of fast low angle shot (FLASH; TR/TE 160/6.6 ms, flip 
angle 75°, one excitation, matrix size 256 × 112), half-Fourier single shot turbo SE (HASTE; 
infinite TR, echo space 10.9 ms, TE 87 ms, flip angle 150°, matrix size 256 × 240), and true 
fast imaging with steady-state precession (true-FISP; TR/TE 7.6/3.5 ms, one excitation, flip 
angle 80°, matrix size 256 × 192) sequences were obtained in each patient immediately after 
ingestion of 1 L of tap water. Field of view varied from 40 to 42 cm. In all MR pulse 
sequences, 8 mm thickness scans were obtained during a single breath-hold. In each patient, 
spiral CT or MRI was performed after overnight fasting to empty the stomach. Time interval 
between the two examinations was either 1 or 2 days. Twenty milligrams of scopolamine 
(Buscopan; Boehringer International, Ingelheim, Germany) was given intramuscularly to 
reduce peristaltic bowel movement before MR examinations. Except for one patient in 
whom the lesion was located in the gastric fundus and who had images taken in the supine 
position, all other patients were imaged in the prone position. 
2.2 MR imaging protocol of resected stomach  
There is MR imaging study with gastric specimen by Kim I et al. (2009). In this study, there 
is gastric specimen distention with filling of saline solution. 1.5-T MRI is used for this study 
with the following multisection spin echo sequences for T1-weighted images, repetition time 
(TR) m sec/echo time (TE) m sec = 500/20, and for T2-weighted images, 2500/90. Two 
numbers of excitation were applied in this scanning. The matrix size was 256X 256. Slice 
thickness was 5 mm and the intersection gap was 1 mm. Field of view was 20 cm. MR scans 
of the gastrectomy specimen were taken along the axial and sagittal planes. A head coil was 
used for scanning.  
2.3.1 Image analysis of gastric carcinoma 
A lesion is considered a cancerous lesion when the thickness of the gastric wall is >6mm and 
abrupt transition is noted between the thickened and adjacent normal gastric wall 
(Matsushita, et al. 1994). A lymph node of >8 mm on its short axis is considered to be 
pathologic (Dorfman, et al. 1991). The depth of tumor invasion on MRI is determined as 
follows: mT1 (no abnormal findings), mT2 (a clear and smooth outer surface of the lesion on 
FLASH/HASTE or intact low signal intensity band surrounding the lesion on true-FISP), 
mT3 (an irregular outer surface with obliteration of perigastric fat plane on FLASH/HASTE 
or interrupted low signal intensity band around the lesion on true-FISP), and mT4 
(contiguous extension of gastric lesion to adjacent organs on any pulse sequences). 
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2.3.2 Image analysis of resected stomach 
The number of visible wall layers and their specific signal intensity (SI) characteristics are 
studied by Kim I et al. (2009). Wall-layer correlation was made on the basis of the layer 
thickness of the visible layers in MRI compared with the ones visible in histology. The 
presence of a tumor, defined as destruction of the normal gastric wall layers, is noted. The 
tumors are examined for variations in SI. The depth of infiltration is evaluated according to 
earlier publications (Dux M., et al. 1997; Cho J-S., et al. 1994). A normal gastric wall is 
identified as having 3 layers. In terms of scanning direction and degree of distention of the 
wall, a gastric wall that is more than 1 cm thick or that showed an abrupt change of pattern 
from normal to pathologic is considered abnormal. The location, gross appearance, size and 
degree of serosal invasion of tumors are evaluated. Location is classified according to four 
areas: antrum, body, body and antrum, and fundus. Gross appearance is classified into four 
categories by Bormann’s classification for advanced gastric carcinoma (Douglass, Nava. 
1985). T and N staging were based on the TNM system developed by the American Joint 
Committee on Cancer (AJCC. 2002). Early gastric cancer is evaluated according to the 
Japanese Research Society for Gastric Cancer (Kajitani. 1981). The degree of tumor invasion 
in the gastric wall according to the T stage is measured as follows: T1 meant that MR 
showed obliteration of SI within the thickened mucosal layer and second submucosal layer, 
T2 meant that thickening of the gastric wall and obliteration of the third layer of muscularis 
propria, and T3 meant irregular SI in the outer margin of the third layer. 
The total number of lymph nodes which were located in the perigastric area is counted. A 
lymph node of >8mm at the short axis is considered to be pathologic (Dorfman, et al. 1991). 
N staging of lymph nodes was performed. N0 is defined as no regional lymph node 
metastasis, N1 as metastasis in one to six regional lymph nodes, N2 as metastasis in seven to 
15 regional lymph nodes, N3 as metastasis in more than 15 regional lymph nodes. 
3. MR imaging finding of gastric carcinoma 
3.1 T staging of gastric carcinoma 
CT is widely used as a primary imaging modality for preoperative staging of gastric cancer. 
Although CT provides detailed information regarding the extent of tumor spread and 
provides guidelines to surgeons to avoid unnecessary exploratory laparotomy for patients 
with unresectable tumors, the role of CT in staging gastric cancer has been controversial. 
The diagnostic accuracy of CT scans in determining the degree of extraserosal invasion and 
identifying metastatic lymph nodes is still not satisfactory (Sussman, et al. 1988; Fukuya, et 
al. 1995; Adachi, et al. 1997; Seong, et al. 1988). Recent MR studies regarding the T staging of 
AGC suggest new possibilities to overcome these limitations of CT (Matsushita, et al. 1994; 
Oi, et al. 1997; Dux, et al. 1997; Costanzi, et al. 1996). A Japanese group reported high 
diagnostic accuracy (88% in T staging) from MRI in evaluating extraserosal invasion of AGC 
using a low signal intensity band on a gradient echo image, which was created by a 
chemical shift misregistration artifact and a phase cancellation artifact (Matsushita, et al. 
1994). In an experimental study, Dux et al. (1997) described that MR staging of gastric cancer 
was technically possible (accuracy of T staging 65% and of N staging 80%), although they 
could not reproduce the results of the Japanese group. On the contrary, Costanzi et al. (1996) 
reported low accuracy of N staging (43%), induced by motion and respiratory artifacts and a 
long acquisition time. Such discrepancies in diagnostic accuracy of MR staging for gastric 
cancer are probably due to the variable imaging techniques and criteria of image 
interpretation. 
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Post contrast study of stomach show highly enhancement on gastric carcinoma and 
relatively well delineation of lesion and surrounding fat plain also well demonstrated 
(Figure 1). In case of serosal involvement of gastric carcinoma, there is fat obliteration of fat 
plain surrounding tumor (Figure 2). 
 
 
Fig. 1. T2 Gastric Carcinoma. 56-year-old man. Post contrast T1WI image show enhancement 
of the mass in stomach antrum and relatively preservation of surrounding fat plane 
(arrows). 
Advanced gastric cancer presented as a thickened wall showing varied contrast 
enhancement from strong to minimal on MR imaging. According to Sohn et al. (2000) study, 
one of eight cases of early gastric cancer is detected on MR imaging. The tumor detection 
rate is 73.3% (22/30) on MR imaging. The overall accuracy of MR imaging for the T factor 
was 73.3% (22/30). On MR imaging, the incidence of under staging was 20% (6/30), whereas 
 
 
Fig. 2. T3 Gastric Carcinoma. 62-year-old woman. Post contrast T1WI show enhanced mass 
in stomach antrum and obliteration of pancreatic fat plane, but this case confirmed T3 
gastric carcinoma without invasion of pancreas (arrows). 
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could not reproduce the results of the Japanese group. On the contrary, Costanzi et al. (1996) 
reported low accuracy of N staging (43%), induced by motion and respiratory artifacts and a 
long acquisition time. Such discrepancies in diagnostic accuracy of MR staging for gastric 
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Post contrast study of stomach show highly enhancement on gastric carcinoma and 
relatively well delineation of lesion and surrounding fat plain also well demonstrated 
(Figure 1). In case of serosal involvement of gastric carcinoma, there is fat obliteration of fat 
plain surrounding tumor (Figure 2). 
 
 
Fig. 1. T2 Gastric Carcinoma. 56-year-old man. Post contrast T1WI image show enhancement 
of the mass in stomach antrum and relatively preservation of surrounding fat plane 
(arrows). 
Advanced gastric cancer presented as a thickened wall showing varied contrast 
enhancement from strong to minimal on MR imaging. According to Sohn et al. (2000) study, 
one of eight cases of early gastric cancer is detected on MR imaging. The tumor detection 
rate is 73.3% (22/30) on MR imaging. The overall accuracy of MR imaging for the T factor 
was 73.3% (22/30). On MR imaging, the incidence of under staging was 20% (6/30), whereas 
 
 
Fig. 2. T3 Gastric Carcinoma. 62-year-old woman. Post contrast T1WI show enhanced mass 
in stomach antrum and obliteration of pancreatic fat plane, but this case confirmed T3 
gastric carcinoma without invasion of pancreas (arrows). 
 
Management of Gastric Cancer 
 
24
that of over staging was 6.7% (2/30). MR imaging is correct in 60% (18/30) of cases. The MR 
imaging findings are concordant with the pathologic findings for 87.5% (7/8) of pT1 tumors, 
66.7% (2/3) of pT2 tumors, 78.6% (11/14) of pT3 tumors, and 40% (2/5) of pT4 tumors. One 
pT2 tumor is under staged as MRT1, two pT3 tumors are under staged as MRT2, and three 
of the pT4 tumors are under staged as MRT3. One pT1 tumor is over staged as MRT2, and 
one pT3 tumor is over staged as MRT4 (Figure 3). MR can delineate pancreatic invasion 
(Figure 4). 
MR imaging showed the 80% detection rate of omental tumor infiltration. Peritoneal 
carcinomatosis is poorly delineated on MR imaging. Kim A et al. (2000) reported the study 
that comparative studies between MR and CT of gastric cancer. In this study, a markedly 
thickened wall considered as a cancerous lesion on MR images and in total T staging, MRI 
showed superior results to CT (81 vs. 73%). 
 
 
(a)                                                                 (b) 
Fig. 3. T3 Gastric Carcinoma. 54-year-old man. A, B. Axial unenhanced (A) and contrast-
enhanced (B) T1-weighted MR images show concentric tumor with strong contrast 
enhancement in gastric body. Extraluminal nodule of gastric tumor and infiltration in 
adjacent fat (arrows, A) are well seen on A. Note few enlarged lymph nodes in left 
perigastric region (arrowheads, A) (Sohn, et al. 2000). 
According to Kim A et al. (2000) study, MRI was superior to CT in T staging (overall 
accuracy 81%; p <0.005). Several cases were overestimated with CT also in the present study, 
and they were mostly the pT2 cases. Six cases of pT2 were interpreted as T3 or T4 on CT 
scan due to the streaky densities in perigastric fat surrounding the gastric mass or due to the 
direct continuity between the gastric mass and the adjacent organs. This finding may have 
been induced by the partial volume-averaging effect of the angled gastric portion or by the 
associated perigastric inflammatory change (Sussman, et al. 1988; Minami, et al. 1992). 
Among these six patients, two were correctly diagnosed by MRI. This fact suggests that MRI 
can be potentially useful in providing multiplanar images and various pulse sequences 
compared with CT. Surgical resection clearly is the only potentially curative therapy for 
gastric cancer. Therefore, under any circumstances, there is no doubt that surgical resection 
is the best treatment of choice for patients with AGC whenever possible. In practice, 
accurate T staging can be less meaningful to surgeons when it is below T3 as the method of 
surgical resection does not change depending on the T stage (Siewert, et al. 1993). The 
differentiation between T3 and T4 is of more value to surgeons and patients prior to 
 
 




Fig. 4. T4 Gastric Carcinoma. 54-year-old woman. Coronal T1-weighted MR image shows 
matted appearance of gastric tumor, duodenal loop, and omentum of hepatic flexure of 
colon (MRT4) (arrows). These structures adhered to each other and were infiltrated by 
tumor, as noted at surgery (pT4). Star indicates pyloric antrum of stomach (Sohn, et al. 
2000). 
surgery. In Kim, A. et al (2000) study, unfortunately, cases with pathologic T4 were 
excluded because most patients who were diagnosed as T4 on preoperative imaging studies 
did not undergo surgery. Although Kim A et al. (2000) could not demonstrate the 
comparative data between the two imaging modalities in T4 staging, MRI seems to be 
superior to CT in T4 staging according to previously published data (diagnostic accuracy 75-
80 vs. 58-75%) (Oi, et al. 1997; Dux, et al. 1997; Adachi, et al. 1997; Fukuya, et al. 1997; Cho, et 
al. 1994). 
3.2.1 Signal intensity characteristics of normal gastric wall 
Interest in the use of MRI for the staging of gastric carcinoma is increasing, but most clinical 
studies stage the local tumor situation without the differentiation of gastric wall layers 
(Sohn, et al. 2000; Goldberg & Thoeni. 1989; Halvorsen & Thomson. 1991; Campeau et al. 
1995). Studies that use depiction of gastric wall layers as a basis for local tumor staging and 
lymph node metastasis are rare (Palmowski, et al. 2006; Dux, et al. 1997). The high quality of 
soft-tissue imaging of MR systems enables the depiction of anatomic wall layers. Auh et al. 
(1994) studied the gastric wall using an experimental 4.7-T system whereas Lubienski et al. 
(2002) used an experimental 2.4-T system. Both groups proved that the depiction of gastric-
wall layers is technically possible. Auh et al. (1994) depicted 3 layers whereas Lubienski et 
al. (2002) was able to differentiate 4 layers and correlated them to the mucosa, lamina 
muscularis mucosa, submucosa and muscularis propria. Typically 3 gastric wall layers are 
visible. The inner layer corresponds to the mucosa and lamina muscularis mucosa and the 
middle layer to the submucosa. The outer layer showed the same SI as the muscularis 
propria in the study of Lubinski’s et al. (2002) and therefore mainly consisted of muscle 
tissue and serosal layers. Palmowski et al. (2006) demonstrated that a reliable depiction of 
gastric-wall layers can be achieved by a conventional 1-T MRI. As no subserosa and serosa 
could be depicted, it must be presumed that they were located on the outer side of the third 
layer. So the third layer represented the muscularis propria, subserosa, and serosa together 
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that of over staging was 6.7% (2/30). MR imaging is correct in 60% (18/30) of cases. The MR 
imaging findings are concordant with the pathologic findings for 87.5% (7/8) of pT1 tumors, 
66.7% (2/3) of pT2 tumors, 78.6% (11/14) of pT3 tumors, and 40% (2/5) of pT4 tumors. One 
pT2 tumor is under staged as MRT1, two pT3 tumors are under staged as MRT2, and three 
of the pT4 tumors are under staged as MRT3. One pT1 tumor is over staged as MRT2, and 
one pT3 tumor is over staged as MRT4 (Figure 3). MR can delineate pancreatic invasion 
(Figure 4). 
MR imaging showed the 80% detection rate of omental tumor infiltration. Peritoneal 
carcinomatosis is poorly delineated on MR imaging. Kim A et al. (2000) reported the study 
that comparative studies between MR and CT of gastric cancer. In this study, a markedly 
thickened wall considered as a cancerous lesion on MR images and in total T staging, MRI 
showed superior results to CT (81 vs. 73%). 
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enhanced (B) T1-weighted MR images show concentric tumor with strong contrast 
enhancement in gastric body. Extraluminal nodule of gastric tumor and infiltration in 
adjacent fat (arrows, A) are well seen on A. Note few enlarged lymph nodes in left 
perigastric region (arrowheads, A) (Sohn, et al. 2000). 
According to Kim A et al. (2000) study, MRI was superior to CT in T staging (overall 
accuracy 81%; p <0.005). Several cases were overestimated with CT also in the present study, 
and they were mostly the pT2 cases. Six cases of pT2 were interpreted as T3 or T4 on CT 
scan due to the streaky densities in perigastric fat surrounding the gastric mass or due to the 
direct continuity between the gastric mass and the adjacent organs. This finding may have 
been induced by the partial volume-averaging effect of the angled gastric portion or by the 
associated perigastric inflammatory change (Sussman, et al. 1988; Minami, et al. 1992). 
Among these six patients, two were correctly diagnosed by MRI. This fact suggests that MRI 
can be potentially useful in providing multiplanar images and various pulse sequences 
compared with CT. Surgical resection clearly is the only potentially curative therapy for 
gastric cancer. Therefore, under any circumstances, there is no doubt that surgical resection 
is the best treatment of choice for patients with AGC whenever possible. In practice, 
accurate T staging can be less meaningful to surgeons when it is below T3 as the method of 
surgical resection does not change depending on the T stage (Siewert, et al. 1993). The 
differentiation between T3 and T4 is of more value to surgeons and patients prior to 
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matted appearance of gastric tumor, duodenal loop, and omentum of hepatic flexure of 
colon (MRT4) (arrows). These structures adhered to each other and were infiltrated by 
tumor, as noted at surgery (pT4). Star indicates pyloric antrum of stomach (Sohn, et al. 
2000). 
surgery. In Kim, A. et al (2000) study, unfortunately, cases with pathologic T4 were 
excluded because most patients who were diagnosed as T4 on preoperative imaging studies 
did not undergo surgery. Although Kim A et al. (2000) could not demonstrate the 
comparative data between the two imaging modalities in T4 staging, MRI seems to be 
superior to CT in T4 staging according to previously published data (diagnostic accuracy 75-
80 vs. 58-75%) (Oi, et al. 1997; Dux, et al. 1997; Adachi, et al. 1997; Fukuya, et al. 1997; Cho, et 
al. 1994). 
3.2.1 Signal intensity characteristics of normal gastric wall 
Interest in the use of MRI for the staging of gastric carcinoma is increasing, but most clinical 
studies stage the local tumor situation without the differentiation of gastric wall layers 
(Sohn, et al. 2000; Goldberg & Thoeni. 1989; Halvorsen & Thomson. 1991; Campeau et al. 
1995). Studies that use depiction of gastric wall layers as a basis for local tumor staging and 
lymph node metastasis are rare (Palmowski, et al. 2006; Dux, et al. 1997). The high quality of 
soft-tissue imaging of MR systems enables the depiction of anatomic wall layers. Auh et al. 
(1994) studied the gastric wall using an experimental 4.7-T system whereas Lubienski et al. 
(2002) used an experimental 2.4-T system. Both groups proved that the depiction of gastric-
wall layers is technically possible. Auh et al. (1994) depicted 3 layers whereas Lubienski et 
al. (2002) was able to differentiate 4 layers and correlated them to the mucosa, lamina 
muscularis mucosa, submucosa and muscularis propria. Typically 3 gastric wall layers are 
visible. The inner layer corresponds to the mucosa and lamina muscularis mucosa and the 
middle layer to the submucosa. The outer layer showed the same SI as the muscularis 
propria in the study of Lubinski’s et al. (2002) and therefore mainly consisted of muscle 
tissue and serosal layers. Palmowski et al. (2006) demonstrated that a reliable depiction of 
gastric-wall layers can be achieved by a conventional 1-T MRI. As no subserosa and serosa 
could be depicted, it must be presumed that they were located on the outer side of the third 
layer. So the third layer represented the muscularis propria, subserosa, and serosa together 
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(Palmowski, et al. 2006). Dux et al. (1997) proved that under experimental conditions, up to 
five layers of the gastric wall can be differentiated on MR imaging as they can in endoscopic 
sonography.  
On MRI, two to three layers with different SI in the normal gastric wall can be depicted (Kim, 
I., et al. 2009). However, there was a mainly three-layered structure (multilayered pattern) of 
the gastric wall by MRI. The inner layer showed an increase of SI and was 1-3 mm thick on the 
T1-weighted images. The second had a lower SI with thickness that varied at different sites in 
the same individual. The outer layer showed a slightly higher SI. On T2-weighted images, the 
inner and outer layers regularly had a low SI, and the middle layer a high SI. On the basis of 
the comparison, these three layers were considered to correspond histologically to the 
mucosal, submucosal, and muscularis propria and serosal layers, respectively (Figure 5).  
 
 
(a)                                                                    (b) 
Fig. 5. MRI and Histology of Normal Gastric Wall. A: T1-weighted (500/20) sagittal image of 
resected gastric wall showed three layers. The inner layer corresponds to the mucosa (m) 
and the middle layer to the submucosa(s). The outer layer basically consists of the 
muscularis propria (p) from which the serosa cannot be differentiated; B: T2-weighted 
(2500/90) MR image showed low SI on mucosa and muscularis propria and relatively high 
SI on submucosa; C: Light microscopic section of normal gastric wall obtained from the 
greater curvature site of stomach body showed three layers which are compatible with inner 
mucosal layer, middle submucosa layer and outer muscularis propria and serosal layer (H-E 
stain; original magnification, × 1) (Kim, I., et al. 2009).  
Kim I et al. (2009) reported that the inner and outer layers as hyperintense and the middle 
layer as hypointense at 1.5-MRI. When the three layers were depicted in the gastric wall, the 
mucosa and the muscularis propria were clearly different from the intervening submucosal 
layer on T1-weighted images. The distinction among the layers is based mainly on the lower 
SI of the submucosa compared with that of the mucosa or muscularis propria. The 
difference between the three layers was also depicted in the T2-weighted images.  
3.2.2 Detection of primary tumor  
MR imaging of gastric carcinoma on resected specimens studied by Kim I et al. (2009) 
showed as follows: two cases of Bormann’s type 1 carcinoma (polypoid type), seven cases of 
Bormann’s type 2 (ulcerative type), six cases of Bormann’s type 3 (ulcerative type with 
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infiltration), and four cases of Bormann’s type 4 (infiltrating type). One case of early gastric 
carcinoma with type IIc was observed, whose lesion was seen as a depression of the mucosa 
with thinning of the gastric wall on axial and sagittal scanning (Figure 6). Gross pathologic 
findings showed tumor lesions as follows; two cases of Bormann’s type 1, four of Bormann’s 
type 2, nine of Bormann’s type 3, four of Bormann’s type 4. One case of early gastric 
carcinoma with type IIc was proved upon histologic examination. The accuracy of MR 
imaging in the Bormann’s type classification was 89% (16 of 19). Differentiation between 
Bormann’s type 2 and type 3 lesions was erroneous in three lesions. 
The location of gastric carcinoma was also identified on the MR images. There were nine 
cases of gastric carcinoma involvement in the gastric antrum, three cases in the stomach 
body, seven cases in the antrum and the body, one case involving the entire stomach. Upon 
gross specimen examination, there was no difference between them and the MRIs.  
 
 
                         (a)                            (b)                                           (c) 
Fig. 6. MRI and Histology of Early Gastric Carcinoma. A: T1-weighted (500/20) axial image 
showed depression of gastric wall and obliteration of submucosal low SI (arrows); B: T1-
weighted sagittal MR image showed depressed mucosa with tumor invasion to submucosa 
layer (arrows); C: Light microscopic section showed depressed mucosa with tumor invasion 
to submucosa (H-E stain; original magnification, × 1) (Kim, I., et al. 2009)). 
3.2.3 Depth of tumor invasion 
According to Kim I et al. (2009) study, MRIs of gastric carcinoma in resected specimens 
showed various findings, including thickening of the gastric wall with irregularity in the 
mucosal SI obliteration, thickening of the gastric wall with first and second layer SI 
obliteration, diffuse thickening of the gastric wall with third layer SI obliteration and 
irregularity with ulceration as well. 
T1-weighted images showed intermediate SI in regions affected by gastric carcinoma 
compared to the surrounding normal mucosa and muscularis propria SI. T2-weighted 
images showed low SI in the gastric carcinoma. Most tumors had a homogenous SI. 
However, in some cases necrosis and calcification caused an inhomogeneous SI. It is not 
possible to differentiate between the muscularis propria, subserosa, and serosa. The reason 
for this inability was that Kim I et al. (2009) considered the subserosa and serosa as being 
located on the outer border of the joint layer representing the muscularis propria, subserosa, 
and serosa. If an infiltration was visible, the tumor was classified as T2 as long as it did not 
reach the outer border. Penetration of the external margin meant at once infiltration of the 
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(Palmowski, et al. 2006). Dux et al. (1997) proved that under experimental conditions, up to 
five layers of the gastric wall can be differentiated on MR imaging as they can in endoscopic 
sonography.  
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the comparison, these three layers were considered to correspond histologically to the 
mucosal, submucosal, and muscularis propria and serosal layers, respectively (Figure 5).  
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stain; original magnification, × 1) (Kim, I., et al. 2009).  
Kim I et al. (2009) reported that the inner and outer layers as hyperintense and the middle 
layer as hypointense at 1.5-MRI. When the three layers were depicted in the gastric wall, the 
mucosa and the muscularis propria were clearly different from the intervening submucosal 
layer on T1-weighted images. The distinction among the layers is based mainly on the lower 
SI of the submucosa compared with that of the mucosa or muscularis propria. The 
difference between the three layers was also depicted in the T2-weighted images.  
3.2.2 Detection of primary tumor  
MR imaging of gastric carcinoma on resected specimens studied by Kim I et al. (2009) 
showed as follows: two cases of Bormann’s type 1 carcinoma (polypoid type), seven cases of 
Bormann’s type 2 (ulcerative type), six cases of Bormann’s type 3 (ulcerative type with 
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infiltration), and four cases of Bormann’s type 4 (infiltrating type). One case of early gastric 
carcinoma with type IIc was observed, whose lesion was seen as a depression of the mucosa 
with thinning of the gastric wall on axial and sagittal scanning (Figure 6). Gross pathologic 
findings showed tumor lesions as follows; two cases of Bormann’s type 1, four of Bormann’s 
type 2, nine of Bormann’s type 3, four of Bormann’s type 4. One case of early gastric 
carcinoma with type IIc was proved upon histologic examination. The accuracy of MR 
imaging in the Bormann’s type classification was 89% (16 of 19). Differentiation between 
Bormann’s type 2 and type 3 lesions was erroneous in three lesions. 
The location of gastric carcinoma was also identified on the MR images. There were nine 
cases of gastric carcinoma involvement in the gastric antrum, three cases in the stomach 
body, seven cases in the antrum and the body, one case involving the entire stomach. Upon 
gross specimen examination, there was no difference between them and the MRIs.  
 
 
                         (a)                            (b)                                           (c) 
Fig. 6. MRI and Histology of Early Gastric Carcinoma. A: T1-weighted (500/20) axial image 
showed depression of gastric wall and obliteration of submucosal low SI (arrows); B: T1-
weighted sagittal MR image showed depressed mucosa with tumor invasion to submucosa 
layer (arrows); C: Light microscopic section showed depressed mucosa with tumor invasion 
to submucosa (H-E stain; original magnification, × 1) (Kim, I., et al. 2009)). 
3.2.3 Depth of tumor invasion 
According to Kim I et al. (2009) study, MRIs of gastric carcinoma in resected specimens 
showed various findings, including thickening of the gastric wall with irregularity in the 
mucosal SI obliteration, thickening of the gastric wall with first and second layer SI 
obliteration, diffuse thickening of the gastric wall with third layer SI obliteration and 
irregularity with ulceration as well. 
T1-weighted images showed intermediate SI in regions affected by gastric carcinoma 
compared to the surrounding normal mucosa and muscularis propria SI. T2-weighted 
images showed low SI in the gastric carcinoma. Most tumors had a homogenous SI. 
However, in some cases necrosis and calcification caused an inhomogeneous SI. It is not 
possible to differentiate between the muscularis propria, subserosa, and serosa. The reason 
for this inability was that Kim I et al. (2009) considered the subserosa and serosa as being 
located on the outer border of the joint layer representing the muscularis propria, subserosa, 
and serosa. If an infiltration was visible, the tumor was classified as T2 as long as it did not 
reach the outer border. Penetration of the external margin meant at once infiltration of the 
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serosa, and the tumor was staged as a T3 carcinoma, according to the AJCC (2002). The MR 
imaging findings of gastric wall invasion included 1 case of T1, 7 of T2 (Figure 7), and 11 of 
T3 (Figure 8). Pathologic results of resected specimens included 3 cases of pT1, 4 of pT2, and 
12 of pT3. Differentiation between T1 and T2 classifications was not difficult in cases 
displaying a distinction between three layers. However, two cases of pT1 were over staged 
as T2. One case of pT2 was over staged as T3. Two cases of pT3 were under staged as T2. 
Differentiation between T2 and T3 lesions was difficult due to the outer muscularis propria 
and serosal layer’s thinness and could not always be demonstrated by MRIs. The level of 




                          (a)                              (b)                                           (c) 
Fig. 7. MRI and Histology of T2 Gastric Carcinoma. A: T1-weighted (500/20) sagittal image 
showed diffuse thickening of gastric wall with obliteration of mucosa, submucosa and 
muscularis propria SI in antrum and lower body, while preserved outer marginal SI; B: T2-
weighted (2000/90) sagittal MR images showed ill defined lesion with minimal increased 
and same SI compared to surrounding normal gastric wall; C: Light microscopic section 
demonstrate proper muscle invasion of gastric cancer (H-E stain; original magnification, × 1) 
(Kim, I., et al. 2009). 
Palmowski et al. (2006) reported that carcinomas show an intermediate SI on T1-weighted 
images, a low SI on T2-weighted images and a high SI on opposed phase images. Opposed 
phase images were not obtained in Kim I et al. (2009) study, but Dux et al. (1997) 
demonstrated that opposed phase images show a very high SI in gastric tumors and insisted 
that this was useful for the staging of gastric carcinoma. In Kim I et al. (2009) study, the 
infiltration of gastric carcinoma was correctly defined in 74% of the cases. This was not 
different from that of CT images that had an accuracy rate of 50%-85% and that of MR 
images that had an accuracy rate of 73% (Sohn, et al. 2000; Botet,et al. 1991; Kim, A., et al. 
2000). Yamada et al. (2001) reported that gastric specimens that were imaged after fixation in 
formalin and then MR imaged could also depict early gastric carcinoma. 
Kim I et al. (2009) demonstrate that the inner and outer layers as hyperintense and the 
middle layer as hypointense at 1.5-MRI. When the three layers were depicted in the gastric 
wall, the mucosa and the muscularis propria were clearly different from the intervening 
submucosal layer on T1-weighted images. The distinction among the layers is based mainly 
on the lower SI of the submucosa compared with that of the mucosa or muscularis propria. 
The difference between the three layers was also depicted in the T2-weighted images. In this 
 
 




Fig. 8. MRI and Histology of T3 Gastric Carcinoma. A: T1-weighted (500/20) sagittal image 
showed thickening of gastric wall with all three layer SI change in lesser and greater 
curvature site of stomach body (arrows); B: T2-weighted (2000/90) sagittal MRI showed 
minimal increase of SI on lesion site and poor delineation of gastric wall SI at out layer 
margin compared to normal gastric wall (arrows); C: Light microscopic section showed 
extension of tumor invasion to serosal layer (HE stain; original magnification, × 1) (Kim, I., 
et al. 2009) . 
study, gastric carcinomas appeared as masses with destruction of the normal structure of 
the gastric wall or diffuse thickening of the gastric wall and showed intermediate SI 
compared to surrounding normal gastric walls on T1-weighted images and low SI on T2- 
weighted images. Both sequences were useful for tumor localization and complement each 
other because some carcinomas in the study could only be recognized by deviating signal 
behavior in one of the 2 sequences. In Kim I, et al. (2009) study, signal characteristics of the 
carcinoma depending on the MR sequence were not analyzed. In this study, one case of 
early gastric carcinoma was depicted on MRI with a shallow depressed wall. This was made 
possible by adequate distention of the resected stomach with saline.  
CT is the most frequently used imaging technique for the staging of gastric cancer. Cho et al. 
(1994) and Fukuya et al. (1997) studied using dynamic or helical CT and reported that the 
normal gastric wall frequently showed a two- or three-layer pattern that was interrupted by 
a tumor; thus, more accurate staging of the T factor could be expected. In addition, the use 
of thin collimation (≤5 mm) could improve the depiction of small lesions and make it 
possible to obtain multiplanar reformatted images. However, it still is difficult for helical CT 
to differentiate between a pT2 tumor and a pT1 tumor with massive submucosal invasion 
because the hypoattenuating stripe corresponding to the intact submucosal layer could be 
obliterated in the latter (Fukuya, et al. 1997). Sohn et al. (2000) also experienced a case of a 
pT2 tumor with minimal invasion of the muscularis propria layer, which showed focal wall 
thickening with preservation of the hypoattenuating stripe. In this study, advanced gastric 
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serosa, and the tumor was staged as a T3 carcinoma, according to the AJCC (2002). The MR 
imaging findings of gastric wall invasion included 1 case of T1, 7 of T2 (Figure 7), and 11 of 
T3 (Figure 8). Pathologic results of resected specimens included 3 cases of pT1, 4 of pT2, and 
12 of pT3. Differentiation between T1 and T2 classifications was not difficult in cases 
displaying a distinction between three layers. However, two cases of pT1 were over staged 
as T2. One case of pT2 was over staged as T3. Two cases of pT3 were under staged as T2. 
Differentiation between T2 and T3 lesions was difficult due to the outer muscularis propria 
and serosal layer’s thinness and could not always be demonstrated by MRIs. The level of 




                          (a)                              (b)                                           (c) 
Fig. 7. MRI and Histology of T2 Gastric Carcinoma. A: T1-weighted (500/20) sagittal image 
showed diffuse thickening of gastric wall with obliteration of mucosa, submucosa and 
muscularis propria SI in antrum and lower body, while preserved outer marginal SI; B: T2-
weighted (2000/90) sagittal MR images showed ill defined lesion with minimal increased 
and same SI compared to surrounding normal gastric wall; C: Light microscopic section 
demonstrate proper muscle invasion of gastric cancer (H-E stain; original magnification, × 1) 
(Kim, I., et al. 2009). 
Palmowski et al. (2006) reported that carcinomas show an intermediate SI on T1-weighted 
images, a low SI on T2-weighted images and a high SI on opposed phase images. Opposed 
phase images were not obtained in Kim I et al. (2009) study, but Dux et al. (1997) 
demonstrated that opposed phase images show a very high SI in gastric tumors and insisted 
that this was useful for the staging of gastric carcinoma. In Kim I et al. (2009) study, the 
infiltration of gastric carcinoma was correctly defined in 74% of the cases. This was not 
different from that of CT images that had an accuracy rate of 50%-85% and that of MR 
images that had an accuracy rate of 73% (Sohn, et al. 2000; Botet,et al. 1991; Kim, A., et al. 
2000). Yamada et al. (2001) reported that gastric specimens that were imaged after fixation in 
formalin and then MR imaged could also depict early gastric carcinoma. 
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Fig. 8. MRI and Histology of T3 Gastric Carcinoma. A: T1-weighted (500/20) sagittal image 
showed thickening of gastric wall with all three layer SI change in lesser and greater 
curvature site of stomach body (arrows); B: T2-weighted (2000/90) sagittal MRI showed 
minimal increase of SI on lesion site and poor delineation of gastric wall SI at out layer 
margin compared to normal gastric wall (arrows); C: Light microscopic section showed 
extension of tumor invasion to serosal layer (HE stain; original magnification, × 1) (Kim, I., 
et al. 2009) . 
study, gastric carcinomas appeared as masses with destruction of the normal structure of 
the gastric wall or diffuse thickening of the gastric wall and showed intermediate SI 
compared to surrounding normal gastric walls on T1-weighted images and low SI on T2- 
weighted images. Both sequences were useful for tumor localization and complement each 
other because some carcinomas in the study could only be recognized by deviating signal 
behavior in one of the 2 sequences. In Kim I, et al. (2009) study, signal characteristics of the 
carcinoma depending on the MR sequence were not analyzed. In this study, one case of 
early gastric carcinoma was depicted on MRI with a shallow depressed wall. This was made 
possible by adequate distention of the resected stomach with saline.  
CT is the most frequently used imaging technique for the staging of gastric cancer. Cho et al. 
(1994) and Fukuya et al. (1997) studied using dynamic or helical CT and reported that the 
normal gastric wall frequently showed a two- or three-layer pattern that was interrupted by 
a tumor; thus, more accurate staging of the T factor could be expected. In addition, the use 
of thin collimation (≤5 mm) could improve the depiction of small lesions and make it 
possible to obtain multiplanar reformatted images. However, it still is difficult for helical CT 
to differentiate between a pT2 tumor and a pT1 tumor with massive submucosal invasion 
because the hypoattenuating stripe corresponding to the intact submucosal layer could be 
obliterated in the latter (Fukuya, et al. 1997). Sohn et al. (2000) also experienced a case of a 
pT2 tumor with minimal invasion of the muscularis propria layer, which showed focal wall 
thickening with preservation of the hypoattenuating stripe. In this study, advanced gastric 
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cancer was easily detectable on both MR imaging and helical CT; however, the incidence of 
detectability of early gastric cancer was low on both techniques. MR imaging was slightly 
more accurate than helical CT in the T staging of gastric cancer, but this difference was not 
statistically significant (p > 0.05). MR imaging and helical CT showed understaging more 
frequently than overstaging because of the frequent understaging of pT4 tumors. The low 
concordance rates of pT4 tumors on MR imaging and helical CT were partly caused by the 
fact that patients with evident CTT4 or MRT4 tumors did not undergo surgery and therefore 
were not included in this study. Also, invasion into the transverse mesocolon was difficult 
to detect. Under normal conditions, the transverse mesocolon can be identified on CT scans 
and MR images as the fatty plane extending from the pancreas to the transverse colon. 
However, cachexia and a distended stomach frequently efface this fatty plane in patients 
with advanced gastric cancer, thereby hindering proper evaluation. For pancreatic invasion, 
the accuracy was the same for both techniques; however, the number of cases of pancreatic 
invasion (n = 2) was too small to analyze in this study. Lee et al. (1994) suggested the 
superiority of MR imaging over CT because the difference in signal intensity of the stomach 
and pancreas could make the detection of tumor invasion into the pancreas easier on MR 
images. However, further study is needed to evaluate the usefulness of MR imaging for this 
purpose. Early or miliary peritoneal carcinomatosis without ascites was difficult to detect 
preoperatively, but omental infiltration was easily detected on both MR imaging and helical 
CT in most (80%) (Sohn, et al. 2000). Generally, MR imaging is a powerful imaging tool with 
its high soft-tissue contrast, multiplanar imaging capability and ability to provide 
biochemical and anatomic information, technical versatility for sequence selection and 
modification, and its lack of ionizing radiation. However, excessive motion artifacts 
resulting from a combination of long imaging time and physiologic motion such as 
respiration, peristalsis, and cardiovascular pulsation, have made MR imaging unsuitable for 
the staging of gastric cancer. The recent development of fast imaging techniques with 
breath-hold sequences has allowed rapid data acquisition, thereby reducing the problem of 
motion artifacts. Additionally, the use of phased array coils has increased the signal-to- 
noise ratio and the spatial resolution in abdominal MR images. Many kinds of oral contrast 
agents distend the stomach for MR imaging, and these can be divided into positive 
(producing high signal intensity on T1- and T2-weighted images), negative (producing low 
signal intensity on T1- and T2-weighted images), and biphasic (producing opposite signal 
intensities on T1- and T2- weighted images) contrast agents (Halvorsen, et al. 1996). 
4. Imaging findings of regional lymph nodes  
4.1 Metastasis to regional lymph nodes 
Clinically, N staging appears to be a more significant factor than T staging in determining 
the type of surgery to be performed and in predicting the patient's prognosis (Belcastro, et 
al. 1990). In AGC, the importance of noting the nodal stage N2 and differentiating it from 
the N1 stage is well known. This is because N2 nodes are not routinely removed at surgery 
and, as a result, are the causes of a large number of treatment failures following surgery 
(Levine & Megibow. 1994). Nevertheless, there has been no consensus until now as to how 
to measure lymph nodes (short or long axis) or the size that should be considered pathologic 
(Trenkner, et al. 1994). Wide ranges of sensitivity (48-91%) have been reported for nodal 
staging with CT (Sussman, et al. 1988; Botet, et al. 1991; Dehn, et al. 1984; Triller, et al. 1986). 
Fukuya et al. (1995) suggested that diagnosing lymphadenopathy is problematic for nodes 
of<14 mm in size: 87.2% were negative for metastases. Hence, they used a size criterion of 15 
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mm for positive metastatic lymph nodes. However, application of the 15 mm criterion can 
produce high specificity but can induce low sensitivity in N staging. 
8 mm at the short axis of lymph node used as the size criterion (Dorfman, et al. 1991), and 
the N staging accuracy of spiral CT was slightly superior to that of MRI in Kim A et al. 
(2000) study (p > 0.05). The relatively inferior N staging results of MRI to those of CT were 
related to a low detection rate of small-sized lymph nodes, as reported by Dux et al. (1997). 
The accuracy of CT in T and N staging of AGC was also variable in several reports (Cho, et 
al. 1994; Ziegler, et al. 1993; Minami, et al. 1992) and ranged from 73.1 to 83% in T staging 
and from 51 to 70% in N staging. According to these reports, CT has a tendency to 
overestimate T stage and underestimate N stage. Understaging occurs because it is difficult 
to identify fine metastases including peritoneal carcinomatosis, whereas overstaging occurs 
due to the obliteration of fat plane between the gastric lesion and adjacent organs, which is 
known to be an unreliable sign suggesting invasion of the adjacent structure. MR imaging 
correctly revealed regional lymph node involvement in 55% (16/29), understaged 34.5% 
(10/29), and overstaged 10% (3/29) according by Sohn et al. (2000). There is no significant 
difference between MR imaging and helical CT in the staging of regional lymph node 
metastasis. Lymph nodes showed a high SI on opposed phased images (Dux, et al. 1997). 
MRI had low rate in depicting lymph node metastasis, with an accuracy of 47 %. MRI can 
reliably depict several anatomical layers of the gastric wall and also MRI of gastric 
carcinoma could enable accurate diagnosis of location, gross appearance, degree of gastric 
wall invasion of the tumors and delineation of regional lymph node metastasis. A clear 
image of the tumor can be achieved. Therefore, an evaluation of the local tumor stage of 
gastric carcinoma and Sohn et al. (2000) assumed that MR multiplanar imaging would be 
more accurate in nodal staging than helical CT with only axial images, but with a relative 
lack of experience and unfamiliarity with MR anatomy in coronal and sagittal images for 
lymph node detection, he could not prove the superiority of MR imaging over helical CT in 
nodal staging. Sohn et al. (2000) also considered the detectability of lymph node metastases 
would be improved by radiologists having more experience with interpretation of coronal 
and sagittal MR images. The detection rate of lymph node metastasis was low for both 
techniques. The low detection rate was due to frequent microscopic nodal invasion and the 
fact that reactive or inflammatory nodal enlargement could not be differentiated from 
metastatic nodal enlargement on MR imaging or helical CT. An accurate assessment of 
metastatic lymph nodes was difficult when they were grouped together or attached to a 
gastric mass. Though an exophytic tumor growth can sometimes mimic a regional lymph 
node metastasis on axial helical CT, coronal or sagittal MR imaging can easily differentiate 
them. Perigastric lymph node metastasis based on morphologic criteria is technically 
possible. Therefore, the additional application of signal intensity as a pathologic lymph node 
criterion or additional pulse sequences such as Gd-enhanced, breath-hold gradient echo 
images with fat suppression or breath-hold short T1 inversion recovery (STIR) images could 
be helpful in improving N staging with MRI. 
4.2 Regional lymph node metastasis of resected stomach 
According to Kim I et al. (2009) study, the lymph nodes presented with intermediate SI on 
T1-weighted images, intermediate SI on T2-weighted images. The sizes were measured as 
being from 0.35 cm to 3.5 cm on MR imaging (Figure 9, 10). The accuracy of N staging by 
MRI was 47%. 
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cancer was easily detectable on both MR imaging and helical CT; however, the incidence of 
detectability of early gastric cancer was low on both techniques. MR imaging was slightly 
more accurate than helical CT in the T staging of gastric cancer, but this difference was not 
statistically significant (p > 0.05). MR imaging and helical CT showed understaging more 
frequently than overstaging because of the frequent understaging of pT4 tumors. The low 
concordance rates of pT4 tumors on MR imaging and helical CT were partly caused by the 
fact that patients with evident CTT4 or MRT4 tumors did not undergo surgery and therefore 
were not included in this study. Also, invasion into the transverse mesocolon was difficult 
to detect. Under normal conditions, the transverse mesocolon can be identified on CT scans 
and MR images as the fatty plane extending from the pancreas to the transverse colon. 
However, cachexia and a distended stomach frequently efface this fatty plane in patients 
with advanced gastric cancer, thereby hindering proper evaluation. For pancreatic invasion, 
the accuracy was the same for both techniques; however, the number of cases of pancreatic 
invasion (n = 2) was too small to analyze in this study. Lee et al. (1994) suggested the 
superiority of MR imaging over CT because the difference in signal intensity of the stomach 
and pancreas could make the detection of tumor invasion into the pancreas easier on MR 
images. However, further study is needed to evaluate the usefulness of MR imaging for this 
purpose. Early or miliary peritoneal carcinomatosis without ascites was difficult to detect 
preoperatively, but omental infiltration was easily detected on both MR imaging and helical 
CT in most (80%) (Sohn, et al. 2000). Generally, MR imaging is a powerful imaging tool with 
its high soft-tissue contrast, multiplanar imaging capability and ability to provide 
biochemical and anatomic information, technical versatility for sequence selection and 
modification, and its lack of ionizing radiation. However, excessive motion artifacts 
resulting from a combination of long imaging time and physiologic motion such as 
respiration, peristalsis, and cardiovascular pulsation, have made MR imaging unsuitable for 
the staging of gastric cancer. The recent development of fast imaging techniques with 
breath-hold sequences has allowed rapid data acquisition, thereby reducing the problem of 
motion artifacts. Additionally, the use of phased array coils has increased the signal-to- 
noise ratio and the spatial resolution in abdominal MR images. Many kinds of oral contrast 
agents distend the stomach for MR imaging, and these can be divided into positive 
(producing high signal intensity on T1- and T2-weighted images), negative (producing low 
signal intensity on T1- and T2-weighted images), and biphasic (producing opposite signal 
intensities on T1- and T2- weighted images) contrast agents (Halvorsen, et al. 1996). 
4. Imaging findings of regional lymph nodes  
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Clinically, N staging appears to be a more significant factor than T staging in determining 
the type of surgery to be performed and in predicting the patient's prognosis (Belcastro, et 
al. 1990). In AGC, the importance of noting the nodal stage N2 and differentiating it from 
the N1 stage is well known. This is because N2 nodes are not routinely removed at surgery 
and, as a result, are the causes of a large number of treatment failures following surgery 
(Levine & Megibow. 1994). Nevertheless, there has been no consensus until now as to how 
to measure lymph nodes (short or long axis) or the size that should be considered pathologic 
(Trenkner, et al. 1994). Wide ranges of sensitivity (48-91%) have been reported for nodal 
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Fukuya et al. (1995) suggested that diagnosing lymphadenopathy is problematic for nodes 
of<14 mm in size: 87.2% were negative for metastases. Hence, they used a size criterion of 15 
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mm for positive metastatic lymph nodes. However, application of the 15 mm criterion can 
produce high specificity but can induce low sensitivity in N staging. 
8 mm at the short axis of lymph node used as the size criterion (Dorfman, et al. 1991), and 
the N staging accuracy of spiral CT was slightly superior to that of MRI in Kim A et al. 
(2000) study (p > 0.05). The relatively inferior N staging results of MRI to those of CT were 
related to a low detection rate of small-sized lymph nodes, as reported by Dux et al. (1997). 
The accuracy of CT in T and N staging of AGC was also variable in several reports (Cho, et 
al. 1994; Ziegler, et al. 1993; Minami, et al. 1992) and ranged from 73.1 to 83% in T staging 
and from 51 to 70% in N staging. According to these reports, CT has a tendency to 
overestimate T stage and underestimate N stage. Understaging occurs because it is difficult 
to identify fine metastases including peritoneal carcinomatosis, whereas overstaging occurs 
due to the obliteration of fat plane between the gastric lesion and adjacent organs, which is 
known to be an unreliable sign suggesting invasion of the adjacent structure. MR imaging 
correctly revealed regional lymph node involvement in 55% (16/29), understaged 34.5% 
(10/29), and overstaged 10% (3/29) according by Sohn et al. (2000). There is no significant 
difference between MR imaging and helical CT in the staging of regional lymph node 
metastasis. Lymph nodes showed a high SI on opposed phased images (Dux, et al. 1997). 
MRI had low rate in depicting lymph node metastasis, with an accuracy of 47 %. MRI can 
reliably depict several anatomical layers of the gastric wall and also MRI of gastric 
carcinoma could enable accurate diagnosis of location, gross appearance, degree of gastric 
wall invasion of the tumors and delineation of regional lymph node metastasis. A clear 
image of the tumor can be achieved. Therefore, an evaluation of the local tumor stage of 
gastric carcinoma and Sohn et al. (2000) assumed that MR multiplanar imaging would be 
more accurate in nodal staging than helical CT with only axial images, but with a relative 
lack of experience and unfamiliarity with MR anatomy in coronal and sagittal images for 
lymph node detection, he could not prove the superiority of MR imaging over helical CT in 
nodal staging. Sohn et al. (2000) also considered the detectability of lymph node metastases 
would be improved by radiologists having more experience with interpretation of coronal 
and sagittal MR images. The detection rate of lymph node metastasis was low for both 
techniques. The low detection rate was due to frequent microscopic nodal invasion and the 
fact that reactive or inflammatory nodal enlargement could not be differentiated from 
metastatic nodal enlargement on MR imaging or helical CT. An accurate assessment of 
metastatic lymph nodes was difficult when they were grouped together or attached to a 
gastric mass. Though an exophytic tumor growth can sometimes mimic a regional lymph 
node metastasis on axial helical CT, coronal or sagittal MR imaging can easily differentiate 
them. Perigastric lymph node metastasis based on morphologic criteria is technically 
possible. Therefore, the additional application of signal intensity as a pathologic lymph node 
criterion or additional pulse sequences such as Gd-enhanced, breath-hold gradient echo 
images with fat suppression or breath-hold short T1 inversion recovery (STIR) images could 
be helpful in improving N staging with MRI. 
4.2 Regional lymph node metastasis of resected stomach 
According to Kim I et al. (2009) study, the lymph nodes presented with intermediate SI on 
T1-weighted images, intermediate SI on T2-weighted images. The sizes were measured as 
being from 0.35 cm to 3.5 cm on MR imaging (Figure 9, 10). The accuracy of N staging by 
MRI was 47%. 
 





Fig. 9. MRI of N1 Gastric Carcinoma. A: T1-weighted (500/20) MR image showed single 
lymph node on lesser curvature site of stomach body (Arrow); B: T2-weighted (2000/90) 




Fig. 10. MRI and Histology of N2 Gastric Carcinoma. A: T1-weighted (500/20) MRI showed 
two lymph nodes in lesser curvature site of stomach antrum (arrows). Eight lymph nodes 
are detected in total in perigastric area (not shown); B: T2-weighted (2000/90) MRI showed 
intermediate SI in the lymph nodes (arrows); C: Light microscopic section showed two 
lymph nodes in lesser curvature site of gastric antrum (arrows) (HE stain; original 
magnification, × 1) (Kim, I., et al. 2009). 
 
MR Imaging of Gastric Carcinoma 
 
33 
MRI in combination with standard sequences demonstrated the potential of MRI in the 
staging of gastric carcinomas. Although the result obtained in N-staging was not acceptable, 
it should be explored further. However, there could be shown not only MR findings of 
gastric wall invasion but also perigastric lymph node involvement in the gastric carcinoma. 
MRI is useful for staging of T staging of gastric cancer, whereas MRI has shown some 
limitations in N staging. MRI can not completely replace spiral CT in staging AGC at the 
present time. However, MRI can be potentially useful as an alternative method of staging 
gastric cancer in that it provides multiplanar images. The evaluation of lymph node 
metastasis on MRIs had some limitation (Kim, I., et al. 2009), since the size criteria was used 
only on MRIs and there was no trial of contrast enhancement because of in vitro study of 
gastric carcinoma. Lymph node borders and signal intensity were not also evaluated for 
diagnosis of lymph node metastasis. But some cases of lymph nodes showed intermediate SI 
on T1 and T2-weighted images in the tumor infiltration region and this was correctly 
correlated with the histology. According to Dux et al. (1997) study, lymph nodes showed a 
high SI on opposed phased images. MRI had low rate in depicting lymph node metastasis, 
with an accuracy of 47 %. However, the result was similar to the other reports (Yamada, et 
al. 2001). MRI can reliably depict several anatomical layers of the gastric wall and also MRI 
of gastric carcinoma could enable accurate diagnosis of location, gross appearance, degree of 
gastric wall invasion of the tumors and delineation of regional lymph node metastasis. A 
clear image of the tumor can be achieved.  
5. Discussion 
Gastric carcinomas show an intermediate SI on T1-weighted images, a low SI on T2-
weighted images and a high SI on opposed phase images (Palmowski, et al. 2006). Opposed 
phase images show a very high SI in gastric tumors and insisted that this was useful for the 
staging of gastric carcinoma (Dux, et al. 1997) and demonstrate that the infiltration of gastric 
carcinoma was correctly defined in 74% of the cases. Cho et al. (1994) and Fukuya et al. 
(1997) studied using dynamic or helical CT and reported that the normal gastric wall 
frequently showed a two- or three-layer pattern that was interrupted by a tumor; thus, more 
accurate staging of the T factor could be expected. In addition, the use of thin collimation (≤5 
mm) could improve the depiction of small lesions and make it possible to obtain 
multiplanar reformatted images. However, it still is difficult for helical CT to differentiate 
between a pT2 tumor and a pT1 tumor with massive submucosal invasion because the 
hypoattenuating stripe corresponding to the intact submucosal layer could be obliterated in 
the latter. Sohn et al. (2000) also experienced a case of a pT2 tumor with minimal invasion of 
the muscularis propria layer, which showed focal wall thickening with preservation of the 
hypoattenuating stripe. Sohn et al. (2000) demonstrated that advanced gastric carcinoma 
was easily detectable on both MR imaging and helical CT; however, the incidence of 
detectability of early gastric cancer was low on both techniques. MR imaging was slightly 
more accurate than helical CT in the T staging of gastric cancer, but this difference was not 
statistically significant (p > 0.05).  
The evaluation of lymph node metastasis on MRIs had some limitation, since the size 
criteria was used only on MRIs and there was no trial of contrast enhancement because of in 
vitro study of gastric carcinoma. Lymph node borders and signal intensity were not also 
evaluated for diagnosis of lymph node metastasis. But some cases of lymph nodes showed 
intermediate SI on T1 and T2-weighted images in the tumor infiltration region and this was 
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MRI in combination with standard sequences demonstrated the potential of MRI in the 
staging of gastric carcinomas. Although the result obtained in N-staging was not acceptable, 
it should be explored further. However, there could be shown not only MR findings of 
gastric wall invasion but also perigastric lymph node involvement in the gastric carcinoma. 
MRI is useful for staging of T staging of gastric cancer, whereas MRI has shown some 
limitations in N staging. MRI can not completely replace spiral CT in staging AGC at the 
present time. However, MRI can be potentially useful as an alternative method of staging 
gastric cancer in that it provides multiplanar images. The evaluation of lymph node 
metastasis on MRIs had some limitation (Kim, I., et al. 2009), since the size criteria was used 
only on MRIs and there was no trial of contrast enhancement because of in vitro study of 
gastric carcinoma. Lymph node borders and signal intensity were not also evaluated for 
diagnosis of lymph node metastasis. But some cases of lymph nodes showed intermediate SI 
on T1 and T2-weighted images in the tumor infiltration region and this was correctly 
correlated with the histology. According to Dux et al. (1997) study, lymph nodes showed a 
high SI on opposed phased images. MRI had low rate in depicting lymph node metastasis, 
with an accuracy of 47 %. However, the result was similar to the other reports (Yamada, et 
al. 2001). MRI can reliably depict several anatomical layers of the gastric wall and also MRI 
of gastric carcinoma could enable accurate diagnosis of location, gross appearance, degree of 
gastric wall invasion of the tumors and delineation of regional lymph node metastasis. A 
clear image of the tumor can be achieved.  
5. Discussion 
Gastric carcinomas show an intermediate SI on T1-weighted images, a low SI on T2-
weighted images and a high SI on opposed phase images (Palmowski, et al. 2006). Opposed 
phase images show a very high SI in gastric tumors and insisted that this was useful for the 
staging of gastric carcinoma (Dux, et al. 1997) and demonstrate that the infiltration of gastric 
carcinoma was correctly defined in 74% of the cases. Cho et al. (1994) and Fukuya et al. 
(1997) studied using dynamic or helical CT and reported that the normal gastric wall 
frequently showed a two- or three-layer pattern that was interrupted by a tumor; thus, more 
accurate staging of the T factor could be expected. In addition, the use of thin collimation (≤5 
mm) could improve the depiction of small lesions and make it possible to obtain 
multiplanar reformatted images. However, it still is difficult for helical CT to differentiate 
between a pT2 tumor and a pT1 tumor with massive submucosal invasion because the 
hypoattenuating stripe corresponding to the intact submucosal layer could be obliterated in 
the latter. Sohn et al. (2000) also experienced a case of a pT2 tumor with minimal invasion of 
the muscularis propria layer, which showed focal wall thickening with preservation of the 
hypoattenuating stripe. Sohn et al. (2000) demonstrated that advanced gastric carcinoma 
was easily detectable on both MR imaging and helical CT; however, the incidence of 
detectability of early gastric cancer was low on both techniques. MR imaging was slightly 
more accurate than helical CT in the T staging of gastric cancer, but this difference was not 
statistically significant (p > 0.05).  
The evaluation of lymph node metastasis on MRIs had some limitation, since the size 
criteria was used only on MRIs and there was no trial of contrast enhancement because of in 
vitro study of gastric carcinoma. Lymph node borders and signal intensity were not also 
evaluated for diagnosis of lymph node metastasis. But some cases of lymph nodes showed 
intermediate SI on T1 and T2-weighted images in the tumor infiltration region and this was 
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correctly correlated with the histology. MRI can be shown gastric wall invasion but also 
perigastric lymph node involvement in the gastric carcinoma. Advances in the variation of 
sequence techniques, as well as application of ultrafast imaging techniques, may be more 
useful preoperative staging of gastric carcinomas by MRI. MR imaging could be a useful 
alternative to helical CT because of its high resolution of soft tissue, its multiplanar imaging 
capability, and its lack of ionizing radiation. In addition, MR imaging could be useful for 
patients who cannot undergo CT because of renal impairment, pregnancy, or 
hypersensitivity to CT contrast materials. 
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1. Introduction 
Gastric carcinoma is the fourth most common carcinoma in the world, with an estimated 
one million new cases every year, and it is the second most common cause of death from 
carcinoma (Ferlay et al., 2010). Surgery is the mainstay of treatment of gastric carcinoma. 
Despite recent advances in surgical treatment, the overall prognosis of patients with gastric 
carcinoma has not improved significantly because the neoplasm is often diagnosed at an 
advanced stage of the disease. Local and systemic recurrences are common, even after 
complete resection of the primary tumour and regional lymph nodes. Multimodality 
therapy, consisting of surgery with adjuvant or neoadjuvant radiotherapy, chemotherapy or 
both, has been used recently as a means to improve the survival rate of patients with gastric 
carcinoma. Current data suggest that this carcinoma is best managed with a tailored 
therapeutic regimen based on thorough preoperative staging of the tumour and an 
understanding of established prognostic factors (Stein et al., 2000).  
The International Union Against Cancer (Unio Internationalis Contra Cancrum: UICC) TNM 
Classification of Malignant Tumours, 7th edition (Sobin et al., 2009), provides the latest, 
internationally agreed-upon standards to describe and categorise cancer stages and 
progression. Staging of gastric carcinoma was performed according to the UICC TNM 
staging for the T stage, N stage and M stage. The T stage refers to the depth of the invasion 
of the primary tumour, the N stage refers to the number of metastatic lymph nodes and the 
M stage indicates the presence or absence of systemic metastases (Table 1). For the N stage, 
the UICC TNM staging detailed in the 7th edition (Sobin et al., 2009) is a classification system 
based on the number of metastatic lymph nodes, a variable that has proved to be an 
independent prognostic factor in gastric carcinoma. In contrast, the Japanese Classification 
of Gastric Carcinoma (JCGC), 13th edition, provides lymph node station numbers for 
anatomically separate sites of regional lymph nodes (Japanese Gastric Cancer Association 
[JGCA], 1998). This classification is based on the study of lymphatic flow and surgical 
results. There was a difference in the two classification systems, particularly regarding 
lymph node metastasis, but near standardization was reached in 2010. For the year 2011, not 
enough data have been collected based on the new standards. We describe lymph node 
metastasis based on the JCGC, 13th edition, which classifies lymph node metastasis 
according to the anatomic sites of metastatic lymph nodes (Table 2).  
Current preoperative staging techniques, such as endoscopy, barium studies, computed 
tomography (CT) and endoscopic ultrasonography (EUS), are of limited accuracy, and 
invasive procedures often are used for better assessment of the stage of the disease. Positron 
emission tomography (PET) has been evaluated recently in the staging of gastric carcinoma.  
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T  Primary tumor 
TX: Primary tumour cannot be assessed 
T0: No evidence of primary tumour 
Tis: Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria,  
 high grade dysplasia 
T1: Tumour invades lamina propria, muscularis mucosae, or submucosa 
 T1a: Tumour invades lamina propria or muscularis mucosae 
 T1b: Tumour invades submucosa 
T2: Tumour invades muscularis propria 
T3: Tumour invades subserosa 
T4: Tumour perforates serosa or invades adjacent structures 
 T4a: Tumour perforates serosa 
 T4b: Tumour invades adjacent structures 
N  Regional Lymph Nodes 
NX: Regional lymph nodes cannot be assessed 
N0: No regional lymph node metastasis 
N1: Metastasis in 1 to 2 regional lymph nodes 
N2: Metastasis in 3 to 6 regional lymph nodes  
N3: Metastasis in 7 or more regional lymph nodes 
 N3a: Metastasis in 715 regional lymph nodes 
 N3b: Metastasis in 16 or more regional lymph nodes 
M  Distant Metastasis 
M0: No distant metastasis 
M1: Distant metastasis 
Stage Grouping 
Stage 0: Tis, N0, M0 Stage IIIA: T4a, N1, M0 
Stage IA: T1, N0, M0  T3, N2, M0 
Stage IB: T2, N0, M0  T2, N3, M0 
 T1, N1, M0 Stage IIIB: T4b, N0, M0 
Stage IIA: T3, N0, M0  T4b, N1, M0 
 T2, N1, M0  T4a, N2, M0 
 T1, N2, M0  T3, N3, M0 
Stage IIB: T4a, N0, M0 Stage IIIC: T4a, N3, M0 
 T3, N1, M0  T4b, N2, M0 
 T2, N2, M0  T4b, N3, M0 
 T1, N3, M0 Stage IV: Any T, Any N, M1 
                                                                                   
Table 1. UICC TNM, 7th edition, staging for gastric carcinoma 
                                                                                   
Extent of lymph node metastasis (N) 
N0: No evidence of lymph node metastasis 
N1: Metastasis to Group 1 lymph nodes, but no metastasis to Group 2 or 3 lymph nodes 
N2: Metastasis to Group 2 lymph nodes, but no metastasis to Group 3 lymph nodes 
N3: Metastasis to Group 3 lymph nodes 
NX: Unknown 
Table 2. JCGC, 13th edition, N staging for gastric carcinoma 
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The regional lymph nodes are classified into three groups depending upon the location of 
the primary tumour. This grouping system is based on the results of studies of lymphatic 
flow at various tumour sites, together with the observed survival rate associated with 
metastasis at each nodal station. 
2. PET imaging 
PET instrumentation has been available for over 35 years. Recently it has become clear that 
PET, using the glucose metabolism tracer 18F-fluoro-2-deoxy-D-glucose (FDG), will have a 
major role in the management of patients, particularly in oncology. Imaging with FDG-PET 
is based on the altered glucose uptake of neoplastic cells (Fig. 1). FDG is a radiolabelled 
glucose analogue that accumulates in cells after cellular uptake, mainly by glucose 
transporters (GLUTs) located on the cell membrane and intracellular phosphorylation by 
hexokinases. GLUT-1 is the main cell surface protein facilitating the active uptake of FDG. 
Neoplastic cells overexpress GLUT-1 on their membranes, resulting in higher uptake. The 
expression of GLUT-1 itself correlates with tumour aggressiveness and carcinoma-related 
mortality (Kawamura et al., 2001). 
 
 
Fig. 1. Representative FDG-PET image of a patient with primary gastric carcinoma. (A) 
Whole-body anterior projection image of FDG-PET examination highlighting tumour FDG 
uptake in the gastric wall. (B) Transversal slice of whole-body FDG-PET examination with 
tumour FDG uptake in the gastric wall.  
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Apart from visual analysis, an often-used semi-quantitative method to assess the uptake of 
FDG in a tumour is the standardised uptake value (SUV): 
Regional radioactivity concentrationSUV (Lindholmet al.,  1993).
Total injected dose / body weight
=  
This value is the measurement of FDG uptake in a tumour volume normalised on the basis 
of the distribution volume. SUVs are dependent on several parameters, such as time after 
FDG injection, tumour size, blood glucose level and spatial resolution of the reconstructed 
image (Boellaard et al., 2004; Thie, 2004). Relative values, such as SUV changes, measured 
with accorded and comparable protocols are reliable. Moreover, inter-observer correlations 
are consistently high (Ott et al., 2003). 
2.1 Patient preparation 
Patient preparation for a whole-body FDG-PET examination is essential, both to optimise 
image quality and to minimise physiologic variants and artifacts (Shreve et al., 1999). 
Patients should fast for a minimum of four hours to ensure that serum glucose and 
endogenous serum insulin levels are low at the time of FDG administration. Glucose 
competes with FDG for cellular uptake, and there is some evidence that elevated serum 
glucose levels will lower the observed FDG uptake in malignant neoplasms (Lindholm et al., 
1993). Equally significantly, elevated serum insulin promotes FDG uptake in muscle (Fig. 2. 
A), so a recent carbohydrate meal or even a snack or the administration of exogenous insulin 
to lower blood glucose levels can yield extensive muscle uptake. Such muscle uptake will 
not interfere with the evaluation of centrally located abnormalities such as lung nodules or 
mediastinal lymph nodes. In general, a serum glucose level of less than 150 mg/dL at the 
time of FDG accumulation is preferred; a level lower than 200 mg/dL is acceptable. With 
serum glucose levels above 200 mg/dL, noticeable degradation in image quality due to 
reduced tissue uptake of FDG and sustained blood pool tracer activity can occur. It is 
relatively easy to measure serum glucose prior to FDG administration, and this 
measurement is routine at many centres. Use of exogenous insulin to reduce serum glucose 
immediately prior to FDG administration is not generally recommended since it will result 
in accelerated FDG uptake in muscle (Fig. 2. B). 
2.2 Image acquisition 
2.2.1 Attenuation correction 
Whole-body FDG-PET imaging is performed with attenuation correction. As patient 
movement between the transmission and emission image acquisitions may result in 
registration artifacts in the attenuation-corrected images, the emission and transmission 
image acquisitions should be temporally as close as possible when sealed-source 
transmission scans are used.  
2.2.2 Image acquisition time 
Image acquisition time and FDG dose are related, but not in the entirely inverse fashion of 
single-photon radiotracer imaging. Regarding sealed-source transmission scans with image 
segmentation, acquisition time per bed position is two minutes or less. CT-based attenuation 
 
 




Fig. 2. A and B. Effect of endogenous and exogenous insulin. (A) Whole-body anterior 
projection image of a patient who ate candies prior to FDG administration and had a serum 
glucose level of 220 mg/dL, and (B) a patient given 6 units of regular insulin intravenously 
prior to FDG administration to reach a normalised serum glucose level of 95 mg/dL. In both 
cases, there is extensive skeletal muscle uptake, uniform and symmetrical, due to the action 
of insulin.  
correction allows a whole-body transmission scan without noise or segmentation errors to 
be performed in less than 30 seconds with multi-detector helical CT. Shallow relaxed 
breathing is essential to minimise image registration errors when X-ray CT is used for the 
transmission image sonogram because when CT acquisition is performed during free 
breathing, the temporal relation (seconds) is quite different from the PET emission 
acquisition (a few to several minutes).  
2.2.3 Radiopharmaceutical dose 
Due to the nature of contaminating scatter and random coincidence events, the relationship 
between the FDG dose and usable image counting statistics is neither direct nor linear. This 
relationship depends on the geometry of the tomograph, the type of detector crystal, the size 
of the patient and the reconstruction algorithm used. In general, ring tomographs in 2D 
mode with thick axial septa will increase usable true coincidences with increasing 
administered dose to the upper range of the dosimetry-limited FDG dose (about 700 MBq) 
(Jones et al., 1982). Increasing the administered dose can reduce the emission image 
acquisition time, for example, from eight minutes to four minutes per bed position. 
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Apart from visual analysis, an often-used semi-quantitative method to assess the uptake of 
FDG in a tumour is the standardised uptake value (SUV): 
Regional radioactivity concentrationSUV (Lindholmet al.,  1993).
Total injected dose / body weight
=  
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Tomographs with greater axial cross-plane acceptance and finer septa, and especially 
tomographs operating in full 3D mode, will reach limiting random coincidence count rate 
contributions with administered doses as low as 200 MBq or less.  
2.2.4 Time of imaging after tracer injection 
Imaging acquisition following FDG administration for body imaging is commenced 40 to 60 
minutes following FDG administration. This delay is based in part on the time required for a 
majority of the activity to clear from the blood pool and for most of the tumour 
accumulation of the tracer to occur. In fact, there is continued accumulation of FDG in 
malignant neoplasms and other FDG-avid tissues such as bone marrow beyond one hour, 
with continued clearance of blood pool activity (Hamberg et al., 1994). Hence, a longer delay 
in the commencement of image acquisition has been advocated to enhance the tumour-to-
background ratio and to allow more complete clearance of upper urinary tract activity. For 
tomographs that are count-rate limited, a longer delay of 90 to 120 minutes, with a 
correspondingly higher FDG dose, may provide optimal whole-body imaging.  
2.2.5 Imaging display and interpretation 
Whole-body FDG-PET images are routinely displayed as a series of orthogonal tomographic 
images in the transversal, coronal and sagittal planes, together with a whole-body rotating 
projection image. The rotating projection image provides an invaluable rapid assessment of 
the overall status of FDG-avid malignancy in the body and can be very helpful in discerning 
the 3D relationships of abnormalities to normal structures. Interpretation of whole-body 
images is thus best accomplished using both the rotating whole-body projection image and 
the serial tomographic images.  
Some disagreement remains over the use of semi-quantitative measures of FDG uptake for 
routine application in oncology, with some centres using SUV routinely and others relying 
entirely on visual interpretation. SUV cannot be relied upon as an absolute criterion of 
malignancy because the degree of FGD uptake implies a probability of malignancy rather 
than an established diagnosis. Even more importantly, the SUVs reported in publications 
have been obtained using varying methods and do not represent a standardised parameter 
(Keyes et al., 1995). On the other hand, when a patient undergoes serial PET imaging using 
the same tomograph in order to assess a change in FDG uptake for therapy monitoring, SUV 
or a similar semi-quantitative measurement may well be a necessary adjunct to visual 
interpretation. 
2.3 Clinical utility of FDG-PET in gastric carcinoma 
2.3.1 Primary tumour staging (T stage) 
Most studies included in this review examined the feasibility of primary tumour detection 
by FDG-PET in gastric carcinoma. The studies show that FDG-PET is not an accurate 
imaging technique for the primary diagnosis of a gastric primary tumour as it combines 
high specificity with low sensitivity. About 20% of patients with gastric carcinoma are non-
assessable by FDG-PET. The sensitivity rate for detecting the primary tumour varies 
between 58 and 94% amongst studies (median 81.5%), and the specificity ranges from 78 to 
100% (median 98%) (Chen et al., 2005; Mochiki et al., 2004; Mukai et al., 2006; Stahl et al., 
2003; Yeung et al., 1998; Yoshioka et al., 2003; Yun et al., 2005). The detection of gastric 
carcinoma by FDG-PET is complicated by background signalling, partly due to the high 
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physiological uptake of FDG in the normal gastric wall. Moreover, variable and sometimes 
intense, highly located uptake background activity is observed in the normal gastric wall, 
resembling false-positive pathological uptake (Mochiki et al., 2004; Stahl et al., 2003). 
Actively creating gastric distension by water ingestion could augment FDG-PET specificity 
(Kamimura et al., 2007, 2009; Ott et al., 2003; Yun et al., 2005). After water ingestion, the 
physiological FDG uptake in the gastric wall became a cystic structure with a mild and even 
distribution of FDG along the thin wall, and the focal tumour uptake was more clearly 
visualised under gastric distension by water ingestion (Fig. 3) (Kamimura et al., 2009). 
 
 
Fig. 3. FDG-PET images of a patient before and after water ingestion. A 63-year-old male 
with gastric carcinoma of the lower part of the stomach (moderately differentiated tubular 
adenocarcinoma). Transversal (left), coronal (middle) and sagittal (right) FDG-PET images of 
the patient. (A) Before ingestion of water, diffuse physiological FDG uptake in the stomach 
is higher than that in the liver, and it is difficult to distinguish the tumour uptake from 
physiological FDG uptake in the stomach. (B) After ingestion of water, diffuse physiological 
FDG uptake in the gastric wall is reduced, and the focal tumour uptake is more clearly 
visualised (arrows).  
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Sensitivity of primary tumour identification by FDG-PET is influenced by several other 
determinants. The location of the tumour (i.e. upper/middle/lower one-third) has been 
shown to influence the sensitivity of FDG-PET (Mochiki et al., 2004; Mukai et al., 2006; Ott et 
al., 2003; Stahl et al., 2003). Even in the normal gastric wall, different SUV uptakes have been 
found between the upper and lower parts of the stomach. Two studies found a higher 
detection rate by FDG-PET of a gastric carcinoma located in the proximal part of the 
stomach compared to a distal carcinoma (Koga et al., 2003; Mukai et al., 2006). A second 
determinant is tumour size or T stage. The sensitivity of FDG-PET ranges from 26 to 63% in 
early gastric carcinoma (median 43.5%; SUV range 2.12.8) to 9398% in locally advanced 
gastric carcinoma (median 94%; SUV range 4.37.9) (Chen et al., 2005; Mochiki et al., 2004; 
Mukai et al., 2006; Stahl et al., 2003; Yeung et al., 1998; Yoshioka et al., 2003; Yun et al., 2005). 
FDG-PET as part of screening programs for the detection of gastric carcinoma in 
asymptomatic patients yields even worse results (Shoda et al., 2007). A sensitivity of 10% 
was found, with primarily false-positive findings (Shoda et al., 2007). There are various 
explanations for this difference. Several studies report a correlation between tumour 
invasion as an independent factor and overexpression of GLUT-1 receptors. Possibly, the 
increased need for glucose due to augmented cell metabolism and cell division in advanced 
carcinoma is the cause of GLUT-1 overexpression and higher FDG uptake (Yamada et al., 
2006). The relative volume effect may be a reason for the higher detection rate of advanced 
gastric carcinoma as the discrimination between physiological and pathological gastric wall 
uptake increases. This effect makes FDG-PET an inaccurate method for screening and 
primary tumour detection (Shoda et al., 2007). Furthermore, a clear difference in the 
sensitivity of FDG-PET is found between different histological carcinoma subtypes. 
According to the Japanese Classification (JGCA, 1998), gastric carcinoma can be divided into 
papillary, tubular (well-differentiated type, moderately differentiated type), poorly 
differentiated (solid type, non-solid type), mucinous adenocarcinoma and signet ring cell 
carcinoma. The non-intestinal (i.e. diffuse) subtype and carcinomas containing signet ring 
cells display a consistently low detectability by FDG-PET (Mukai et al., 2006; Ott et al., 2003; 
Stahl et al., 2003). For tubular adenocarcinoma and moderately differentiated 
adenocarcinoma, SUV counts of 7.7 to 13.2 were found, which were significantly higher 
compared to those for mucinous adenocarcinoma and signet ring cell carcinoma (4.1 to 7.7) 
(Chen et al., 2005; Mochiki et al., 2004; S. K. Kim et al., 2006; Yoshioka et al., 2003; Yun et al., 
2005). This result is due to a higher expression of GLUT-1 on the cell membrane of the 
neoplastic cells, as proven for cohesive gastric carcinoma (i.e. tubular adenocarcinoma, 
poorly differentiated adenocarcinoma) (Kawamura et al., 2001; W. S. Kim et al., 2000). Other 
factors influencing the low FDG uptake in mucinous adenocarcinoma and signet ring cell 
carcinoma are the diffuse growth pattern of non-intestinal gastric carcinoma, the high 
content of metabolically inert mucus and the low tumour cell density (Kawamura et al., 
2001; Ott et al., 2003; Stahl et al., 2003). For these entities, FDG-PET seems to have little value 
in the primary detection of gastric carcinoma. 
2.3.2 Regional lymph node metastases (N stage) 
In the N stage, the UICC TNM staging uses a classification system based on the number of 
metastatic lymph nodes only (Sobin et al., 2009). We describe lymph node metastasis based 
on the JCGC, 13th edition, which classifies lymph node metastasis according to the anatomic 
sites of metastatic lymph nodes (JGCA, 1998). 
 
PET Imaging in Gastric Carcinoma 
 
45 
Five studies investigated the value of FDG-PET in detecting lymph node metastasis (Fig. 4) 
(Chen et al., 2005; S. K. Kim et al., 2006; Mochiki et al., 2004; Mukai et al., 2006; Yun et al., 
2005). Sensitivity for metastasis to N1 lymph nodes was very low, ranging from 18 to 46% 
(median 27.5%) compared to CT (sensitivity of 5889%; median 68%). This lack of sensitivity 
could be explained by the relatively low spatial resolution of FDG-PET (5 to 7 mm). The 
perigastric lymph nodes, therefore, cannot be distinguished from the primary tumour or the 
normal stomach wall. FDG-PET and CT have low sensitivities of 3346% and 4463% in 
detecting metastases at the N2 and N3 lymph node stations, respectively. Specificity, in 
contrast, was higher in N1 and N2 lymph node stations with FDG-PET, ranging between 91 
and 100% (median 96%), compared to CT (Chen et al., 2005; Mochiki et al., 2004; Mukai et 
al., 2006; Yun et al., 2005). FDG-PET has a better positive predictive value for lymph node 
metastasis in comparison to CT, which may alter the planning of therapy, as treatment 
strategies, especially for N3 lymph node metastasis, change from curative surgery to 
palliative measures (Chen et al., 2005; Mochiki et al., 2004). A combination of anatomy-based 
imaging by CT and metabolically based imaging by FDG-PET using PET/CT might, 
therefore, augment the detection or denial of lymph node involvement. 
 
 
Fig. 4. Representative FDG-PET images of a patient with primary gastric carcinoma with 
regional lymph node involvement. A 79-year-old male with gastric carcinoma of the upper 
part of the stomach (moderately differentiated tubular adenocarcinoma). Anterior whole-
body projection (A), transversal (B) and coronal (C) FDG-PET images of the patient show 
intense tumour FDG uptake (T arrows) in the gastric wall and regional lymph node 
metastasis (LN arrows).  
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2.3.3 Distant metastatic disease (M stage) 
Not much is known about the role of FDG-PET in detecting distant metastasis. However, 
whole-body FDG-PET can point out distant metastases in some cases (Fig. 5).  
 
 
Fig. 5. Representative FDG-PET images of a patient with primary gastric carcinoma with 
liver metastases. A 75-year-old male with gastric carcinoma of the middle part of the 
stomach (moderately differentiated tubular adenocarcinoma). Anterior whole-body 
projection (A), transversal (B) and coronal (C) FDG-PET images of the patient show avid 
tumour FDG uptake (T arrow) in the gastric wall and multiple liver metastases (M arrows).  
One series found respective sensitivities and specificities of 85% and 74% for the detection of 
liver metastasis, 67% and 88% for lung metastasis, 50% and 63% for peritonitis 
carcinomatosis,  24% and 76% for ascites, 4% and 100% for pleuritis carcinomatosis and 30% 
and 82% for bone metastasis (Yoshioka et al., 2003). As is the case for peritoneal 
carcinomatosis, the low number of metastatic tumour cells in ascites, pleura and bone may 
explain the low FDG-PET sensitivity. Two patterns of FDG uptake are known to be 
indicators of peritoneal metastasis: diffuse uptake spreading uniformly throughout the 
abdomen and pelvis, thus obscuring visceral outlines, and discrete foci of uptake located 
randomly and anteriorly within the abdomen or independently within the pelvis and 
unrelated to solid viscera or nodal stations (Lim et al., 2006; Turlakow et al., 2003). Lim et al. 
demonstrated that although the sensitivity of PET to detect peritoneal metastasis was 
significantly lower than that of CT (35 vs. 77%), the specificity of PET was significantly 
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higher than that of CT (99 vs. 92%) (Lim et al., 2006). Current CT scanning has poor 
sensitivity as well, showing specificity even worse than that of FDG-PET. Diagnostic 
laparoscopy still plays an undefined role in staging gastric carcinoma. It is highly sensitive 
for peritoneal metastasis detection; however, it has little value in predicting regional lymph 
node metastasis (Burke et al., 1997; Lowy et al., 1996). The risks and morbidity of a staging 
laparoscopy outweigh the benefits, as eventually only a small number of patients will 
benefit from it (Lehnert et al., 2002). With the higher sensitivity of CT and the higher 
specificity of PET, fusion of these imaging modalities may be more useful than either one 
alone. In case of suspicion of peritoneal carcinomatosis based on PET and/or CT, diagnostic 
laparoscopy could be performed to prevent unnecessary laparotomies. 
2.3.4 Assessment of response to therapy 
The use of neoadjuvant chemotherapy in the treatment of gastric carcinoma has evolved 
greatly in recent years (Cunningham et al., 2006; Hartgrink et al., 2004; Schuhmacher et al., 
2001). Better surgicopathological results could be obtained with this treatment modality, 
especially by reducing microscopically irradical resections, residual tumour positive lymph 
nodes and tumour invasion in adjacent organs upon surgery. It is vital to discriminate 
between responders and non-responders to chemotherapy, as chemotherapy in the latter 
group could result in unnecessary risk for therapy-related morbidity with co-existing 
tumour growth. In 80% of all patients, gastric tumours are assessable by FDG-PET, and 
around 3040% of gastric carcinoma patients are responders with current chemotherapy 
regimens as defined by tumour regression (Di Fabio et al., 2007; Ott et al., 2003). 
Histopathological complete tumour regression is infrequently found (Cunningham et al., 
2006; Hartgrink et al., 2004; Ott et al., 2003; Schuhmacher et al., 2001). Thoracoabdominal CT 
scanning is commonly used to monitor tumour response. CT-observed tumour response 
depends on tumour size reduction, which is a relative late sign of response (RECIST criteria) 
(Therasse et al., 2000). An earlier sign of response is chemotherapy-induced reduction in 
tumour metabolic rate, which can be detected by FDG-PET. Two relatively small studies (44 
and 22 patients) showed that the fractional change in glucose consumption could be 
assessed by FDG-PET immediately following the first cycle of chemotherapy (Di Fabio et al., 
2007; Ott et al., 2003). Moreover, FDG-PET has been shown to be a predictor of not only 
neoadjuvant chemotherapy-induced clinical and histopathological response but also overall 
survival (Di Fabio et al., 2007; Ott et al., 2003). Patients with a metabolic response had a two-
year survival rate of 90%, in contrast to 40% in non-responders (Ott et al., 2003). In addition, 
100% of the non-responders were detected by FDG-PET and were subsequently withdrawn 
from neoadjuvant therapy in order to proceed to immediate surgery. FDG-PET evaluated 
treatment correctly in ~80% of responders and non-responders combined (Di Fabio et al., 
2007; Ott et al., 2003). Future goals are the delineation and validation of SUV-decrement 
thresholds with adequate sensitivity and specificity to discriminate between beneficiaries 
and non-beneficiaries of neoadjuvant chemotherapy. Currently, a 35% decrease in SUV as 
the cut-off level shows 75% sensitivity (Di Fabio et al., 2007; Ott et al., 2003). The role of 
FDG-PET in monitoring tumour response in gastric carcinoma must be examined further, 
with the potential for clinically interesting results. 
2.3.5 Detection of recurrent disease 
Tumour recurrence is directly associated with gastric carcinoma-related mortality, 
particularly early recurrence (< 1 year disease-free survival) (Shiraishi et al., 2000). 
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2.3.3 Distant metastatic disease (M stage) 
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Fig. 5. Representative FDG-PET images of a patient with primary gastric carcinoma with 
liver metastases. A 75-year-old male with gastric carcinoma of the middle part of the 
stomach (moderately differentiated tubular adenocarcinoma). Anterior whole-body 
projection (A), transversal (B) and coronal (C) FDG-PET images of the patient show avid 
tumour FDG uptake (T arrow) in the gastric wall and multiple liver metastases (M arrows).  
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higher than that of CT (99 vs. 92%) (Lim et al., 2006). Current CT scanning has poor 
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tumour growth. In 80% of all patients, gastric tumours are assessable by FDG-PET, and 
around 3040% of gastric carcinoma patients are responders with current chemotherapy 
regimens as defined by tumour regression (Di Fabio et al., 2007; Ott et al., 2003). 
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2007; Ott et al., 2003). Moreover, FDG-PET has been shown to be a predictor of not only 
neoadjuvant chemotherapy-induced clinical and histopathological response but also overall 
survival (Di Fabio et al., 2007; Ott et al., 2003). Patients with a metabolic response had a two-
year survival rate of 90%, in contrast to 40% in non-responders (Ott et al., 2003). In addition, 
100% of the non-responders were detected by FDG-PET and were subsequently withdrawn 
from neoadjuvant therapy in order to proceed to immediate surgery. FDG-PET evaluated 
treatment correctly in ~80% of responders and non-responders combined (Di Fabio et al., 
2007; Ott et al., 2003). Future goals are the delineation and validation of SUV-decrement 
thresholds with adequate sensitivity and specificity to discriminate between beneficiaries 
and non-beneficiaries of neoadjuvant chemotherapy. Currently, a 35% decrease in SUV as 
the cut-off level shows 75% sensitivity (Di Fabio et al., 2007; Ott et al., 2003). The role of 
FDG-PET in monitoring tumour response in gastric carcinoma must be examined further, 
with the potential for clinically interesting results. 
2.3.5 Detection of recurrent disease 
Tumour recurrence is directly associated with gastric carcinoma-related mortality, 
particularly early recurrence (< 1 year disease-free survival) (Shiraishi et al., 2000). 
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Peritoneal recurrence is especially common (Shiraishi et al., 2000). No curative treatment 
modalities are left for these patients, and the aim of care is palliation. An exception to this 
rule is late recurrence (> 5 years disease-free survival), which coincides with sporadic 
carcinoma mortality (Shiraishi et al., 2000). The extent of lymph node metastasis at primary 
diagnosis is the most important independent factor determining the timing of tumour 
recurrence (Shiraishi et al., 2000). Clinical surveillance is the most frequently used follow-up 
modality, as current endoscopic and radiologic (ultrasonography, barium study and CT) 
techniques are not sensitive enough for early recurrence detection and no reliable 
biochemical markers are known to correlate with recurrence (Jadvar et al., 2003; De Potter et 
al., 2002). Radiological examination, based on anatomical findings, is limited by 
postoperative non-cancerous changes. The detection of active neoplastic metabolism 
theoretically increases the advantage of FDG-PET over CT. However, FDG-PET lacks 
diagnostic accuracy in the early detection of recurrence, with sensitivity and negative 
predictive values of 70 and 60%, respectively (Jadvar et al., 2003). The high physiological 
remnant gastric uptake and the low spatial resolution of current hardware prevent the 
detection of early recurrence by FDG-PET (Jadvar et al., 2003; Yun et al., 2005). Creating 
gastric distension by water ingestion increases the ability of FDG-PET to discriminate 
between physiological and pathological gastric uptake and could reduce false-positivity 
(Kamimura et al., 2009; Yun et al., 2005). On the other hand, the use of PET/CT fusion 
images could decrease the number of false-positive FDG-PET scans by locating FDG-avid 
foci on anatomical landmarks. 
2.4 Tumour imaging with other tracers 
Other potentially useful PET tracers for the evaluation of gastric carcinoma are 3-deoxy-3-
18F-fluorothymidine (FLT) and 11C-choline (choline). FLT is a pyrimidine analogue that has 
proven to be a stable PET tracer that accumulates in proliferating tissue and malignant 
tumours (Shields et al., 1998). FLT is a substrate for thymidine kinase 1, which is an enzyme 
involved in the production of thymidine monophosphate. Hermann et al. performed a pilot 
study assessing the feasibility of FLT-PET compared to FDG-PET in gastric carcinoma 
(Herrmann et al., 2007). They found a sensitivity of 100% of FLT-PET for primary tumour 
detection (60% of tumours were signet ring cell carcinoma), compared to a sensitivity of 
FDG-PET of 69%. Background activity was low. These findings suggest that FLT-PET is a 
potentially useful imaging modality for the detection and staging of gastric carcinoma, 
especially for histologic subtypes with low FDG uptake. Kameyama et al. also reported that 
the sensitivity of FLT-PET was as high as that of FDG-PET for the detection of gastric 
carcinoma (Kameyama et al., 2009). The cellular uptake of choline presumably reflects its 
incorporation into phosphatidylcholine, a cell membrane constituent (Hara et al., 1998). The 
increased uptake of choline in tumour cells is thought to be related to the high rate of 
tumour cell duplication and cell membrane biosynthesis. In patients with oesophageal 
carcinoma, Kobori et al. reported that choline-PET was more sensitive than FDG-PET for 
detecting very small mediastinal lymph node metastases (Kobori et al., 1999). However, 
FDG-PET was more sensitive than choline-PET in detecting metastases in the upper 
abdomen due to intense normal uptake of choline in the liver. On the other hand, Pieterman 
et al. reported that both FDG and choline-PET visualised primary tumours of thoracic 
carcinoma but that the detection of lymph node metastases was inferior and the detection of 
brain metastases was superior to those of FDG-PET (Pieterman et al., 2002). Choline-PET 
does not appear to have been applied to the evaluation of gastric carcinoma.  
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Further investigations are needed to determine the value of FLT and choline-PET in gastric 
carcinoma. 
3. Conclusion 
FDG-PET has a limited role in primary tumour detection due to its low sensitivity, 
especially in early and non-intestinal gastric carcinoma. However, gastric distention by oral 
water may decrease physiological gastric uptake of FDG to result in better diagnostic 
accuracy for advanced gastric carcinoma. FDG-PET has a slightly better positive predictive 
value for the detection of lymph node metastasis in comparison to CT; furthermore, it has 
reasonable sensitivity for liver and lung metastases. FDG-PET, therefore, improves 
preoperative staging in advanced gastric carcinoma. FDG-PET could have a significant role 
in monitoring tumour response during neoadjuvant chemotherapy because it adequately 
detects therapy responders at an early stage. Furthermore, FDG-PET is accurate in 
predicting histopathological response and even long-term prognosis, making it a valuable 
adjunct to neoadjuvant gastric carcinoma treatment. The results of positron emission 
tomography in the evaluation and monitoring of gastric carcinoma may improve in the near 
future. The use of PET/CT fusion imaging has improved diagnostic performance in several 
carcinoma types (Czernin et al., 2007), and its use in gastric carcinoma is currently under 
investigation (Hur et al., 2010). The use of other PET tracers, such as FLT and choline, holds 
promise for the future. Therefore, continued research into PET imaging in gastric carcinoma 
should be advocated. 
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rule is late recurrence (> 5 years disease-free survival), which coincides with sporadic 
carcinoma mortality (Shiraishi et al., 2000). The extent of lymph node metastasis at primary 
diagnosis is the most important independent factor determining the timing of tumour 
recurrence (Shiraishi et al., 2000). Clinical surveillance is the most frequently used follow-up 
modality, as current endoscopic and radiologic (ultrasonography, barium study and CT) 
techniques are not sensitive enough for early recurrence detection and no reliable 
biochemical markers are known to correlate with recurrence (Jadvar et al., 2003; De Potter et 
al., 2002). Radiological examination, based on anatomical findings, is limited by 
postoperative non-cancerous changes. The detection of active neoplastic metabolism 
theoretically increases the advantage of FDG-PET over CT. However, FDG-PET lacks 
diagnostic accuracy in the early detection of recurrence, with sensitivity and negative 
predictive values of 70 and 60%, respectively (Jadvar et al., 2003). The high physiological 
remnant gastric uptake and the low spatial resolution of current hardware prevent the 
detection of early recurrence by FDG-PET (Jadvar et al., 2003; Yun et al., 2005). Creating 
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images could decrease the number of false-positive FDG-PET scans by locating FDG-avid 
foci on anatomical landmarks. 
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Other potentially useful PET tracers for the evaluation of gastric carcinoma are 3-deoxy-3-
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proven to be a stable PET tracer that accumulates in proliferating tissue and malignant 
tumours (Shields et al., 1998). FLT is a substrate for thymidine kinase 1, which is an enzyme 
involved in the production of thymidine monophosphate. Hermann et al. performed a pilot 
study assessing the feasibility of FLT-PET compared to FDG-PET in gastric carcinoma 
(Herrmann et al., 2007). They found a sensitivity of 100% of FLT-PET for primary tumour 
detection (60% of tumours were signet ring cell carcinoma), compared to a sensitivity of 
FDG-PET of 69%. Background activity was low. These findings suggest that FLT-PET is a 
potentially useful imaging modality for the detection and staging of gastric carcinoma, 
especially for histologic subtypes with low FDG uptake. Kameyama et al. also reported that 
the sensitivity of FLT-PET was as high as that of FDG-PET for the detection of gastric 
carcinoma (Kameyama et al., 2009). The cellular uptake of choline presumably reflects its 
incorporation into phosphatidylcholine, a cell membrane constituent (Hara et al., 1998). The 
increased uptake of choline in tumour cells is thought to be related to the high rate of 
tumour cell duplication and cell membrane biosynthesis. In patients with oesophageal 
carcinoma, Kobori et al. reported that choline-PET was more sensitive than FDG-PET for 
detecting very small mediastinal lymph node metastases (Kobori et al., 1999). However, 
FDG-PET was more sensitive than choline-PET in detecting metastases in the upper 
abdomen due to intense normal uptake of choline in the liver. On the other hand, Pieterman 
et al. reported that both FDG and choline-PET visualised primary tumours of thoracic 
carcinoma but that the detection of lymph node metastases was inferior and the detection of 
brain metastases was superior to those of FDG-PET (Pieterman et al., 2002). Choline-PET 
does not appear to have been applied to the evaluation of gastric carcinoma.  
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Further investigations are needed to determine the value of FLT and choline-PET in gastric 
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accuracy for advanced gastric carcinoma. FDG-PET has a slightly better positive predictive 
value for the detection of lymph node metastasis in comparison to CT; furthermore, it has 
reasonable sensitivity for liver and lung metastases. FDG-PET, therefore, improves 
preoperative staging in advanced gastric carcinoma. FDG-PET could have a significant role 
in monitoring tumour response during neoadjuvant chemotherapy because it adequately 
detects therapy responders at an early stage. Furthermore, FDG-PET is accurate in 
predicting histopathological response and even long-term prognosis, making it a valuable 
adjunct to neoadjuvant gastric carcinoma treatment. The results of positron emission 
tomography in the evaluation and monitoring of gastric carcinoma may improve in the near 
future. The use of PET/CT fusion imaging has improved diagnostic performance in several 
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1. Introduction 
With advances in endoscopic techniques and the widespread use, detection rates for early 
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due to their own inherent drawbacks, such as blurred visualization and/or legal restrictions 
(Hayashi et al., 2003; Hiratsuka et al., 2001; Ichikura et al., 2002; Kim, M.C. et al., 2004; 
Kitagawa & Kitajima, 2002; Miwa et al., 2003; Tanaka et al., 2004). Accordingly, standardized 
tracers remain to be determined.  
Photosensitizers are used for the treatment of various carcinomas in a remedy that is well 
known as photodynamic therapy (Fisher et al., 1995; Kvam et al., 1990; Sharman et al., 1999). 
Photosensitizing agents preferentially accumulate in tumor tissues, and elicit cytocidal 
effects on tumor cells when excited at a wavelength specific for each agent (Sharman et al., 
1999). Photodynamic therapy makes use of photosensitizers with these unique properties to 
achieve highly selective and localized treatment of various carcinomas (Sharman et al., 
1999). ATX-S10Na (II) is a hydrophilic chlorine derivative with a major absorption 
wavelength of approximately 670 nm, and emits red fluorescence when excited at its 
absorption wavelength. ATX-S10Na (II) has been developed as a second-generation 
photosensitizer, which is eliminated more rapidly from the body than previously known 
first-generation photosensitizers. Therefore, major adverse reactions such as skin 
photosensitivity have been markedly reduced, compared to those of the first generation 
photosensitizers (Matsumoto et al., 2003; Mori et al., 2000a, 2000b; Nakajima et al., 1992, 
1998). In addition, ATX-S10Na (II) has a high affinity and specificity for tumor tissues, and 
thereby selectively accumulates in tumor tissues (Matsumoto et al., 2003; Mori et al., 2000a, 
2000b; Nakajima et al., 1992, 1998). To our knowledge, our study was the first report that 
describes the use of a hydrophilic photosensitizer, ATX-S10Na (II), for the detection of SNs 
in orthotopic transplants of human gastric carcinoma (Koyama et al., 2007a).  
In the present chapter, we showed a novel fluorescence-guided imaging system to detect 
SNs using a photosensitizing agent, ATX-S10Na (II), as a novel fluorescent tracer, and its 
usefulness for a fluorescence-guided lymphatic mapping system in an animal model of 
human gastric carcinoma. In the model, human gastric carcinoma cells were implanted 
orthotopically into nude rats. ATX-S10Na (II) was injected subserosally into the primary 
tumor lesion, and visualized by a fluorescence spectrolaparoscope. ATX-S10Na (II) would 
serve as a novel tracer in sentinel node navigation surgery for gastric carcinoma.  
1.1 Concept of sentinel node 
The sentinel node (SN) is defined as the first lymph node (LN) to receive lymphatic drainage 
from a primary tumor, and therefore it is commonly accepted that SN is the first LN in 
which tumor cells from the primary lesion form lymphatic metastases (Sobin, 2003; Fig. 1). 
Detection of a metastatic tumor in the SN could mean metastasis of tumor cells to the 
downstream LNs. Conversely, absence of metastatic tumors in the SN indicates that the 
downstream LNs most likely do not contain metastatic tumor cells.  
2. Photosensitive fluorescent tracer 
ATX-S10Na (II) [13,17-bis(1-carboxypropionyl) carbamoylethyl-8-ethenyl-2-hydroxy-3- 
hydroxy-iminoethylidene-2,7,12,18-tetramethyl-prophyrin tetrasodium salt], is synthesized, 
purified and supplied by Photochemical Co. (Okayama, Japan). Its structure (C42H41N7Na4 
O12; molecular weight 927.77, Fig.2) and metabolism were described in detail previously 
(Matsumoto et al., 2003; Mori et al., 2000a, 2000b; Nakajima et al., 1992, 1998). When the 
photosensitizer is activated by irradiation with excitation light of 450±40 nm (mean ± SD), it 
emits a strong red fluorescence of 667 nm wavelength (Fig. 3). Therefore, we are able to 
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detect the sentinel node by the red fluorescence of ATX-S10Na (II) which is injected at the 
primary tumor. The reagent is stored as a powder in the dark at -80C, and dissolved in 
phosphate-buffered saline to a final concentration of 5 mg/ml each time immediately before 
use. 
3. Orthotopic xenograft model of human gastric carcinoma 
3.1 Cell line 
The OCUM-2M LN cell line was originally derived from human scirrhous gastric carcinoma 
(Fujihara et al., 1998). This cell line forms LN metastases, when it is injected orthotopically 
into the stomach of athymic nude rats. Cells are cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal calf serum, 100 U/ml penicillin, and 100 
mg/ml streptomycin in a humidified atmosphere containing 5% CO2 at 37C. The cells in 
the log phase of growth are washed twice with phosphate-buffered saline, treated with 
trypsin and collected by centrifugation. The cell pellets are dissolved in DMEM and 
adjusted at a concentration of 5×107 cells/ml. Cells are used in the experiments only when 
their viability exceeds 95%, as determined by the trypan blue dye-exclusion test.  
3.2 Tumor cell implantation 
Five- to seven-week-old female athymic nude rats (F344/N Jcl-rnu; CLEA Japan, Co., Tokyo, 
Japan) are housed in a temperature-controlled pathogen-free facility, maintained on a 12- 
hour light/12-hour dark cycle, and provided with commercially available rat chow and tap 
water ad libitum. Rats are pretreated by irradiation with 3 Gy of X-rays 3 days before tumor 
cell inoculation to reduce the number of active natural killer lymphocytes (Fig. 4). Rats are 
anesthetized for all procedures by an intraperitoneal injection of pentobarbital sodium (40 
mg/kg body weight), and then an incision is made in the upper abdominal median line. The 
stomach is exposed, and a total of 1×106 OCUM-2M LN cells in a volume of 20 μl of DMEM 
is injected subserosally into the middle anterior wall of the lesser curvature of the stomach 
with a 29-gauge needle. After the orthotopic implantation of tumor cells, the abdominal wall 
is sutured and closed using 6-0 surgical sutures. All procedures are performed in a patho- 
gen-free environment. To monitor the growth of inoculated tumor cells, sera are obtained by 
periorbital bleeding weekly, and the serum levels of CA19-9, a marker of tumor growth, are 
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measured by radioimmunoassay using a commercially available kit (Fujirebio, Inc., Tokyo). 
When the level of serum CA19-9 values increases above 6 units/ml, which is a sign of tumor 
growth, the presence of SNs is investigated with a fluorescence spectrolaparoscope. 
3.3 Establishment of orthotopic xenograft 
In our experiment, 95% of nude rats inoculated with tumor cells showed the establishment 
of orthotopic xenografts of human gastric carcinoma (Koyama et al, 2007a). The primary 
lesions of the implanted tumors grew up to the median size of 5.0 mm (range, 2.2–8.2 mm) 
by the largest diameter. In tumor-bearing rats, the median size of the left gastric LNs (Lg-
LNs) was 3.9 mm (range, 2.5-14.3 mm) in diameter. Fig. 5 shows a representative example of 
the primary lesion in the stomach and the enlarged Lg-LN. Subserosally inoculated OCUM-
2M LN cells developed into a solid tumor (“primary lesion”; Fig. 5, black arrowhead) at the 
middle anterior wall of the lesser curvature of the stomach. Enlarged Lg-LN (Fig. 5, white 
arrowhead), which had tumor metastases, was also observed. The corresponding Lg-LN 
specimen displays poorly differentiated adenocarcinoma, which is a characteristic feature of 
OCUM-2M LN, human scirrhous carcinoma of the stomach (Fig. 6; bar = 100 µm).  
To confirm the presence of tumor cells in LNs (LN metastasis), human β-actin was amplified 
specifically by cDNA synthesis of total RNA extracted from tissue samples and subsequent 
reverse transcriptase-polymerase chain reaction (RT-PCR). The LN metastases were 
histopathologically observed in 56% of tumor-bearing rats. These tissues were positive for 
human β-actin by RT-PCR (Koyama et al, 2007a). Control rats did not develop solid tumors 
and showed no changes in the lymphatic system.  
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4. Detection of sentinel nodes by fluorescence spectrolaparoscope 
4.1 Fluorescence spectrolaparoscope 
Re-laparotomy is performed on tumor-implanted rats under general anesthesia, when 
serum CA19-9 concentrations increase above 6 units/ml. After an exposure of the stomach, 
ATX-S10Na (II) solution at a total volume of 40–60 μl is injected using a 29-gauge needle into 
the serosal side of the implanted tumor [Fig. 7(a)]. ATXS10Na (II) injected into the primary 
lesion is excited by the light of 450±40 nm [Fig. 7(b), 7(c) and 7(d)], which is emitted from the 
tip of the laparoscope equipped with a xenon lamp and a bandpass excitation filter of 
450±40 nm. ATX-S10Na (II) localized in tissues emits fluorescence of 667 nm, which is 
visualized using a bandpass emission filter of >510-nm. The emission filter is useful for 
blocking the excitation light and other components such as natural autofluorescence of the 
surrounding tissues. An image-intensified charge-coupled device (CCD) camera is 
furnished with two built-in filters, a conventional white-light filter and an emission filter of 
>510-nm, and is attached to the ocular end of the laparoscope through the adaptor. The 
dynamic image of excited ATX-S10Na (II) is monitored in real-time on an RGB display via an 
image processing system, and recorded on a camcorder with 192×104 pixels for 60 minutes 
after the injection. The intensity and exposure time of the excitation light are constant 
throughout these experiments. 
4.2 Dynamic imaging and distribution of photosensitizer 
Fluorescence distribution of ATX-S10Na (II) in the abdomen is visualized as vivid red color 
on the imaging board using the spectrolaparoscope. In tumor-bearing rats, ATX-S10Na (II) 
solution is injected into the tumor of primary lesion via stomach serosa using a 29-gauge 
syringe [Fig. 7 (a); white arrowhead]. The red-fluorescent ATX-S10Na (II) is clearly identified 
and uptaken rapidly into the lymphatic tissue around the primary lesion [Fig. 7 (b)]. 
Subsequently, the red-emitting fluorescence is incorporated rapidly into the Lg-LN [Fig. 7 
(c) and (d); white arrowhead] through the afferent lymphatic vessels [Fig. 7 (c) and (d); 
white arrows]. The migration of ATX-S10Na (II) takes place within a period of 5 minutes of 
the injection. The fluorescence intensity increases, reaching a peak and plateau 
approximately at 1–9 minutes, and persists without attenuation during the entire observa- 
tion time. In contrast, no or little fluorescence is detected in the surrounding non-lymphatic 
tissues. The contrast between the red fluorescent tissues and non-fluorescent area is distinct, 
and all investigators can identify the red fluorescent nodes easily. In control rats, fluorescent 
dye is incorporated rapidly into the lymph vessels around the injection site, migrates 
through them and disappears within 3 minutes. Of note, none of the LN is stained with the 
fluorescence in the control rats. 
4.3 Sentinel nodes and nodal metastases 
According to the sentinel node (SN) concept, the first LN into which ATX-S10Na (II) flows is 
regarded as the “SN”. Fig. 8 shows an example in which ATX-S10Na (II) was incorporated 
rapidly into afferent lymphatic vessels around the primary lesion, lymphatic network, and 
flowed first into the Lg-LN. Thus, the Lg-LN was regarded as the SN. The Lg-LN was 
occupied with tumor cell metastases, showing poorly differentiated adenocarcinoma with a 
characteristic feature of OCUM-2M LN, human scirrhous carcinoma of the stomach [Fig. 8 
(d); hematoxylin and eosin stain], and was visualized by the red-fluorescence of ATX-S10Na 
(II) [Fig. 8 (a), (b) and (c)]. The incision was made in the isolated red-fluorescent Lg-LN at 
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(a) Injection of ATX-S10Na (II)                 (b) Uptake into lymphatic tissue 
    
(c) Visualization of lymph nodes               (d) Visualization of lymph nodes 
Fig. 7. Detection of lymphatic tissues by ATX-S10Na (II) 
the dotted line [Fig. 8 (b)], and the uptake of red fluorescence into metastatic lesion was 
observed as shown in Fig. 8 (c) and (d). We provisionally termed the red-fluorescent LNs 
“red nodes’’, similar to those designated as ‘‘blue or green nodes’’ using vital dyes (Hayashi 
et al., 2003; Hiratsuka et al., 2001; Ichikura et al., 2002) or ‘‘hot nodes’’ using radioactive 
particles (Hayashi et al., 2003).  
After the completion of each experiment, the Lg-LN (SN) was separated, and the other LNs 
located downstream of Lg-LN or SN, including the hepatic, splenic and pancreatico- 
duodenal LNs, were harvested en bloc. In all LN samples dissected, the presence of human 
β-actin mRNA was investigated by RT-PCR to assess the presence of metastases of tumor 
cells (Koyama et al., 2007a). In 25 out of 27 rats, ATX-S10Na (II) was incorporated into the 
Lg-LN (SN), which was identified as a red node. Of note, human β-actin was positive in 24 
out of these 25 red nodes (SNs). To our surprise, human β-actin was also positive in all LNs 
located downstream of human-β-actin-positive red-fluorescent Lg-LNs (SNs) in these 24 
rats. In contrast, human β-actin was negative in the downstream LNs of the rat with a 
human-β-actin-negative red-fluorescent Lg-LN (SN). In the remaining 2 out of 27 rats, the 
ATX-S10Na (II) was incorporated into the hepatic LNs (SNs), but not into the Lg-LN (non-
SN). Therefore, the hepatic LN but not the Lg-LN was identified as a red node (SN) in these 
two rats. Interestingly, both of the two non-red Lg-LNs (non-SNs) were negative for human 
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(a) Injection of ATX-S10Na (II)                 (b) Uptake into lymphatic tissue 
    
(c) Visualization of lymph nodes               (d) Visualization of lymph nodes 
Fig. 7. Detection of lymphatic tissues by ATX-S10Na (II) 
the dotted line [Fig. 8 (b)], and the uptake of red fluorescence into metastatic lesion was 
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located downstream of human-β-actin-positive red-fluorescent Lg-LNs (SNs) in these 24 
rats. In contrast, human β-actin was negative in the downstream LNs of the rat with a 
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(a) Uptake of ATX-S10Na (II)                  (b) Incision into isolated Lg-LN 
   
(c) Incised side of isolated Lg-LN              (d) Histopathological findings 
Fig. 8. Lymph nodes detected by ATX-S10Na (II) 
β-actin, whereas both of the two red-fluorescent hepatic LNs (SNs) were positive for human 
b-actin. On the single-section specimens, 19 human-β-actin-positive red-fluorescent Lg-LNs 
were poorly differentiated adenocarcinoma, and others showed no malignant findings. In 
control rats, human β-actin was negative in both Lg-LNs and other LNs.  
 
 
Fig. 9. Uptake of ATX-S10Na (II) in Case 1         
Novel Biomedical Imaging Approach for Detection 




Fig. 10. Uptake of ATX-S10Na (II) in Case 2 
 
 
Fig. 11. Isolation of red-emitting Lg-LN stained with ATX-S10Na (II) 
In another two examples (Fig. 9 and 10), red-fluorescent ATX-S10Na (II) was incorporated 
rapidly into afferent lymphatic vessels around the primary lesion, lymphatic network, and 
flowed first into the Lg-LN. The lymph nodes as well as afferent lymphatic vessels were 
visualized vividly by this method. Although Case 2 (Fig. 10) was bleeding heavily during 
experiment, red-emitting LNs were detected easily. After the completion of observation, a 
red- emitting Lg-LN with metastasis of poorly differentiated adenocarcinoma was harvested 
and dissected in Case 1 (Fig. 11). The LN continued to emit red fluorescence in the similar 
degree of intensity at least for 30 minutes. Thus, ATX-S10Na (II) could efficiently visualize 
lymphatic network around the primary lesion, afferent lymphatic vessel and sentinel node. 
This method is simple and convenient, since it dose not require radioisotope or gamma probe. 
5. Advantage of photosensitizer to tracer 
5.1 Visualization of sentinel nodes by strong emission of red fluorescence 
ATX-S10Na (II) emits strong red fluorescence with excitation wavelength (Nakajima et al., 
1998). As shown in Fig. 7 to 10, the distribution of ATX-S10Na (II) in lymphatic network can 
be detected clearly and easily by the red fluorescence marking. This photographic 
visualization allows any observer to clearly identify SNs, and to easily determine the 
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location and orientation of SNs in the orthotopic xenograft animal model. Such direct real-
time visualization is not possible using radioactive tracers, which must be measured by 
scintillation probes or gamma camera (Hayashi et al., 2003; Kim et al., 2004; Kitagawa & 
Kitajima, 2002; Tanaka et al., 2004). Of note, this novel procedure would be easily conducted 
in human and in community hospitals without difficulties, because it does not require 
complicated procedures, special facilities or radioactive substances. Other non-fluorescent 
dye tracers (Hiratsuka et al., 2001; Ichikura et al., 2002; Hayashi et al., 2003; Miwa et al., 
2003; Tanaka et al., 2004) cannot provide such a vivid and colorful contrast. The visual and 
technical advantage of ATX-S10Na (II) may assist every surgeon to assess SNs accurately in 
sentinel node navigation surgery, and potentially prevent an oversight for false-negative 
LNs.  
5.2 Rapid incorporation into lymphatic tissues 
As a general rule, photosensitizers are systemically administered via a peripheral intrave- 
nous route before laser irradiation in photodynamic therapy for various carcinomas. As 
shown in Fig. 7, however, ATX-S10Na (II) is incorporated rapidly into lymphatic tissues after 
subserosal injection into the primary tumor. Our study confirmed for the first time that 
ATX-S10Na (II) is taken up by local lymphatic tissues when it is subserosally injected into 
the primary tumor lesion (Koyama et al., 2007a). One possible explanation for the 
phenomenon is that the chemical structure of ATX-S10Na (II) is water-soluble, but not lipid-
soluble (Matsumoto et al., 2003; Mori et al., 2000a, 2000b; Nakajima et al., 1992, 1998). Since 
the uptake of ATX-S10Na (II) into lymphatic system is rapid and its fluorescence can be 
consistently observed in real time, this approach appears to be useful for shortening the time 
required for SN biopsy and surgical procedure. Of importance, the ATX-S10Na (II)-guided 
method is not associated with the “shine-through’’ phenomenon, whereby the large hot spot 
at the injection site of radioactive tracers disturbs the detection of SNs around the primary 
tumor lesion.  
5.3 High affinity and specific uptake to tumor cells 
ATX-S10Na (II) is a high affinity molecule for tumor cells. Its preferential uptake in target 
tumor cells results in selective accumulations in tumor tissues, indicating that the tumor- 
specificity of photodynamic therapy depends largely on the oncotropic properties of photo- 
sensitizers (Fisher et al., 1995; Kvam et al., 1990; Matsumoto et al., 2003; Mori et al., 2000a, 
2000b; Nakajima et al., 1992, 1998; Sharman et al., 1999). As shown in Fig. 8, ATX-S10Na (II) 
can be taken up by LNs that are involved with tumor metastases. However, the precise 
mechanisms of tumor-specific uptake of ATX-S10Na (II) remain unclear. It is proposed that 
ATX-S10 Na (II) is incorporated into tumor cells by fluid phase endocytosis, receptor-
mediated endocytosis, or orphan transporters (Mori et al., 2000b). Alternatively, another 
possible mechanism is that lymphatic flow is delayed or altered in LNs filled with metastatic 
tumor cells, resulting in preferential retention of ATX-S10Na (II) in such LNs. In our 
previous study, the presence of tumor metastases in LNs was assessed by RT-PCR of human 
β-actin (Koyama et al., 2007a). To our surprise, human β-actin was positive in all LNs 
located downstream of human-β-actin-positive Lg-LN that was regarded as SN. In contrast, 
LNs located downstream of human-β-actin-negative Lg-LN (SN) were negative for human 
β-actin. In addition, all human-β-actin-positive Lg-LNs (SNs) were red nodes, whereas all 
non-red Lg-LNs (non-SNs) were human β-actin-negative. Considering the higher positive 
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rates by RT-PCR assay than conventional histopathological examination (Bilchik et al., 2001; 
Kitagawa & Kitajima, 2002; Maruyama et al., 1999; Natsugoe, et al., 1998; Noura et al., 2002), 
these results showed high sensitivity and specificity of the ATX-S10Na (II)-guided method 
for the detection of SNs. Because micrometastasis occurs frequently in gastric carcinoma, the 
system using ATXS10Na (II) may be a novel technology to detect micrometastases with high 
sensitivity, resulting in reduction of false-negative LNs. 
5.4 Little toxicity in human 
No obvious toxicity was observed in rats that were injected locally with ATX-S10Na (II) at a 
dose of 1.3–2.5 mg/kg in our study (Koyama et al., 2007a). This dosage is much smaller than 
that of systemic administration given intravenously at a dose of 5–25 mg/kg, which caused 
little, if any, toxicity in vivo (Matsumoto et al., 2003; Mori et al., 2000a; Nakajima et al., 1992, 
1998). Since ATX-S10Na (II) is a hydrophilic photosensitizer with a low-molecular weight, its 
clearance from tissues and body (within 24 hours) is much faster than that of the first 
generation photosensitizers. Therefore, it has substantially less adverse effects (Matsumoto 
et al., 2003; Mori et al., 2000a; Nakajima et al., 1992; Nakajima et al., 1998). We acknowledge 
that our studies were conducted in an orthotopic xenograft rat model (Koyama et al, 2007a, 
2007b), in which the structure and anatomy of the regional lymphatic network may be 
different from those of human system (Ichikura et al., 2002; Miwa et al., 2003). Alternatively, 
the rat model may not be comparable to early gastric carcinoma in humans, for which 
sentinel node navigation surgery is more suitable (Hiratsuka et al., 2001; Isozaki et al., 2004). 
Clear visualization of lymphatic system by ATX-S10Na (II) may be only true of the animal 
model. However, our studies do demonstrate the potential usefulness of ATX-S10Na (II) as a 
tracer of SNs by assessing tumor metastases with RT-PCR (Koyama et al., 2007a, 2007b). In 
25 out of 27 rats, Lg-LN (SN) was identified as a red node, and most of these Lg-LNs (SNs) 
were positive for human β-actin, which was an indication of tumor metastasis. Of interest, 
ATX-S10Na (II) was incorporated into the hepatic LN (SN), but not into the Lg-LN (non-SN) 
in two out of 27 rats, and human β-actin was positive only in the hepatic LN (SN), but not in 
the Lg-LN (non-SN) in these rats. These findings support the notion that SN is the first LN 
to receive lymphatic drainage and tumor cells from a primary tumor, and ATX-S10Na (II) is 
useful for the detection of SNs. 
6. Other dye tracers and comparison with ATX-S10Na (II) 
Patent blue violet (Hayashi et al., 2003; Karube et al., 2004; Miwa et al., 2003; Simsa et al., 
2003), isosulfan blue (Hundley et al., 2002; Isozaki et al., 2004; Lee et al., 2005; Osaka et al., 
2004; Ryu et al., 2003; Song t al., 2004) and indocyanine green (ICG) (Hiratsuka et al., 2001; 
Ichikura et al., 2002; Nimura et al., 2004) have been used as vital dye tracers for the detection 
of SNs in gastric carcinoma. The detection rates of SNs were 72–96%, 91–100% and 99–100%, 
respectively. These favorable results must be carefully interpreted because SN mapping is 
dependent on the technical learning curve and skills of the surgeon (Ichikura et al., 2002; 
Simsa et al., 2003; Nimura et al., 2004). The sensitivity was 77–90%, 46–100% and 64–90%, 
respectively, suggesting that non-SNs could contain tumor cell metastases. In most of these 
reports, the presence of metastasis in LNs was determined by conventional haematoxylin 
and eosin staining. False-negative rates may increase when more sensitive methods such as 
multiple sectioning, immunohistochemical staining or RT–PCR technique are used.  
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Some biomedical imaging techniques use the characteristic feature of ICG; this dye absorbs 
infrared rays, which enhances its visibility (Flower & Hochheimer, 1976; Kohso et al., 1990). 
Enhanced visualization of ICG by using a near-infrared endoscopy substantially improves 
the rate of SN detection in patients with gastric carcinoma, compared with the use of ICG 
alone (Nimura et al., 2004). Interestingly, SNs illuminated with a near-infrared endoscope 
are clear enough to be identified by all observers, whereas SNs stained by ICG alone are not 
always visible to all investigators. As a result, the ICG-guided method combined with a 
near- infrared endoscope was reported to increase the sensitivity significantly from 64% of 
patients and 50% of LNs to 100% and 100%, respectively (Nimura et al., 2004). The combi- 
nation method appears to be a promising approach for biomedical imaging in living 
tissue.  
As shown in Fig. 7 to 10, the rapid migration of ATX-S10Na (II) along the lymphatic system 
is clearly visualized and easily identified in real time by the strong red fluorescence. Such 
visualization is clearer than that of enhanced visualization of ICG with a near-infrared 
laparoscope (Koyama et al., 2007b). Since a much darker operating room is required to 
ensure the detection of ICG through a near-infrared endoscopy, it may be difficult to 
perform other procedures. One explanation for the high-quality visualization of ATX-S10Na 
(II) is that the excitation wavelength peak (450 ± 40 nm) is completely separate from the 
emission wavelength peak (667 nm). With the visual advantage of ATX-S10Na (II), SNs 
would not be missed, and the time required for the surgical procedure may be shortened. 
In a comparative study using an orthotopic xenograft rat model, there was no significant 
difference in the detection rates of SNs, the sensitivity, and the number of stained nodes 
between ATX-S10Na (II) - and enhanced ICG-guided methods (Koyama et al., 2007b). These 
results suggest that the ATX-S10Na (II)-guided method is comparable to or possibly superior 
to the enhanced ICG-guided method. In addition, the number of ICG-stained nodes varies 
widely, since the number and distribution of stained nodes become larger and wider as the 
injection dose is increased (Ichikura et al., 2002). In the dual-mapping technique with dye 
and radioactive tracers, significant differences in distributions are noted between the two 
tracers (Hayashi et al., 2003; Karube et al., 2004). These findings raise the question of 
whether dye or radioactive traces flow into the lymphatic system in the same manner as 
metastatic cancer cells. ATX-S10Na (II) may resolve the issue, because it has a high 
specificity and affinity for tumor cells (Nakajima et al, 1992, 1998; Mori et al., 2000b). In the 
future, novel fluorescence-based reagents (Kim, S. et al., 2004; Ueno et al., 2005), including 
photosensi- tizers, will be developed as tracers that improve diagnostic accuracy in sentinel 
node navigation surgery.  
7. Conclusion 
A novel system using a hydrophilic photosensitizer ATX-S10Na (II) in combination with a 
fluorescence spectrolaparoscope is useful for the detection of cancer-containing sentinel 
nodes in an orthotopic xenograft animal model of human gastric carcinoma. ATX-S10Na (II) 
would serve as a novel tracer in sentinel node navigation surgery. This system has great 
potential application for the decision of minimally invasive surgery without radical 
extensive regional lymphadenectomy in early gastric carcinoma. A comparative study of 
ATX-S10Na (II) versus other dye tracers will determine whether the red-fluorescent tracer 
system is useful for lymphatic mapping in sentinel node navigation surgery for patients 
with early gastric carcinoma. 
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Some biomedical imaging techniques use the characteristic feature of ICG; this dye absorbs 
infrared rays, which enhances its visibility (Flower & Hochheimer, 1976; Kohso et al., 1990). 
Enhanced visualization of ICG by using a near-infrared endoscopy substantially improves 
the rate of SN detection in patients with gastric carcinoma, compared with the use of ICG 
alone (Nimura et al., 2004). Interestingly, SNs illuminated with a near-infrared endoscope 
are clear enough to be identified by all observers, whereas SNs stained by ICG alone are not 
always visible to all investigators. As a result, the ICG-guided method combined with a 
near- infrared endoscope was reported to increase the sensitivity significantly from 64% of 
patients and 50% of LNs to 100% and 100%, respectively (Nimura et al., 2004). The combi- 
nation method appears to be a promising approach for biomedical imaging in living 
tissue.  
As shown in Fig. 7 to 10, the rapid migration of ATX-S10Na (II) along the lymphatic system 
is clearly visualized and easily identified in real time by the strong red fluorescence. Such 
visualization is clearer than that of enhanced visualization of ICG with a near-infrared 
laparoscope (Koyama et al., 2007b). Since a much darker operating room is required to 
ensure the detection of ICG through a near-infrared endoscopy, it may be difficult to 
perform other procedures. One explanation for the high-quality visualization of ATX-S10Na 
(II) is that the excitation wavelength peak (450 ± 40 nm) is completely separate from the 
emission wavelength peak (667 nm). With the visual advantage of ATX-S10Na (II), SNs 
would not be missed, and the time required for the surgical procedure may be shortened. 
In a comparative study using an orthotopic xenograft rat model, there was no significant 
difference in the detection rates of SNs, the sensitivity, and the number of stained nodes 
between ATX-S10Na (II) - and enhanced ICG-guided methods (Koyama et al., 2007b). These 
results suggest that the ATX-S10Na (II)-guided method is comparable to or possibly superior 
to the enhanced ICG-guided method. In addition, the number of ICG-stained nodes varies 
widely, since the number and distribution of stained nodes become larger and wider as the 
injection dose is increased (Ichikura et al., 2002). In the dual-mapping technique with dye 
and radioactive tracers, significant differences in distributions are noted between the two 
tracers (Hayashi et al., 2003; Karube et al., 2004). These findings raise the question of 
whether dye or radioactive traces flow into the lymphatic system in the same manner as 
metastatic cancer cells. ATX-S10Na (II) may resolve the issue, because it has a high 
specificity and affinity for tumor cells (Nakajima et al, 1992, 1998; Mori et al., 2000b). In the 
future, novel fluorescence-based reagents (Kim, S. et al., 2004; Ueno et al., 2005), including 
photosensi- tizers, will be developed as tracers that improve diagnostic accuracy in sentinel 
node navigation surgery.  
7. Conclusion 
A novel system using a hydrophilic photosensitizer ATX-S10Na (II) in combination with a 
fluorescence spectrolaparoscope is useful for the detection of cancer-containing sentinel 
nodes in an orthotopic xenograft animal model of human gastric carcinoma. ATX-S10Na (II) 
would serve as a novel tracer in sentinel node navigation surgery. This system has great 
potential application for the decision of minimally invasive surgery without radical 
extensive regional lymphadenectomy in early gastric carcinoma. A comparative study of 
ATX-S10Na (II) versus other dye tracers will determine whether the red-fluorescent tracer 
system is useful for lymphatic mapping in sentinel node navigation surgery for patients 
with early gastric carcinoma. 
Novel Biomedical Imaging Approach for Detection 
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1. Introduction 
Even though an overall incidence of the gastric cancer has been declined it remains as the 
second leading cause of  cancer-related deaths world widely with the highest incidence in 
Korea and Japan. [1] 
Over the past decade, however, the overall survival rate of patients with gastric cancer has 
been increased. This increased survival resulted from not only the early detection with an 
intensive surveillance in accordance of the development of an endoscopy but also the 
aggressive surgery approaches including an extensive lymph node dissection; combined 
with a resection of adjacent organs, if indicated. Additionally the improved perioperative 
management on the patients has improved the survival. [2] 
Since the first case of a laparoscopy-assisted gastrectomy was reported by Kitano et al. in 
1994, [3] the number of patients underwent  laparoscopic gastrectomy for early gastric 
cancer (EGC) has been increased rapidly especially in Korea and Japan, where there is a 
high incidence of EGC. According to survey by the Korean Gastric Cancer Association in 
2009, the number of gastric cancer operations performed laparoscopically has surprisingly 
increased (Fig. 1). 
The technical innovations in laparoscopic instrument and the advances in the surgical 
techniques  have allowed for a widespread acceptance of a laparoscopic surgery in gastric 
cancer management. The Advantages of the laparoscopic gastrectomy over the conventional 
open surgery include a reduced postoperative pain, an enhanced recovery, a shorter 
hospital stay, and a better cosmesis. [4,5] Although there is a high level of an  evidence to 
support short-term efficacy of a laparoscopic gastrectomy for EGC, still the long term results 
accounts on the patients’ survival  are still infrequent. The technical feasibility of the 
laparoscopic radical lymphadenectomy must need to be proven in the long-term, and the 
oncologic concerns involved in laparoscopic gastrectomy such as the oncological effects of a 
pneumoperitoneum, must still be resolved. A prospective multi-center randomized clinical 
trial has started to assess the short- and long-term outcomes of laparoscopic gastrectomy for 
early stage gastric cancer (KLASS trial, Korean Laparoscopic Gastro-intestinal Surgery 
Study Group) on March 2005.  
This review will summarize the current status for laparoscopic surgery for gastric cancer, 
ongoing controversies on the clinical trial, and the future perspectives of the minimally 
invasive treatment.  
 5 
Laparoscopic Surgery for Gastric Cancer 
Kyo Young Song and Jung Ho Shim 
Division of Gastrointestinal Surgery, Department of Surgery, 
Minimal Access and Robotic Surgery Center, Seoul St. Mary’s Hospital, 
College of Medicine, The Catholic University of Korea, Seoul, 
Republic of Korea 
1. Introduction 
Even though an overall incidence of the gastric cancer has been declined it remains as the 
second leading cause of  cancer-related deaths world widely with the highest incidence in 
Korea and Japan. [1] 
Over the past decade, however, the overall survival rate of patients with gastric cancer has 
been increased. This increased survival resulted from not only the early detection with an 
intensive surveillance in accordance of the development of an endoscopy but also the 
aggressive surgery approaches including an extensive lymph node dissection; combined 
with a resection of adjacent organs, if indicated. Additionally the improved perioperative 
management on the patients has improved the survival. [2] 
Since the first case of a laparoscopy-assisted gastrectomy was reported by Kitano et al. in 
1994, [3] the number of patients underwent  laparoscopic gastrectomy for early gastric 
cancer (EGC) has been increased rapidly especially in Korea and Japan, where there is a 
high incidence of EGC. According to survey by the Korean Gastric Cancer Association in 
2009, the number of gastric cancer operations performed laparoscopically has surprisingly 
increased (Fig. 1). 
The technical innovations in laparoscopic instrument and the advances in the surgical 
techniques  have allowed for a widespread acceptance of a laparoscopic surgery in gastric 
cancer management. The Advantages of the laparoscopic gastrectomy over the conventional 
open surgery include a reduced postoperative pain, an enhanced recovery, a shorter 
hospital stay, and a better cosmesis. [4,5] Although there is a high level of an  evidence to 
support short-term efficacy of a laparoscopic gastrectomy for EGC, still the long term results 
accounts on the patients’ survival  are still infrequent. The technical feasibility of the 
laparoscopic radical lymphadenectomy must need to be proven in the long-term, and the 
oncologic concerns involved in laparoscopic gastrectomy such as the oncological effects of a 
pneumoperitoneum, must still be resolved. A prospective multi-center randomized clinical 
trial has started to assess the short- and long-term outcomes of laparoscopic gastrectomy for 
early stage gastric cancer (KLASS trial, Korean Laparoscopic Gastro-intestinal Surgery 
Study Group) on March 2005.  
This review will summarize the current status for laparoscopic surgery for gastric cancer, 
ongoing controversies on the clinical trial, and the future perspectives of the minimally 
invasive treatment.  
 




Fig. 1. Annual number of laparoscopic procedures performed for gastric adenocarcinoma in 
Korea. Orange bar, wedge resection; yellow bar, distal gastrectomy; green bar, total 
gastrectomy; sky blue bar, gastrojejunostomy; purple bar, other procedures 
2. History and the current status of laparoscopic surgery for gastric cancer 
The history of laparoscopic gastric surgery dates from 1992, when Peter Goh of Singapore 
performed the first entirely laparoscopic Billroth II distal gastrectomy on a patient 
affected with chronic gastric ulcer. [6] The first laparoscopic wedge resection for gastric 
cancer was carried out by Ohgami et al. [7] They used a T-fastener and performed an 
intragastric mucosal resection for a patient with EGC in 1992. (Fig. 2) And Ohashi et al. 
attempted the intragastric mucosal resection (IGMR) for EGC of the stomach located at 
the posterior wall for the first time [8]. The aim of both procedures was to minimize the 
extent of gastric resection for the treatment of a malignant disease with a low risk of 
lymph node metastasis, therefore to reduce  the accompanying  physiologic side effects by 
the standard gastrectomy. 
In June 1993, J.S. Azagra performed their first laparoscopic gastrectomy for gastric cancer. 
[9] Kitano et al. had reported the first laparoscopy-assisted distal gastrectomy (LADG) with 
D1+α lymph node dissection for EGC in 1994. Since then, various  types of laparoscopic 
gastric surgery have been successfully performed using laparoscopy. Recent advances in 
techniques for performing the lymph node dissection and the development of new 
instrumentations, such as stapling devices and ultrasonic devices, have made it possible to 
perform almost all the procedures in gastrectomy with lymphadenectomy laparoscopically 
which comparable to the open conventional surgery.  Function-preserving surgery, such as 
pylorus preserving surgery, proximal gastrectomy, and segmental gastrectomy has been 
also successfully performed by laparoscopy.  
 




Source : World J Surg 1999;23:187-193. [7] 
Fig. 2. Lesion lifting technique with T-fastener originally reported by Ohgami et al. in 1992. 
Recently, these laparoscopic gastrectomies have been increased remarkably in Japan and 
Korea. A national Japanese survey showed that more than 4500 patients with gastric cancer 
underwent laparoscopic gastrectomy in 2007. [10] Although LADG was first reported as a 
minimally invasive surgery for EGC, some aggressive surgeons successfully performed  
extended (D2) lymph node dissection on patient so that LADG can be used to treat AGC. 
[11,12] There are surgeons who are now trying to expand the indications of laparoscopy-
assisted gastrectomy to the treatment options for an advanced gastric cancer. In 1999, 
Uyama et al. [13] reported the result of LADG with D2 lymph node dissection for advanced 
cancer. With the exception of early reports, the retrieved number of lymph nodes in 
laparoscopic surgery for advanced gastric cancer has been reported as equivalent to that in 
open surgery. Korean surgeons could acquire advanced-laparoscopic skills for gastrectomy 
by maintaining the exchange fellowship program and the clinical researches with the expert 
in Japan. Considering that the majority of gastric cancer patients in Korea are managed by a 
limited number of  experts at high-volume centers, it was easy for the Korean surgeons to 
catch up with high level of the proficiency. The wide acceptance and the development of  
laparoscopic surgery for malignant gastric disease in the West have been increased slowly.  
Laparoscopy-assisted  distal, subtotal, or total gastrectomy for early and advanced gastric 
cancer is now emerging in the West with progressive acceptance among various groups, 
although this upward trend  has been slowed by the difference in natural history of gastric 
adenocarcinoma in the East compared with the West. [14] 
3. Optimal extent of lymph node dissection for gastric cancer 
The extent of lymph node dissection for gastric cancer has consistently been a subject of 
debate world widely. Three types of laparoscopic lymph node dissection are performed 
(Table 1): perigastric lymph node dissection (D1 + α), additional lymph node dissection 
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along the common hepatic artery (D1 + β), and extended lymph node dissection covered for 
non-regional lymph nodes. (D2). [15]  
 
 
Source: Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma; 2nd English 
Edition. [15] 
Fig. 3. Perigastric regional lymph node stations. 
D2 dissection has been a standard procedure in Japan and Korea although it was not based 
on the clinical trial. Two European randomized trials comparing D2 with D1 dissection was 
failed to  show a survival benefit of D2 dissection, which was resulted in  high rate of a 
postoperative mortality. [16, 17] However, the survival benefit in these trials seems to be 
biased on the technical factors and the patients’ selection factors which was resulted in the 
high rate of  postoperative complications and high operative mortality rates. A report from 
the retrospective analyses series have shown superior stage-by-stage survival rates when 
compared with data from other countries in which D2 dissection is not a standard 
procedure. Extended lymph node dissection remains a standard of care in the Far East and 
also in Western specialized units where it can be conducted safely. [18] 
 
D0 : No dissection or incomplete dissection of the Group 1 nodes 
D1 : Dissection of all the Group 1 nodes 
D2 : Dissection of all the Group 1 and Group 2 nodes 
D3 : Dissection of all the Group 1, Group 2 and Group 3 nodes 
Table 1. Definition of lymph node dissection(D) 
With the advances of laparoscopic technique in gastric cancer surgery, the standard surgical 
procedure for EGC has been discussed. Initially, laparoscopic gastrectomy was indicated 
only for EGC patients with a low risk of lymph node metastasis. The Japanese Gastric 
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Cancer Association proposed clinical guidelines for the treatment of gastric cancer in 2001. 
Based on those recommendations, laparoscopic gastrectomy (LG) is recommended for 
gastric cancer patients with a preoperative stage Ia (cT1N0M0) diagnosis. Although a 
number of institutes adhere to the guideline, laparoscopic gastrectomy has also been 
referred to as a pre-established technique that is still under clinical investigation due to the 
uncertain quality of lymph node dissection and the lack of proof based on long term follow-
up data. [15] 
Yasuda et al. [19] recommended D1 + α lymph node dissection for submucosal cancer 
measured  1–4 cm in diameter based on pathologic report.  Hyung et al. [20] proposed D2 
lymph node dissection for a differentiated submucosal cancer more than 2.5 cm in diameter 
and for undifferentiated submucosal cancer more than 1.5cm. The Japanese Gastric Cancer 
Association (JGCA) guidelines have set  the optimal lymph node dissection level for EGC. 
Based on a large nationwide registry data, JGCA defined  modified gastrectomies A and B 
(MG-A, MG-B) for treatment of EGC.  MG-A is indicated for clinically mucosal cancer or 
small (< 1.5cm) differentiated-type submucosal cancer. And MG-A proposed dissecting the 
perigastric nodes and those along the left gastric artery are resected (D1 + No. 7). MG-B is 
indicated for the submucosal cancers and small (< 2 cm) EGC with clinical N1 disease. In 
this procedure, the nodes along the hepatic artery (No. 8a) and celiac artery (No. 9) should 
be resected in addition to those of MG-A. In other EGCs (N1 and > 2 cm, or N2), D2 
standard gastrectomy is recommended. In total gastrectomy for proximal EGC, the spleen 
may be preserved because the lymph nodes metastases in the splenic hilar nodes are 
extremely rare in EGC.  
4. Procedure of laparoscopy assisted distal gastrectomy 
Under a pneumoperitoneum at a pressure of 12 mmHg, the greater omentum is divided 
proximally about 4 to 5 cm from the gastroepiploic arcade toward the lower pole of the 
spleen using laparoscopic ultrasonic shears (Harmonic Scalpel; Ethicon Endo-Surgery, 
Cincinnati,OH, USA). For the patients with gastric cancer located in the middle third of the 
stomach, the roots of left gastroepiploic vessels are exposed and divided with double 
clipping at their origin from the splenic artery. For the patients with gastric cancer located in 
the lower third of the stomach, the superior mesenteric vein is exposed with an aid of 
ultrasonic shears and hooks, and fatty tissue with small lymph nodes (No. 14v) is cleared 
(Fig. 4). The right gastroepiploic vein is divided at the level of the pancreas border, and the 
right gastroepiploic artery is then divided at its roots by double clipping after No. 4sb 
lymph nodes are divided away from the greater curvature. After the right gastric artery 
have been exposed and divided at its origin by double clipping, the duodenum is transected 
1 cm distal to the pylorus via an endoscopic stapler (Endocutter 45 staple; Ethicon, Endo-
Surgery, Cincinnati,OH, USA). The lymph nodes with fatty tissue along the hepatic artery 
(No. 12a), the anterosuperior aspect of common hepatic artery (No. 8a), the celiac axis (No. 
9), and the proximal splenic artery (No. 11p) are dissected along each artery using an 
ultrasonic dissector and a hook-type monopolar bovie. The left gastric vein is divided, and 
the root of the left gastric artery was exposed and divided with double clipping, thereby 
allowing dissection of the left gastric artery lymph nodes (No. 7). The perigastric lymph 
nodes are dissected along the upper lesser curvature up to the esophagogastric junction. The 
mobilized stomach is then pulled out through this minilaparotomy. After removing the 
specimens, Billroth I gastroduodenostomy using a circular stapler (Proximate CDH 25; 
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Ethicon Endo-Surgery, Cincinnati, OH, USA) or Billroth II gastrojejunostomy by hand 
sewing are performed. [21] 
 
 
Fig. 4. Intraoperative view after completion of the laparoscopic lymph node dissection 
White  arrow indicates the superior mesenteric vein (a), the portal vein (b), and the splenic 
artery (c). 
 
          
Fig. 5. Laparoscopy assisted distal gastrectomy. The position of patients and operating team 
are different between theinstitutions. The author prefer to use semi-lithotomy position and 
operator stands at patient’s right side.(left) After full mobilization of stomach and resection 
of duodenum, half to two thirds of stomach is resected and gastroduodenal anastomosis is 
followed.(right) 
5. Function preserving laparoscopic surgery 
To improve the quality of life after gastrectomy, various types of the function-preserving 
surgery were designed to perform in the laparoscopic  era. The proximal gastrectomy, the 
pylorus preserving gastrectomy, or the vagus nerve preserved  gastrectomy is the good 
examples for the function-preserving gastrectomies. Laparoscopic proximal gastrectomy has 
performed for EGC located in the proximal third of the stomach. [22] Pylorus-preserving 
gastrectomy (PPG) was originally indicated as a treatment option for gastric ulcers, but is 
now applied for patients with EGC located in the distal two-thirds of the stomach. The distal 
2/3 of the stomach is resected but approximately 2 cm from a  pyloric cuff should be 
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preserved in this procedure. The hepatic and pyloric branches of the vagus nerve are also 
should be  preserved. All the regional lymph nodes, except the suprapyloric nodes (No. 5) 
can be dissected as in the standard D2 operation. PPG is currently indicated for EGC, 
located at the mid third of the stomach, which the nodal metastasis to No. 5 is extremely 
uncommon. The incidence of postgastrectomy dumping syndrome and the risk of the stone 
formation in a gall bladder (GB)  appears to be decreased, and the tendency of the body 
weight recovery is acceptable compared to that of Billroth I reconstruction. [23] Following 
the establishment of laparoscopy-assisted PPG (LAPPG), this procedure has been used in 
many institutions. [24]  
 
 
Fig. 6. Pylorus preserving gastrectomy. The pyloric cuff, 2-3 cm from the pyloric ring, is 
preserved together with the hepatic and pyloric branch of the anterior vagal trunk. Source: 
Scand J Surg. 2006; 95(4):249-255. [25] 
6. Short-term outcomes after laparoscopic gastrectomy 
Analysis of data from various retrospective case series almost invariably revealed show that 
laparoscopic gastrectomy can now be performed safely with less amount of the blood loss, 
although it usually requires a little bit longer operating time. (Table 2) 
Only six RCTs that compared LADG to ODG have been published (Table 3). Kitano et al. 
[26] had reported no difference in the morbidity and mortality rates between 14 LADG and 
14 ODG for EGC. An RCT by Huscher et al., [27] compared  the clinical outcomes of LADG 
with those of ODG for EGC and AGC showed that the morbidity and mortality rates were 
almost the same between the  two procedures. These results suggest that LADG is 
technically feasible in patients with gastric cancer. Korean Surgeons performed a multi-
institutional, prospective, randomized trial for LADG to assess the short- and long-term 
outcomes of laparoscopy assisted distal gastrectomy (LADG) for EGC in Korea (Korea 
Laparoscopic Gastrointestinal Surgery Study Group, KLASS trial). A total of 342 patients 
were randomized (LADG, 179 patients; ODG, 161 patients). [28] There were no significant 
intraoperative complications or incidence of open conversion in the LADG group.  Early 
complications occurred in 20 patients (11.6%) in the LADG group and 27 patients (15.08%) 
in the ODG group, and the late  complications occurred in three patients each,  (1.74% and 
1.67%) among the two  groups; there were no statistically significant differences in terms of 
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are different between theinstitutions. The author prefer to use semi-lithotomy position and 
operator stands at patient’s right side.(left) After full mobilization of stomach and resection 
of duodenum, half to two thirds of stomach is resected and gastroduodenal anastomosis is 
followed.(right) 
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pylorus preserving gastrectomy, or the vagus nerve preserved  gastrectomy is the good 
examples for the function-preserving gastrectomies. Laparoscopic proximal gastrectomy has 
performed for EGC located in the proximal third of the stomach. [22] Pylorus-preserving 
gastrectomy (PPG) was originally indicated as a treatment option for gastric ulcers, but is 
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2/3 of the stomach is resected but approximately 2 cm from a  pyloric cuff should be 
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preserved in this procedure. The hepatic and pyloric branches of the vagus nerve are also 
should be  preserved. All the regional lymph nodes, except the suprapyloric nodes (No. 5) 
can be dissected as in the standard D2 operation. PPG is currently indicated for EGC, 
located at the mid third of the stomach, which the nodal metastasis to No. 5 is extremely 
uncommon. The incidence of postgastrectomy dumping syndrome and the risk of the stone 
formation in a gall bladder (GB)  appears to be decreased, and the tendency of the body 
weight recovery is acceptable compared to that of Billroth I reconstruction. [23] Following 
the establishment of laparoscopy-assisted PPG (LAPPG), this procedure has been used in 
many institutions. [24]  
 
 
Fig. 6. Pylorus preserving gastrectomy. The pyloric cuff, 2-3 cm from the pyloric ring, is 
preserved together with the hepatic and pyloric branch of the anterior vagal trunk. Source: 
Scand J Surg. 2006; 95(4):249-255. [25] 
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although it usually requires a little bit longer operating time. (Table 2) 
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[26] had reported no difference in the morbidity and mortality rates between 14 LADG and 
14 ODG for EGC. An RCT by Huscher et al., [27] compared  the clinical outcomes of LADG 
with those of ODG for EGC and AGC showed that the morbidity and mortality rates were 
almost the same between the  two procedures. These results suggest that LADG is 
technically feasible in patients with gastric cancer. Korean Surgeons performed a multi-
institutional, prospective, randomized trial for LADG to assess the short- and long-term 
outcomes of laparoscopy assisted distal gastrectomy (LADG) for EGC in Korea (Korea 
Laparoscopic Gastrointestinal Surgery Study Group, KLASS trial). A total of 342 patients 
were randomized (LADG, 179 patients; ODG, 161 patients). [28] There were no significant 
intraoperative complications or incidence of open conversion in the LADG group.  Early 
complications occurred in 20 patients (11.6%) in the LADG group and 27 patients (15.08%) 
in the ODG group, and the late  complications occurred in three patients each,  (1.74% and 
1.67%) among the two  groups; there were no statistically significant differences in terms of 
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complications rates between these two groups. Re-operations were  performed in 3 patients 
in the LADG group; (1) omentectomy was performed because of intra-abdominal bleeding, 
(2)  segmental resection of an afferent loop was performed, and (3)primary repair of an 
leakage at the anastomotic site was done to control peritonitis. In the ODG group, three 
patients underwent reoperation because of the anastomotic leakage, the postoperative 
adhesive ileus, and the  wound dehiscence. Mortality occurred in two patients in the LADG 
group; one patient who died of  liver function failure due to the chronic hepatitis B, in 
combination with multiple organ failure. And the other one  who had liver cirrhosis (Child 
B) and chronic renal failure die of a sudden exacerbation of chronic liver disease and 
resulted in acute liver failure.  Even with the aid of the intensive care, these patients have 
died in 30 and 31 days postoperatively. The morbidities and mortalities were not statistically 
different between the two groups (P> 0.49). 
 
Study (year) Country 
n Level of 
L/N dissection Indication LADG ODG 
Adachi (2000) Japan 49 53 D1+ α T1a or T1b 
Shimizu (2000) Japan 21 31 D1+ α T1a 
Yano (2001) Japan 24 35 D1+ α T1a or superficial T1b 
Migoh (2003) Japan 10 17 D1+ α T1a or T1b 
Miura (2004) Japan 89 342 D1,D2 T1a or T1b 
Noshiro (2005) Japan 37 31 D2 T1 or T2N0 
Tanimura (2005) Japan 235 200 D2 T1 or T2aN0 
Mochiki (2005) Japan 89 60 D1+β T1N0 
Naka (2005) Japan 20 22 D1+ β T1N0 
Kim (2005) Korea 16 16 D2 T1a or T1b 
Kim (2005) Korea 71 76 D1+ α, β, D2 T1aN0 
Cho (2006) Korea 38 35 D1+ β, D2 T1N0-1, T2N0 
Ikenaga (2006) Japan 47 33 D1+ β T1a 
Lee (2006) Korea 136 120 D1+ β T1a 
Shin (2007) Korea 80 97 D1+ β T1a or T1b 
Song (2007) Korea 44 31 D2 T1a or T1b 
Table 2. Retrospective studies for comparing open versus laparoscopic gastrectomy 
Kodera et al. [29] performed meta-analyses of the following parameters based on 
randomized trials only, of which there are currently 6 comparing laparoscopy-assisted distal 
gastrectomy with open distal gastrectomy; the estimated blood loss, the operating time, the 
number of lymph nodes retrieved, the morbidity and mortality. Quality of the randomized 
trials would have to be considered as rather mixed, as the KLASS trial is the only 
multicenter trial with a large sample size. Most notably, the estimated blood loss was 
reduced at the cost of longer operating time. Surgical complications seemed to be 
considerably less common with the laparoscopic approach by the meta-analysis, although 
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Authors Year Country 
Number of patients 
LADG ODG 
Kitano 2002 Japan 14 14 
Lee 2005 Korea 24 23 
Hayashi 2005 Japan 14 14 
Huscher 2005 Italy 30 29 
Kim YW 2008 Korea 82 82 
Kim HH 2010 Korea 179 161 
Table 3. Characteristics of the 6 randomized clinical trials 
statistical significance had been lacking in the individual studies. A surprisingly high 
morbidity for open surgery in a trial by Lee and colleagues [30] was thought to be caused by 
the  inclusion of pulmonary complications. The reason that it was so unusually frequent is 
unknown, but might be attributed to inadequate criteria for reporting such events,  it could 
have occurred by chances, or the limited number of cohort size of the individual trials.  In-
hospital mortality was acceptable ranges and minimized  in all of the studies, as has been 
shown in other retrospective case series of both laparoscopic and open surgery in the Far 
East. On the other hand, the quality of lymphadenectomy in terms of the number of the 
retrieved lymph nodes highly favored open surgery. This result conflicts with earlier 
findings by some single-institutional retrospective studies, but a meta-analysis of 
randomized trials only should be regarded as less biased. Whether the difference in retrieval 
translates into difference in long-term survival remains unknown.  
7. Long-term outcomes after laparoscopic gastrectomy 
There was a report of an odd recurrence among patients operated on during the 1990s that 
casts doubt about the oncologic feasibility of laparoscopic surgery for gastric cancer when 
the surgical technique is im-mature. [31] However, long-term outcomes of the same case 
series as a whole were excellent. Lee et al. [32] reported the long term oncologic outcomes 
from laparoscopic gastrectomy 601 cases. At a median follow-up time of 35.9 months (range 
3 to 113 months), cancer recurrence occurred in 15 patients and metachronous gastric 
remnant cancer was detected in 6 patients. The 5-year overall and disease-free survival rates 
were 94.2% and 89.9%, respectively, for stage IA tumors, 87.4% and 82.7% for stage IB, 
80.8% and 70.7% for stage IIA, and 69.6% and 63.1% for stage IIB. 
A more extensive retrospective analysis of patients by expert laparoscopic surgeons also 
revealed excellent outcomes. Japanese Laparoscopic Surgery Study Group analyzed 1,185 
cases of laparoscopy-assisted distal gastrectomy. [33] At a median follow-up time of 36 
months, estimated 5-year disease-free survival rates were 99.8% for stage IA, 98.7% for stage 
IB, and 85.7% for stage II. Similarly, the excellent retrospective data suggested the non-
inferiority of the laparoscopic approach to treat early-stage cancer have been reported from 
the KLASS group. [34] A retrospective multicenter study was performed using data from a 
cohort of 1,485 patients who had undergone laparoscopy-assisted gastrectomy for gastric 
cancer at ten institutions from 1998 to 2005. The 5-year overall survival of 1,417 patients was 
95.5%, and disease-free survival was 94.1%. Fifty of 1,417 patients (3.5%) had recurrences. 
Incidence of recurrence was 1.6% (19/1186) in early gastric cancer and 13.4% (31/231) in 
advanced gastric cancer. 
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Table 2. Retrospective studies for comparing open versus laparoscopic gastrectomy 
Kodera et al. [29] performed meta-analyses of the following parameters based on 
randomized trials only, of which there are currently 6 comparing laparoscopy-assisted distal 
gastrectomy with open distal gastrectomy; the estimated blood loss, the operating time, the 
number of lymph nodes retrieved, the morbidity and mortality. Quality of the randomized 
trials would have to be considered as rather mixed, as the KLASS trial is the only 
multicenter trial with a large sample size. Most notably, the estimated blood loss was 
reduced at the cost of longer operating time. Surgical complications seemed to be 
considerably less common with the laparoscopic approach by the meta-analysis, although 
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Kim YW 2008 Korea 82 82 
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Table 3. Characteristics of the 6 randomized clinical trials 
statistical significance had been lacking in the individual studies. A surprisingly high 
morbidity for open surgery in a trial by Lee and colleagues [30] was thought to be caused by 
the  inclusion of pulmonary complications. The reason that it was so unusually frequent is 
unknown, but might be attributed to inadequate criteria for reporting such events,  it could 
have occurred by chances, or the limited number of cohort size of the individual trials.  In-
hospital mortality was acceptable ranges and minimized  in all of the studies, as has been 
shown in other retrospective case series of both laparoscopic and open surgery in the Far 
East. On the other hand, the quality of lymphadenectomy in terms of the number of the 
retrieved lymph nodes highly favored open surgery. This result conflicts with earlier 
findings by some single-institutional retrospective studies, but a meta-analysis of 
randomized trials only should be regarded as less biased. Whether the difference in retrieval 
translates into difference in long-term survival remains unknown.  
7. Long-term outcomes after laparoscopic gastrectomy 
There was a report of an odd recurrence among patients operated on during the 1990s that 
casts doubt about the oncologic feasibility of laparoscopic surgery for gastric cancer when 
the surgical technique is im-mature. [31] However, long-term outcomes of the same case 
series as a whole were excellent. Lee et al. [32] reported the long term oncologic outcomes 
from laparoscopic gastrectomy 601 cases. At a median follow-up time of 35.9 months (range 
3 to 113 months), cancer recurrence occurred in 15 patients and metachronous gastric 
remnant cancer was detected in 6 patients. The 5-year overall and disease-free survival rates 
were 94.2% and 89.9%, respectively, for stage IA tumors, 87.4% and 82.7% for stage IB, 
80.8% and 70.7% for stage IIA, and 69.6% and 63.1% for stage IIB. 
A more extensive retrospective analysis of patients by expert laparoscopic surgeons also 
revealed excellent outcomes. Japanese Laparoscopic Surgery Study Group analyzed 1,185 
cases of laparoscopy-assisted distal gastrectomy. [33] At a median follow-up time of 36 
months, estimated 5-year disease-free survival rates were 99.8% for stage IA, 98.7% for stage 
IB, and 85.7% for stage II. Similarly, the excellent retrospective data suggested the non-
inferiority of the laparoscopic approach to treat early-stage cancer have been reported from 
the KLASS group. [34] A retrospective multicenter study was performed using data from a 
cohort of 1,485 patients who had undergone laparoscopy-assisted gastrectomy for gastric 
cancer at ten institutions from 1998 to 2005. The 5-year overall survival of 1,417 patients was 
95.5%, and disease-free survival was 94.1%. Fifty of 1,417 patients (3.5%) had recurrences. 
Incidence of recurrence was 1.6% (19/1186) in early gastric cancer and 13.4% (31/231) in 
advanced gastric cancer. 
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One Italian prospective, randomized clinical trial with a total of 59 patients was reported in 
2005. [35] Twenty-nine (49.1%) patients were randomized to undergo open subtotal 
gastrectomy (OG), while 30 (50.9%) patients were randomized to the laparoscopic group 
(LG). Five-year overall and disease-free survival rates were 55.7% and 54.8% and 58.9% and 
57.3% in the OG and the LG, respectively. 
These encouraging data prompted several experienced investigators in Japan and Korea to 
extend the indication for laparoscopic approach to more advanced gastric cancers. Also, 
large  multicenter clinical trial had been conducted and studied the  long term oncologic 
outcomes in gastric cancer looked forward to the final results.  
8. Ongoing prospective clinical trials 
Randomized trials to prove the oncologic feasibility and safety of laparoscopic surgery as 
well as to confirm its clinical benefits are mandatory. Korean surgeons who had much larger 
patient cohorts  were actively  to launch a phase III trial. After an initial attempt, they 
launched the KLASS group trial (NCT00452751), a large-scale multi-institutional trial. The 
Japanese Gastric Cancer Treatment Guidelines discreetly selected early-stage cancer (T1N0, 
T1N1 or T2 (MP)-T3 (SS) N0) as tentative targets of laparoscopic surgery. The Koreans 
referred to these guidelines and recruited only patients with preoperative diagnosis of stage 
I disease in the trial. They identified comorbidity of the patients and lack of experience on 
the side of surgeons as risk factors for complications in their preparatory retrospective 
analysis, [36] and only surgeons with experience of more than 50 laparoscopic gastrectomy 
procedures were invited to participate in the phase III trial. The first convincing evidence of 
oncologic outcomes of the laparoscopic procedure will be available in the near future from 
Korea.  
More recently, the Japan Clinical Oncology Group (JCOG) began to recruit surgeons and 
institutions with experience in laparoscopic gastrectomy. This was ultimately to evaluate the 
feasibility of a laparoscopic approach in the forthcoming clinical trials. They first conducted 
a phase II trial, JCOG0703, with the incidence of anastomotic leakage and pancreatic fistula 
as the primary end point, enrolled 176 patients, and found the incidence to be 1.7%. [37] 
Having confirmed the safety of the procedure in this trial, they are currently preparing for a 
phase III trial with long-term survival as an end point. Again, only early-stage cancers 
(preoperative diagnosis of T1N0, T1N1, T2 (MP) and T3 (SS) N0) will be eligible. As like 
mentioned previously, given the small number of events that can be expected from this 
population, the required sample size to show non-inferiority of the laparoscopic surgery 
over open surgery (<5% difference in 5-year survival) was calculated to be as much as 920, 
and the study group expects to complete the recruitment of patients in the following  five 
years. Quality of life assessments using established questionnaires will also be performed 
among the selected institutions, where sufficient assistance from the clinical research 
coordinators could be provided.  
9. Laparoscopic gastrectomy in the west 
In Western countries, a small number of surgeons who challenged this approach did not 
restrict themselves to T1 stage cancer, [38] because most gastric cancers are diagnosed as 
locally advanced disease. A small number of studies comparing open and laparoscopic 
approaches have shown that survival data among those receiving laparoscopy were not 
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inferior to open surgery, although there were significant reductions in pain and incidence of 
the late postoperative complications. They have not been able to extend their experience to 
perform a large-scale randomized comparison between laparoscopic and open surgery as 
they had done with colon cancer, apparently because of the small numbers of operable 
disease and surgeons who are in capable of performing oncologically safe gastric cancer 
surgery which is done in East.  
The experience in laparoscopic gastrectomy for the treatment of gastric adenocarcinoma in 
the West has been mostly encouraged in Europe, with a small and limited series of report 
from  the North America and South America published in recent years. In the United States, 
the first group to describe their experience with laparoscopic gastrectomy with curative 
intent for GC was Reyes et al. from Mount Sinai Medical Center, in 2001. [39] In this 
retrospective case-matched study with 36 patients (25 with malignant disease), they 
compared 18 laparoscopic surgeries with 18 open gastrectomies. Of those with GC, from the 
laparoscopic group, 9 patients had histologically confirmed adenocarcinoma and 3 with 
carcinoid tumors compared with 12 adenocarcinomas and 1 gastric lymphoma in the open 
group. All resected margins in the laparoscopic group were free of tumor, whereas 2 
patients in the open group (stages II and III) had R1 resections, likely related to selection 
bias for these more advanced, open cases. There were no significant differences in extent of 
lymph node dissection or in intraoperative complications between the two groups. The 
laparoscopic approach required a significantly longer operative time (4.2 h vs. 3.0 in the 
open group) likely related to the learning curve of this procedure. However, there were 
significantly reduced amount of  blood loss with fewer transfusions required, earlier return 
to normal bowel function, lower incidence of the postoperative ileus, and significantly 
reduced hospital stay in the laparoscopic versus open groups (6.3 vs. 8.6 days).  
In 2006, Varela et al. [40] published the second experience with laparoscopic gastrectomy for 
GC in the United States, representing to date the largest American experience reported. 
After 15 consecutive laparoscopic gastrectomies, of which 2 were total, 4 proximal, 4 
subtotal, 2 distal, and 3 laparoscopic esophagogastrectomies, no conversion to open surgery 
was reported, and there were no significant differences in operative time, transfusion rate, 
number of lymph nodes resected, median length of stay, and morbidity, although there was 
significantly lower blood loss among the laparoscopic group, demonstrating both the 
feasibility and safety of the laparoscopic approach.  
10. Future perspectives  
With increasing the experience and the level of the expertise of oncologic surgeons in the 
minimally invasive approach to gastric resection for cancer, it is becoming evident that 
laparoscopy, as a surgical modality for gastrectomy,  provides equivalent oncologic 
resections with lymphadenectomy that is comparable to the open approach, with no 
compromise in terms of the disease recurrence or long-term survival, based on preliminary 
studies. In addition, based on the known benefits of the minimally invasive approach, 
including the reduced risks of surgery related trauma,  the amount of the blood loss, pain, 
and earlier recovery for the patient, we are encouraged to expand our indications of 
laparoscopic surgery.  This has been stimulated by the advances in the field of the  
minimally invasive surgery for benign abdominal disease, and the results from multiple 
Eastern studies of early-stage cancer. Although an open surgical approach should be 
applied for any case with concerns of resectibility of the cancer lesion, the safety margin, or 
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locally advanced disease. A small number of studies comparing open and laparoscopic 
approaches have shown that survival data among those receiving laparoscopy were not 
 
Laparoscopic Surgery for Gastric Cancer 
 
83 
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surgery which is done in East.  
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from  the North America and South America published in recent years. In the United States, 
the first group to describe their experience with laparoscopic gastrectomy with curative 
intent for GC was Reyes et al. from Mount Sinai Medical Center, in 2001. [39] In this 
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compared 18 laparoscopic surgeries with 18 open gastrectomies. Of those with GC, from the 
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carcinoid tumors compared with 12 adenocarcinomas and 1 gastric lymphoma in the open 
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laparoscopic approach required a significantly longer operative time (4.2 h vs. 3.0 in the 
open group) likely related to the learning curve of this procedure. However, there were 
significantly reduced amount of  blood loss with fewer transfusions required, earlier return 
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reduced hospital stay in the laparoscopic versus open groups (6.3 vs. 8.6 days).  
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After 15 consecutive laparoscopic gastrectomies, of which 2 were total, 4 proximal, 4 
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was reported, and there were no significant differences in operative time, transfusion rate, 
number of lymph nodes resected, median length of stay, and morbidity, although there was 
significantly lower blood loss among the laparoscopic group, demonstrating both the 
feasibility and safety of the laparoscopic approach.  
10. Future perspectives  
With increasing the experience and the level of the expertise of oncologic surgeons in the 
minimally invasive approach to gastric resection for cancer, it is becoming evident that 
laparoscopy, as a surgical modality for gastrectomy,  provides equivalent oncologic 
resections with lymphadenectomy that is comparable to the open approach, with no 
compromise in terms of the disease recurrence or long-term survival, based on preliminary 
studies. In addition, based on the known benefits of the minimally invasive approach, 
including the reduced risks of surgery related trauma,  the amount of the blood loss, pain, 
and earlier recovery for the patient, we are encouraged to expand our indications of 
laparoscopic surgery.  This has been stimulated by the advances in the field of the  
minimally invasive surgery for benign abdominal disease, and the results from multiple 
Eastern studies of early-stage cancer. Although an open surgical approach should be 
applied for any case with concerns of resectibility of the cancer lesion, the safety margin, or 
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capability of operating surgeons , it appears that the minimally invasive surgical approach 
can be here to stay. However, until more mature long-term follow-up data on advanced 
gastric cancer treated by minimally invasive approaches are defined, these  approaches 
should be limited to  those patients with  early- stage gastric cancer. To establish 
laparoscopic surgery as a standard treatment for advanced gastric cancer, multicenter RCTs 
comparing the short- and long-term outcomes of laparoscopic surgery versus open surgery 
are needed. As the indications are continued to expand to treat more advanced tumors and 
with the supporting data data from the additional prospective studies, we will be able to 
clearly define the oncologically appropriate application of laparoscopic gastrectomy for all 
stages of gastric adenocarcinoma.  
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1. Introduction 
Gastric cancer remains as one of the leading causes of death worldwide (Yoshida et al., 
2004). Middle third and distal  cancers tend to decline worldwide. However, in the western 
populations  proximal gastric cancers tend to increase even though the incidence of  those 
cancers stays the same in Japan. Today, the incidence of early gastric cancer has reached 
above 50% in Japan while in the west two thirds of gastric cancers are at an advanced stage 
at the time of diagnosis (Biondi, 2010). This problem is complicated further by a recurrence 
rate of 40% to 65% in patients resected with curative intent (Dicken, 2005). Currently,  the 
only potentially curative option for gastric cancer is surgery which may promise complete 
resection, although the extent of regional lymphadenectomy (LND)  has been a matter of 
considerable debate. 
2. Surgery of the stomach 
Radical resection of stomach and the related lymphatic drainage has been the way of 
treatment of gastric cancer (GC) in west and Japan. The debate has been carried out on what 
extent the resection must be carried out. Japanese investigators assert that the extended 
LND (D2) removes tumor in the regional lymph nodes (LNs) before it can metastasize. In 
addition, it is argued that extended LND improves staging accuracy. On the other hand, 
western surgeons have argued that the benefits promised by extended lymphadenectomy 
may be reversed by the high complication rate even if they have any. Theoretically, the 
removal of a wider range of LNs by extended LN dissection increases the chances for cure. 
In fact, the pattern of recurrence after extended surgery is completely  different from that 
after limited surgery and involves locoregional recurrence in the majority of cases 
(Gunderson & Sosin, 1982). An extended LN dissection might have an influence on the 
locoregional recurrence rate. However, if the patients have already developed 
micrometastases or if no LNs are affected, such resection might be irrelevant and harmful, in 
terms of increased morbidity and mortality (Tanizawa & Terashima, 2010). 
2.1 The classification of lymph node tiers 
The Japanese Research Society for the study of gastric cancer published a manual in 1963 
standardizing LND and pathologic evaluations for GC; these guidelines recognized 16 
different LN  stations that surround the stomach. These 16 nodal stations are grouped 
according to the location and extension of the primary tumor (N0-N4) and the extent of 
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lymphadenectomy is classified according the level of LND ( D1-D4). In D1 dissections, only 
the perigastric nodes directly attached along the lesser curvature and greater curvatures of 
the stomach are removed (stations 1-6, N1 level). An incomplete N1 dissection is labelled a 
D0 lymphadenectomy. D2 dissections (N2 level) add the removal of nodes along the left 
gastric artery (station 7), common hepatic artery (station 8), celiac trunk (station 9), splenic 
hilus, and splenic artery (station 10 and 11).  D3 dissections include the dissection of lymph 
nodes at stations 12 through 14, along the hepatoduodenal ligament and the root of the 
mesentery (N3 level). Finally D4 resections add the stations 15 and 16 in the paraaortic and 
the paracolic region (N4 level).  The incidence of metastasis to any perigastric station is 
highest when the tumor location is close to it. There is little variation in the metastatic 
pattern along the lesser curvature between tumors of different thirds.  For tumors of antrum 
right paracadiac lymph nodes are staged as second tier while left paracardiac lymph nodes 
are N3. For tumors of cardia  the 5th and 6th lymph node stations are in the second tier (Kim  
et al., 2001) . 
2.2 The regional lymph nodes 
No. 1 Right paracardial LN 
No. 2 Left paracardial LN 
No. 3 LN along the lesser curvature 
No. 4sa LN along the short gastric vessels 
No. 4sb LN along the left gastroepiploic vessels 
No. 4d LN along the right gastroepiploic vessels 
No. 5 Suprapyloric LN 
No. 6 Infrapyloric LN 
No. 7 LN along the left gastric artery 
No. 8a LN along the common hepatic artery (Anterosuperior group) 
No. 8p LN along the common hepatic artery (Posterior  group) 
No. 9 LN around the celiac artery 
No. 10 LN at the splenic hilum 
No. 11p LN along the proximal splenic artery 
No. 11d LN along the distal splenic artery 
No. 12a LN in the hepatoduodenal ligament (along the hepatic artery) 
No. 12b LN in the hepatoduodenal ligament (along the bile duct) 
No. 12p LN in the hepatoduodenal ligament (behind the portal vein) 
No. 13 LN on the posterior surface of the pancreatic head 
No. 14v LN along the superior mesenteric vein 
No. 14a LN along the superior mesenteric artery 
No. 15 LN along the middle colic vessels 
No. 16a1 LN in the aortic hiatus 
No. 16a2 LN around the abdominal aorta (from the upper margin of the celiac trunk to the 
lower margin of the left renal vein) 
No. 16b1 LN around the abdominal aorta (from the lower margin of the left renal vein to the 
upper margin of the inferior mesenteric artery) 
No. 16b2 LN around the abdominal aorta (from the upper margin of the inferior mesenteric 
artery to the aortic bifurcation) 
No. 17 LN on the anterior surface of the pancreatic head 
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No. 18 LN along the inferior margin of the pancreas 
No. 19 Infradiaphragmatic LN 
No. 20 LN in the esophageal hiatus of the diaphragm 
No. 110 Paraesophageal LN in the lower thorax 
No. 111 Supradiaphragmatic LN 
No. 112 Posterior mediastinal LN 
 
 
Fig. 1. The lymph node stations according  to the Japanese classification 
R0 resection indicates a microscopically margin-negative resection, in which no gross or 
microscopic tumor remains in the primary tumor bed. R1 resection indicates the removal of 
all macroscopic disease but microscopic margins are positive for tumors. R2 indicates gross 
residual disease with gross residual tumor that was not resected (primary tumor, regional 
nodes and macroscopic margin involvement). Resection in the eastern world is a little more 
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complicated: Resection A: no residual disease, with a high cure probability. It implies 
resections satisfying all of the following conditions: tumor without serosal invasion; N0 
treated by D1, D2, or D3 lymph node dissections, or tumor with  first-level lymph node 
treated by D2 or D3 resection; no distant, peritoneal or liver metastases, negative cytological 
examination of peritoneal fluid and proximal and distal margins > 10 mm. Resection B: no 
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histopathologic residual disease but not fulfilling criteria for resection A. Resection C: 
definite residual disease (Biondi,  2010). 
 
The groups of lymph node stations used to define the extent of lymph node dissection 
Location of the tumor 
Station 
Number A, AM M, MA, MC C,CM 
AMC,MAC, 
MCA,CMA 
1 N2 N1 N1 N1 
2 N3 N2 N1 N1 
3,4 N1 N1 N1 N1 
5,6 N1 N1 N2 N1 
7,8,9 N2 N2 N2 N2 
10,11 N3 N2 N2 N2 
12,13,14 N3 N3 N3 N3 
15,16 N4 N4 N4 N4 
A: Antrum, M: Middle, C: Cardia 
Table 1. Groups of lymph node stations used to define the extent of lymph node dissection. 
The Union Internationale Contrale Cancer (UICC)/American Joint Committee on Cancer 
(AJCC) classification, which is most widely used for the staging of gastric cancer, suggests 
that at least 15 lymph nodes should be examined for a correct assessment of N staging. 
Lymph node dissemination is in an orderly fashion through lymphatic channels in gastric 
cancer (Shi & Zou, 2010). However, the type of fixative and clearance solution used by a 
pathology department may influence the number of nodes examined. One study found that 
78% of nodes <5 mm are missed by the routine formalin fixation that is used in most 
Western countries, whereas clearance solutions allow detection of nodes 1 mm in diameter 
(Herrera & Villareal, 1992).  Studies estimate that LNs will be involved with tumors for 3–
5% of cases of gastric adenocarcinoma limited to the mucosa; 11–25% of cases for those 
limited to the sub-mucosa; 50% for T2; and 83% for T3 tumors (Coburn, 2009). 
The 7th editon has brought some changes.  
N0 (N plus zero): The cancer has not spread into the regional lymph nodes. 
N1: The cancer has spread to one to two regional lymph nodes. 
N2: The cancer has spread to three to six regional lymph nodes. 
N3: The cancer has spread to seven or more regional lymph nodes. 
N3a: The cancer has spread to seven to 15 regional lymph nodes. 
N3b: The cancer has spread to more than 16 regional lymph nodes. 
As a critics to TNM classification, it is difficult to directly correlate the number of lymph 
nodes assessed with the extent of lymphadenectomy. Autopsy studies have shown that an 
average of 15 nodes can be harvested from a D1 lymphadenectomy, 27 nodes from a D2 
lymphadenectomy, and 43 nodes from a D3 lymphadenectomy (Wagner et al., 1991).  But 
studies have shown the TNM classification to be an easier way with a more accurate 
prognostic value. But since the fifth edition prior to 1997 AJCG system was based on 
anatomic location of involved nodes rather than their number. Positive nodes >3 cm from 
the primary tumor or nodes associated with celiac or celiac based arteries were deemed N2 
nodes. However, this anatomic scheme caused some problems undermining the concept of 
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anatomical staging. For example, following surgical resection some surgeon-pathologist 
teams harvested nodes on fresh specimens whereas others would harvest nodes only after 
fixation and substantial contraction of the specimen, the alterations that resulted from these 
different  techniques compromised the staging accuracy. Besides, many surgeons in the west 
excluded the N2 node dissection and that also impaired the quality of accurate staging when 
a higher number of lymph nodes were extracted from  a D2 resection. Thus, interpretation 
was harder as Japanese and German surgeons perfomed mainly D2 resection while at that 
time many surgeons in other countries in west ignored D2 resection and thus stage 
migration effect again vitiated the  accurate staging. Therefore, in the western world the 
TNM clasisification has gained wider ground because of better prognostic predictions it has 
offered as justified by  Japanese surgeons.  
A number of investigators have observed progressive decrease in survival with the 
increasing number of involved lymph nodes, with an appearent drop off in survival when 3 
or more nodes are involved. Another drop off have been reported when more than 6 nodes 
are involved. Involvement beyond 15 or 16 nodes has been observed to be largely 
incompetent with long term survival(Hundahl, 2002). As a prognostic tool,  ratio between 
metastatic lymph nodes and the total number of lymph nodes examined was 
proposed(Marchet, 2007). Several cutoff were studied increasing in pentathonic or decimal 
scale starting from zero to mostly >30 %; the survival decreases as the involved lymph node 
ratio increases. In a study by Xu et al. it is proposed  that this scheme may also be usefull for 
patients who had lower than 15 lymph nodes dissected (Xu et al.,2009) .  
2.2 Patterns of relapse and metastasis 
In  striving to achieve cure for gastric cancer it is essential to understand the modes of 
spread and patterns of relapse. Only then an optimum treatment with reasonable 
expectations are possible. The metastatic pathways are:  
2.2.1 Direct extension 
Into neighbouring organs and structures generally resected en-bloc with the stomach. Once a 
lesion has extended beyond the gastric wall, a multitude of organs and structures can be 
involved, dependent on lesion location within the stomach. For proximal lesions, organs or 
structures that may be involved with superior or anterior  extragastric extension include the 
left diaphragm, anterior abdominal wall, or undersurface of the liver, while with posterior 
extension, the celiac artery, body of pancreas (anterior, superior), aorta, or diaphragmatic crura 
may be involved. For body of stomach lesions, anterior extension may involve the anterior 
abdominal wall or liver; lateral extension--the gastrosplenic ligament or spleen; posterior 
extension—the pancreas (tail, body); superior extension—the gastrohepatic ligament or lesser 
omentum; and inferior extension--the transverse colon or mesocolon, or greater omentum. 
With distal gastric lesions, posterior extension may involve the head of pancreas or porta 
hepatis structures; inferior extension--the transverse mesocolon and colon. Adherence from 
inflammatory conditions can mimic direct extension of tumor, but all adhesions between a 
gastric carcinoma and adjacent structures must be regarded as malignant (Gunderson, 2002). 
2.2.2 Lymphatic route 
Lymphatic spread occurs via subserosal and submucosal lymphatic plexuses depending on 
the depth of invasion. The lymphatic drainage of the stomach follows the arterial supply. 
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Although most lymphatics ultimately drain into the celiac nodal area, lymph drainage sites 
can include the splenic hilum, suprapancreatic nodal groups, porta hepatis, and 
gastroduodenal areas. Abundant lymphatic channels are present within both the 
submucosal and subserosal layers of the gastric wall. Microscopic or subclinical spread well 
beyond the visible gross lesion occurs via these lymphatic channels (intramural spread), and 
the surgeon can be misled into thinking that resection margins are free of tumor. 
Accordingly, frozen sections of the gastric resection margins should be obtained 
intraoperatively to ensure   that margins of resection are microscopically uninvolved. The 
submucosal lymphatic plexus is also prominent in the esophagus and the subserosal plexus 
in the duodenum, allowing both proximal and distal intramural tumor spread. Although a 
so-called "duodenal block" occurs with the mucosa scarcely ever being involved for more 
than 1-2 mm beyond the pylorus, the existence of a prominent subserosal plexus allows 
distal spread in as high as 30% to 40% of patients (Gunderson, 2002).  In the stomach, as in 
other organs, the very presence of cancer can alter the normal lymphatic drainage. 
Obstructed vessels can divert the drainage so that metastases appear in unexpected nodes. 
Collateral lymphatics can form, producing a shift in the drainage pattern.  The possibly 
multicentric origin of gastric cancer further complicates a simple approach to the proposed 
resection (Fischer & Bland, 2007).  
2.2.3 Peritoneal disease 
Because stomach is a peritoneal organ once the tumor cells have extended beyond the 
gastric wall to the serosal surface peritoneal spread may happen. Peritoneal spread may 
initially be a localized process confined to the surrounding ligaments (Gunderson, 1982) .   
2.2.4 Hematogenous spread 
For malignancies confined to the stomach the venous drainage is primarily to liver which 
proves an effective filter. As neoplastic cells invade beyond the stomach wall into adjacent 
organs, hematogeanous spread through the lymphatics and venous system of the involved 
organ happens and metastasis to lungs and other organs may happen (Smalley et al., 2002).  
2.3 Patterns of relapse 
There are 5 ways recurrence following surgical removal of gastric carcinoma: lymph node, 
remnant stomach, local, peritoneal and hematogenous recurrence. Sixty percent  to 72% of 
gastric cancer patients succumb to recurrences within the first 2 Hematogenous or 
lymphatic spreads without intraabdominal metastases occur rarely. It may be postulated 
that gastric cancer prefers to spread intraabdominally, and that locoregional control is 
therefore an important issue in treatment strategy years (Wu, 2003)..  Locoregional 
recurrence rates varies from 25% to 96%  depending on different detection methods and 
study populations. 
2.4 Histology and recurrence 
Gastric cancer can recur in different pathways. The possibility of predicting the risk and 
type of recurrence in patients with resectable gatric cancer could have important 
implications for therapy, both in the surgical aproach (extent of lymphadenectomy, partial 
or total resection) and in complemetary therapies.  Marelli et al.  found out that the main 
difference was found on the onset of peritoneal recurrence in a study of 412 patients in 
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which they compared the recurrence patterns of intestinal type and diffuse type years 
(Marelli et al., 2002). Shiriashi et al. confirmed that most recurrences were within the first 
two years after surgery and  rare after 5 years (Shiriashi et al., 2000).  
For intestinal type of the tumor lymph node positivity, depth of invasion, advanced age and 
male gender significantly increases the risk of recurrence. The patterns  of relapse were 
mainly locoregional or hematogenous and peritoneal recurrence was limited. For diffuse 
type of  tumors very high rates of peritoneal recurrence were observed in neoplasms with 
infiltration of the serosa, involvement of second level lymph nodes, and large tumor size. 
Locoregional recurrences were frequent in advanced forms, lymph node–positive cases, and 
tumors larger than 4 cm. The rate of hematogenous recurrence was generally smaller than 
that of peritoneal or locoregional disease. Early forms  and tumors smaller than 4 cm 
recurred primarily via hematogenous route. 
The main difference was found in the onset of peritoneal recurrence; this was observed in 
34% of diffuse-type cases compared to 9% of intestinal-type cases, and was the main 
pathway of spread in the former. Compared to intestinal-type cells, the diffuse type showed 
a greater predisposition to proliferate in the peritoneum, considering that 50% of the cases 
with infiltration of the serosa led to peritoneal carcinomatosis, which was observed in only 
16% of T3 and T4 intestinal-type cases. On the contrary, recurrences of intestinal-type 
tumors were mainly locoregional or hematogenous. The incidence of hematogenous 
recurrence did not show significant differences between the intestinal and the diffuse types; 
in both groups of patients, they observed a higher frequency of this recurrence in lymph 
node–positive cases, a finding in accord with other reports. However, the degree of 
involvement in the  various organs was different, because the intestinal type metastasized 
primarily to the liver, whereas in the diffuse type the liver was involved in only half of the 
cases; in the other cases, hematogenous metastases involved distant organs.  The  data may  
suggest that in the diffuse type, but not in the intestinal type, superextended 
lymphadenectomy may play a more important role in reducing the risk of recurrence. The 
diffuse type may show a greater propensity than the intestinal type to metastasize to third- 
and fourth-level lymph nodes (Marelli et al., 2002).  
In a large series Nakamura et al. demonstrated that there is some correlation between the 
tumor histological type and the gross type. Seventy nine percent of diffusely infiltrating 
tumors and 69% of ulcerative infiltrating tumors were poorly differentiated and 60% of 
polipoid tumors were well differentiated in advanced carcinomas. In early carcinomas 89% 
of Type 1  and 77% of Type IIa lesions were well differentiated. Type llc tumors were either 
well (31%), moderate(19%) or poorly differentiated (50%). In their large series of 10 
thousand patients the most frequently encountered macroscopic type of advanced cacinoma 
was the ulcerative infiltrating tumor (41%), followed by ulcerating circumscribed type(31%).  
In early carcinomas type llc (70%) was the most frequently encountered type,  followed by 
Type II a. In advanced forms well differentiated types showed fairer prognosis (Nakamura 
et al., 1992).  
Adachi et al. demonstrated that patients with poorly differentiated type show a poorer 
prognosis especially when the tumor is bigger than 10 cm or serosal involvement is positive. 
If the tumor did not invade serosa but had lymph node metastasis, survival rate was 
signifcantly lower in the well differentiated group. Moriguchi et al. also demostrated that 
when the tumor invasion was restricted within mucosa or submucosa the well differentiated 
type of tumor were associated with poorer pognosis. This difference can be explained by the 
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characteristics of  well differentiated type which readily develops blood-bourne metastases 
irrespective of the degree of  penetration by tumor cells (Adachi et al.,1997).   
2.5 Lymph nodes and tumors of cardia  
Tumors of cardia are generally larger than the tumors of other parts of the stomach. The 
incidence of serosal invasion, lymph node metastasis and lymphatic and blood vessel 
invasion are higher. With regards to the site of recurrence both lymph node and 
hematogenous recurrence were observed more frequently in the cardia than remaining parts 
of the stomach. The adenocarcinoma of gastric cardia shows involvement of left and right 
paracardial section and the lesser curvature as the predominating areas, then the lower 
posterior mediastinum and left gastric artery and abdominal aorta(Saito et al., 2006). The 
incidence of lymph nodes at the splenic hilum and splenic artery are less,  between 9% and 
20%. The splenic hilar lymph node metastasis increases with the advanced stage(Shin et al., 
2009). In a review of literature by Ashikaga  et al. the incidence of hilar lymph node 
positivity for T1 tumors of cardia is 0,3%, for subserosal  involvement  the incidence is %13 
and 26% when the tumor has infiltrated serosa. The involvement of the hilar lymph node is 
associated with ominous prognosis (Shin et al., 2009).  
For tumors of cardia in order to decide the necessity of  dissection No 10 lymph nodes, 
evaluation of the 4d lymph node metastasis has been proposed. If the 4d lymph nodes are 
uninvolved it is unlikely for the splenic hilus lymph nodes to be involved (Ishikawa et al., 
2009).  
2.6 Lymphadenectomy and pancreaticosplenectomy  
Tumors of the upper and middle stomach are known to metastasize
 
to the splenic artery 
(station 11) and splenic hilar (station
 
10) lymph nodes, and distal pancreatectomy and 
splenectomy were
 
historically routinely performed to clear these nodal stations. Pancreatic 
fistula rates were high, thus significantly
 
increasing the morbidity of the D2 
lymphadenectomy procedure (Yoon et al., 2009).
 
Maruyama et al.  described a pancreas-
preserving D2 lymphadenectomy
 
that resected the spleen and splenic artery along with the 
station
 
10 and 11 lymph nodes(Maruyama et al., 1995).  A retrospective study from Japan of 
nearly
 
400 patients found that there was no survival benefit in patients
 
undergoing total 
gastrectomy combined with distal pancreatectomy
 
and splenectomy over patients 
undergoing total gastrectomy with
 
splenectomy only (Kitamura et al., 1999). Distal 
pancreatectomy is now generally
 
considered to be unwarranted in the routine performance 
of a
 
D2 lymphadenectomy until there is direct extension of the tumor.
 
A retrospective 
Japanese study of 224 patients with proximal
 
gastric cancer found no survival benefit in 
patients who received pancreaticosplenectomy or splenectomy over pancreas and spleen
preservation, but morbidity was significantly greater in the
 
pancreaticosplenectomy group 
(Kodera et al., 1997).  Sasako
 
et al.  estimated the benefit of dissecting the station
 
10 and 11 
lymph nodes for a proximal gastric cancer at 5.6% (Sasako et al., 1995).
 
Hartgrink et al. 
analyzed the patients in the Dutch Gastric
 
Cancer Trial who had lymph node metastases at 
stations 10 and
 
11. Of the 18 patients with station 10 metastases, the 11-year
 
survival rate 
was 11%. Of the 24 patients with station 11 metastases, the 11-year survival rate was 8%. The 
authors concluded that
 
"the relevance of the dissection of these nodes has to be questioned
as the survival benefit is small and morbidity and hospital mortality are significantly 
increased" (Hartgrink et al., 2005). 
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increasing the morbidity of the D2 
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station
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Although most expert gastric cancer surgeons no longer resect the distal pancreas as part of 
a D2 lymphadenectomy unless there is direct tumor extension, the resection of the spleen 
continues to be controversial (Yoon et al., 2009). Two prospective randomized trials of total 
gastrectomy and lymphadenectomy with or without splenectomy have been performed in 
Chile and South Korea. Both studies found no difference in overall survival, and the Chilean 
study found a significantly higher rate of infectious complications in the splenectomy group. 
However, the number of patients in these studies was between 187–207, and thus the power 
of these studies to determine a modest improvement in survival for splenectomy is 
limited(Csendes et al., 2002, Yu et al., 2006).  
3. Scientific basis of lymph node dissection 
3.1 The Japanese evidence 
In the  western world the over-all 5-year survival rate among patients with resectable gastric 
cancers range from 10%-30%, while in Japan the survival for the same subgroup of patients 
is between 50% and 62% largely attributable to the lymph node dissection known as D2 
which was introduced in 1960s. In Japan standard resection refers to  total or subtotal 
gastrectomy with D2 resection.  The 5 year survival rate following D2 lymphadenectomy is 
63,8% and is superior to survival after D1 or D0 lymphadenecomy (41,2% and 20,3% 
respectively)  according to the Japanese Nationwide Registry for Gastric Cancer. The major 
effect of systemic lymph node dissection is the reduction in locoregional recurrence. The 
proportions of local recurrences were decreased by the  introduction of this procedure, 38% 
in 1967-1971, 12% in 1982-1986. Operative mortality rate is very low in Japanese series and 
no different  from D1/D0 patients. According to the Japanese Natiowide registry reports the 
30 days postoperative mortality is 1,7% (Maruyama et al., 1998).  
3.2 The evidence for D2 resection in western world 
The National Comprehensive Cancer Network (NCCN), an alliance of 21 of the world's 
leading cancer center has released a latest guideline in 2010. According to this guideline 
gastric resection should include the regional lymphatics, the perigastric lymph nodes as well 
as those along the celiac axis with at least 15 lymph nodes. Splenectomy is acceptable only 
when spleen or hilus is involved. The guideline points out several studies  the guideline is 
based on.  
Schwarz et al. reviewed  relationships between the number of LNs examined and survival 
among the patients in SEER  (Surveillance, Epidemiology and End Results) database. 
Outcomes were analyzed only for the stage subgroups characterized by the N categories N2 
or N3, and transmural tumor extension (T categories T2b or T3).  Advanced but potentially 
still curable gastric cancer (stages IIIA, IIIB, or stage IV M0) is associated with very high 
recurrence rates after gastrectomy. For every ten extra LNs added to the total LN count, the 
calculated overall survival increased by: 5.7% (T2b-3N2), 4.6% (T2b-3N3), or 5.9%. Despite 
the small incremental increases in survival, benefits based on increasing LN counts were 
obvious for all groups analyzed, but reached statistically significant differences only for the 
N3 subgroup. The findings demonstrate that even in transmural or serosa-positive gastric 
cancer with advanced nodal involvement, more extensive LN dissection and analysis 
influences survival. Stage-based survival prediction of advanced gastric cancer without 
distant metastases depends on total LN number and number of negative LNs. For the 
curative-intent gastrectomy of locoregionally advanced gastric cancer, retrieval and 
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examination of larger numbers of LNs are suggested.  It is  criticized that recommended 
minimum goal of 15 LNs to satisfy current ( 6th edition at the time the study was made)  
AJCC staging criteria appears insufficient . Especially for N3 categories, the minimum goal 
theoretically should be set to at least ten LNs above the number of positive nodes. 
Practically, this would require at least 25 LNs  although counts of 40 or more total LNs 
appear even yet superior. As long as operative morbidity is not affected negatively,  
extended lymphadecectomy (ELND) during potentially curative gastrectomy is 
recommended even for advanced gastric cancer. The NCNN guideline excerpts that  
patients who had more than 15 D2 lymph nodes and patients with more than 20 N3 lymph 
nodes dissected had the best survival outcome (Schwarz & Smith, 2007). As a result the 
NCNN guide has increased the number of lyph nodes necessarily dissected for better 
staging and curativeness in the seventh edition. There is now a cathegory of N3b with 
metastases to 16 or more lymph nodes.  
3.2.1 The Dutch study from the beginning to now 
The Dutch gastric cancer group randomized 711 patients to go under resection with curative 
intent, and randomly assigned them into D1 (380 patients) and D2 (311patients) resection 
groups. The results of this study is extensively eveluated. They demostrated that patients in 
D2 goup suffered from a higher rate of postoperative complications than did those in D1 
group (43% vs 25%), higher postoperative mortality rates (10% vs 4%) and longer hospital 
stay (Bonenkamp et al., 1995). Nevertheless, they found out that the 5-year survival rate did 
not significantly differ between the two groups; 45% in D1 group and 47% in D2 group 
(Bonenkamp et al., 1999). After a median follow up period of 11 years no statistically 
survival difference was encountered between the two groups (D1 30% vs D2 35%)   
(Hartgrink,2004). Noncompliance, which is inadequate removal of 2nd echelon and 
contamination, which is unnecessary removal of the second tier lymph nodes were 
encountered. In Dutch trial while 6% of the patients who were supposedly to go under D1 
resection had additional lymph node dissections, 51% of the patients with D2 resection had 
one or more node stations left undissected (Bonenkamp et al., 1998). 
The learning curve for D2 resection is steep and it has been proposed that it may entail as 
much as 25 operations.  The higher complication rates maybe  attributed to the lack of 
experience of the participating surgeons with D2 resection but in subgroup analysis  higher 
morbdity and mortality rates are asscoiated with pancreaticosplenectomy carried out in the 
D2 group, which was regarded as a part of the R0 surgery especially for proximal cancers at 
the time of the study (de Gara et al., 2003). 
The Dutch gastric study revealed a 30% stage migration when a higher number of lymph 
nodes were examined.  The most prominent feature is that patients with N2 disease in the 
D2 group showed significantly improved survival rates   than those in D1 group (%19 vs 
0%) in consistence with that  in the subgroup analysis Siewart et al.  had demonstrated a 
significant difference  in patients with stages ll and llla in the German study.  In the long 
term follow up the results of the Dutch study confers a lower risk of recurrence in patients 
who underwent D2 resection and higher survival rates. 
In the final analysis of 15 years follow up which was evauated in a 2010 article gastric-
cancer-related death rate was significantly higher in the D2 group (48%, 182 patients) 
compared with the D1 group (37%, 123 patients), whereas death due to other diseases was 
similar in both groups. Local recurrence was 22% (82 patients) in the D1 group versus 12% 
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(40 patients) in D2, and regional recurrence was 19% (73 patients) in D1 versus 13% (43 
patients) in D2.  
Even though the initial conclusions from the Dutch gastric cancer study were discouraging 
especially when a high mortality rate was observed without any significant survival 
improvement, on the final  conclusion D2 lymphadenectomy is the recommended surgical 
approach for patients with resectable (curable) gastric cancer while especially a spleen 
preserving technique is available (Songun et al., 2010). 
3.2.2 The German study 
A total of 1654 patients treated for gastric cancer between 1986 and 1989 at 19 centers 
in Germany and Austria were included. The resected specimen were evaluated 
histopathologically according to a standardized protocol. The extent of lymphadenectomy was 
classified after surgery based on the  number of removed lymph nodes on histopathologic 
assessment (25 or fewer removed nodes, Dl or standard lymphadenectomy; >25 removed 
nodes, D2 or extended lymphadenectomy). Endpoint of the study was death. Median follow-
up of the surviving patients was 8.4 years. There was no difference in the postsurgical 
morbidity and mortality rates between patients with standard and extended lymph node 
dissection, even though they were worse when compared to Japanese statistics.  The 30- and 
90-day mortality rates in the total patient population were 5.1% and 10.6%, respectively. 
Calculated 10-year survival rate was 26.3% ± 4.7% in the total patient population and 36.1% 
± 1.6% in those with an R0 resection. Extended lymph node dissection significantly 
increased the 10-year survival rate and median survival time in patients with UICC stage II 
tumors. In this patient subgroup, extended lymphadenectomy resulted in a marked 
improvement of the 10-year survival rate from 19.9% with standard lymphadenectomy to 
49.2% with extended lymphadenectomy (Siewart et al., 1998).  
3.2.3 The British study 
In 1986 the  Medical Research Council of Great Britain iniated a nationwide, multicenter 
randomized controlled trial (RCT) comparing D1 dissection to D2 dissection of 200 patients 
randomized at each limb. Postoperative mortality was significantly higher in the D2 group 
than D1 (13,1% vs 6,5%). postoperative complications were also higher in the D2 group 
reaching 46%. However, in this trial many surgeons thought that D2 dissection included 
splenectomy and splenectomy was carried out in many distal gastrectomy cases (Cushieri et 
al., 1999) Pancreaticosplenectomy was carried out in 56% of the cases in D2 group. 
Splenectomy with subtotal gastrectomy causes serious ischemia of the remnant stomach 
causing anastomotic leakage or necrosis. The five year overall survival did not differ  in 
either limb (Tanizawa & Terashima,  2010).  
3.2.4 Italian study 
The majority of complications in the Dutch and British trials are associated with 
pancreticosplenectomy. Deguili et al. have  shown the safety of D2 dissection with pancreas 
preservation. In their studies postoperative morbidity is as low as 13-17% with mortality 
rates 0,6-3% without significant difference in mortality and morbidity  between D1 and D2 
results. In their IGCSG-R01 trial  splenopancreatectomy was not considered as a routine part 
of the D2 total gastrectomy. The  spleen was removed according to the Maruyama technique 
only when the tumour was in the left part of the upper stomach or located close to the 
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greater curvature, beyond Demel’s point. The spleen was also preserved in patients with 
clinical T1 tumours. The pancreas was removed only when tumour involvement was 
suspected. As a consequence  the overall morbidity rate after D2 and D1 dissections was 
17.9% and 12.0%. The postoperative 30-day mortality rate was 3.0%after D1 and 2.2% after 
D2 gastrectomy. In specialized centres the rate of complications following D2 dissection is 
much lower than in published randomized Western trials. D2 dissection, in an appropriate 
setting, can therefore be considered a safe option for the radical management of gastric 
cancer in Western patients (Deguili et al., 2004). 
3.2.5 Additional information 
Diaz et al. studied prospectively  126 consecutive patients operated upon for gastric cancer, 
with gastrectomy and D2 lymphadenectomy. Hospital morbidity and mortality, relapses, 
and patient survival after 5 years were studied. The overall hospital mortality rate was 1.6%, 
with a mortality of 2.1% in the patients submitted to total gastrectomy. The overall 
morbidity rate was 29.4% with a 5-year survival of more than 50%. Dehiscence of the 
esophagojejunal anastomosis was recorded in 1.6%. The median follow-up was 73.6 months. 
Relapses were observed in 37% of the patients (76% in the fi rst 2 years). Overall actuarial 
survival after 5 years was 52.3%, and 5-year survival in the patients with R0 resection with 
positive N2 lymph nodes according to the Japanese classification was 26.5% (Diaz et al., 
2008). 
Other reports from  Spain reveal results comparable to Japanese practice applying the D2 
resection. Sierra et al.(2003)  found no significant difference in the length of hospital stay 
(median, 12.1 and 13.1 days), overall morbidity (48.2% and 53.5%), or operative mortality 
(2.3% and 0%) between D1 and D2, respectively. Five-year survival in the D2 group was 
longer (50.6%) than in the D1 group (41.4%) for tumor  stages (tumor-node-metastasis)  
greater than l . 
An RCT performed in the USA investigated the role of post-operative chemoradiotherapy 
and also showed significant survival benefit . However, only 10% of the patients underwent 
D2 dissection, there was a very high rate of local recurrence, and the surgery was not 
standardized among the participating hospitals. Subgroup analysis found survival benefit 
only in D0 or D1, but not in the D2-dissected group(Mac Donald et al., 2001). The study thus 
showed that D0/D1 dissection was insufficient treatment  .  
There are reports about low mortality and morbidity for D2 dissection from various 
european countries. For example, the Latvian Oncology Center in a series of 468 patients has 
in hospital mortality 3,3% and morbidity 16,3% with a five year overall survival of 52,5%. 
The 5 year survival rates according to pT cathegory are 86% for pT1, 65% for pT2 and 43% 
for pT3, 27% for pT4 (Sivins et al., 2009).   
3.3 D2 vs D3 
In a review by Tanizawa and Terashima  three major studies comparing D2 lymphadectomy 
with D3 are discussed. In advanced gastric cancer the incidence of microscopic metastases in 
the paraaortic lymph nodes is 6% to 33% (Takashima & Kosaka, 2005). Since 1980s 
superextended lymph node dissection is carried out in specialized centers in Japan. The  
Japanese Clinical Oncology Group conducted a randomized trial comparing D2 and D2 plus 
paraaortic lymphadenectomy among patients with curable gastic cancer (Sasako et a., 2008).  
The overall morbidity was 24% and even though the mobidity was higher in the D2  plus 
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The overall morbidity was 24% and even though the mobidity was higher in the D2  plus 
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group it did not significantly differ. (28% vs 21%). There was no difference in hospital 
mortaliy between the two groups as well overall survival after 5 years. The blood loss and 
operation time are  signifiantly increased in the D2 plus paraaortic lymph node dissection 
group (Sano et al., 2004).   
The rationale behind D4 resecion is that to obtain a safe dissection margin for the lymph 
node involvement in the N2 and N3 stations. It is proposed that when the D-number is 
greater than the N-number, recurrence can be decreased. Accordingly, D2 gastrectomy is 
effective for N1 patients. In this sense, D4 dissection has been considered to improve the 
survival of patients with N2 or N3 involvement.  D4 dissection had been practiced at many 
Asian institutions and Asian surgeons have proposed D4 dissection as a surgical technique 
to remove micrometastasis in the No. 16 lymph node. Micrometastasis in No. 16 lymph 
nodes was detected in 20% to 31% of patients with advanced gastric cancer, who underwent 
curative gastrectomy (Yonemura et al., 2008). 
The major lymphatic channels from the upper half of the stomach run along the left gastric 
artery (No. 7), posterior gastric artery (No. 11), and splenic artery.  In contrast, lymphatic 
channels from the lower half of the stomach run along not only the common hepatic artery 
(No. 8) but also along the root of the superior mesenteric artery (No. 14).  Efferent lymphatic 
channels from these nodes drain into the No. 16 nodes, which are named No. 16 a2 and 
No.16 b1. Accordingly, No. 16 a2 and No. 16 b1 are considered as the terminal nodes of the 
stomach.  Cancer cells released from the N2 or N3 lymph node stations are trapped in the 
lymph nodes located in the bilateral space around the aorta (No. 16 a2-lateral, -pre, and -
inter), before the systemic spreading of cancer cells through the thoracic duct. According to 
the literature, the 5-year survival rates of N4 patients who underwent D4 resection ranged 
from 14% to 30% (Yonemura et al., 2008). Neither  JCOG tiral and nother  east asian trial did 
not reveal any  significant difference in survival between two groups(Sano et al., 2004; 
Yonemura et al., 2008). There has been a recent study from Poland  that compares the two 
methods revealing that there was no difference in morbidity and mortality but survival yet 
remains to be analysed (Kulig et al. 2007). 
However, a study from Italy on superextended lymphadectomy with a pouplation of 286 
patients, even though it is not a randomized study but a review of cases between 1993 and 
2007,  reveal some long term survival chance for both pN3 and M1a patients, 31% and 17% 
respectively. There is also remarkably high  survival rate in pN2 and pN3 subsets when no 
serosal invasion was demonstrated, reaching upto 60%. The authors of this study, (Roviello 
et al.) has some points on the previous studies carried out in Japan. The overall survival 
rates (5-year survival: 70%) in east asian studies  are at least better by one third than those 
reported by specialized Western centres in advanced forms. The adopted lymphadenectomy 
in D2 group included third level nodes (posterior hepatic artery nodes, posterior 
hepatoduodenal ligament nodes, etc.) in tumour with antral location that lead to a ‘D3 
lymphadenectomy minus paraaortic nodes (PAN) dissection’. The extent of 
lymphadenectomy is indeed demonstrated by the extremely high number of removed nodes 
(mean: 53 for D2 and 73 for D2 plus paraaortic). Cases in which macroscopic involvement of 
PANs was evident at surgery were excluded from the study. As stated by the authors 
themselves, the percentage of involvement was lower than expected (8%) and the potential 
survival benefit possibly weakened. Furthermore, the post hoc subgroup analysis based on 
pathologic N and T stages showed a better survival rate in the D2 plus para-aortic group for 
patients without nodal involvement and for patients with tumour invasion limited to the 
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subserosal layer (less than pT3). An extremely high chance of cure was observed in  patients 
with tumors not involving the serosa (pT2) or absence of nodal metastases (pN0), even if 
survival probability did not reach the results of the Japanese trial. Particularly, long-term 
results were remarkable in pT2 N2 and N3 patients. One could speculate that in these 
particular subsets of patients, where the local control of the disease is essential, D3 
lymphadenectomy may be of value in improving long-term results. On the contrary, in 
serosally exposed neoplasms, which are particularly prone to peritoneal dissemination, the 
extent of lymphadenectomy might not provide a survival advantage with respect to more 
limited dissection (Roviello et al., 2010) .  
As a consequence the NCNN guide does not recommend D2 plus paraaortic lymph node 
dissection for patients with curable gastric cancer (T2b, T3 or T4).  
3.4 Conclusion 
The NCCN 2010 guideline  states that in west the D2 resection is a recommended but not a 
required operation. Modified lymphadectomy without pancreaticosplenectomy is associated 
with low mortality and morbidity as well as with reasonable survival times when 
performed in institutions with sufficient experience in operative and postoperative 
management. While in the east standard surgery is D2 lymphadenectomy and so  far has 
proved longer  5 year survival and less locoregional recurrence rates. Finally, in our study 
although extensive dissection had an increased morbidity, there was no significant statistical 
difference between the D1 and D2 procedures (Yuksel et al., 2009). As a conclusion, we think 
that D2 dissection can be carried out with safety in centers with experience.   
4. Sentinel lymph node dissection 
Sentinel node is the first lymph node that receives the drainage from primary tumor. A 
sentinel biopsy for gastric cancer is an intra operative diagnostic tool to detect lymph node 
metastasis (Ishii et al., 2008). The sentinel node hypothesis states that the histopathologic 
status of the first node on the lymphatic drainage pathway from a primary tumor reflects 
the tumor status of the entire lymphatic drainage basin .  Underlying this hypothesis is the 
assumption that the surgeon can correctly and consistently identify this node(Hsueh et al., 
2001). 
The history of sentinel lymph node mapping dates back to 1977. Cabanas described and 
used the technique of lymphangiograms in patients with penile carcinoma (Cabanas, 1977). 
Later it gained more common use in the treatment of malignant melanoma and breast 
cancer. For epithelial tumors lymphatic spread is a common route of metastasis and the 
nodal status is important for staging and therefore in planning the surgical and adjuant 
therapies. Nodal involvement in gastric cancer depends on the depth of invasion and it is 
between 2-18%  for tumors limited with mucosa or submucosa, and around 50 % for tumors 
which has invaded muscularis propria or subserosa, T1 and T2 respectively. Therefore in 
some cases there is a chance of resecting more tissue than what may be required. Given the 
high morbidity rates associated with extended dissections in elderly population and in 
general, especially in western countries, when compared to more limited dissections, 
alternative treatments to avoid the risks associated with this procedure has been discussed 
among surgeons. D2 lymph node dissection may be unnecessary for patients without lymph 
node metastasis (Cozzaglio et al., 2011). To decrease the perioperative morbidity and 
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alternative treatments to avoid the risks associated with this procedure has been discussed 
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mortality and to improve the quality of life, less invasive surgery has been employed on 
patients with node-negative gastric cancer. However, it is difficult to precisely diagnose 
lymph node metastasis using preoperative examinations such as endoscopic 
ultrasonography and computed tomography (Li et al., 2008).  
Miwa et al. (2001) demonstrated that extended lymphadenectomy in patients with early 
gastric cancer (EGC) resulted in a significantly lower 10-year recurrence rate than limited 
lymph node dissection (D1). Among node-positive patients, the recurrence rate following 
D2 was significantly lower than that after D1. Among node-negative patients, there was no 
difference in recurrence rate between two groups. Based on these observations he suggested 
that there are two optimal methods of node dissections in EGC surgery based on nodal 
status. He further stated that sentinel node concept is important to understand nodal status 
and introduced the sentinel node concept to gastric area. In 34 of 35 patients, metastatic 
nodes were located along the lymphatic basins. Among them, 15 patients had metastasis 
only in the sentinel lymph nodes. Of 5 gastric lymphatic basins, 42% of the patients had 
involvement of one, 47% 2, and 12% 3. These results show that each EGC has its own 
lymphatic basins in which metastasis can develop. The more numbers of the sections there 
are, the higher the likelihood of nodal metastasis. This means that each frozen section slice 
carries the risk of being false negative. Therefore we should always dissect the lymphatic 
basins even in cases with no sentinel node metastasis. In addition, patients with sentinel 
nodes containing metastasis should be treated with the D2 procedure (Miwa et al., 2001). 
The current Japanese guideline recommendations for early cancers that are seemingly 
lymph node negative are as follows: 
For  Stage IA (T1N0) tumors Endoscopic Mucosal Resection EMR or modified gastrectomy 
(MG) is indicated  according to the following instruction. 
 
Depth of invasion Histology Size Indication 
Mucosa(M) differentiated 2cm EMR 
Mucosa(M) else  MG A 
Submucosa(SM) differentiated 1.5cm MG A 
Submucosa(SM) else  MG B 
Table 2. Treatment indication for Stage IA 
EMR should be indicated to patients with small mucosal cancer with no lymph node 
metastasis. The JGSA database suggests that intestinal type mucosal cancer less than 2cm in 
diameter has no lymph node metastasis. En-bloc resection is preferable because of risk of 
residual cancer left behind EMR, and 2cm is the upper limit of en-bloc resection. Then, 
accurate assessment of the depth of wall invasion, histological type and size of tumor is 
mandatory before carrying out EMR. Mucosal cancer that does not meet this condition 
should be treated by MG A. MG A is also indicated to the differentiated submucosal cancer 
less than 1.5 cm in diameter. Submucosal cancer that does not meet this condition should be 
treated by MG B. Type of gastrectomy is shown in Table 3. 
The lymphatic basins are defined as the area containing the stained or radiologically marked 
lymphatic vessels and are divided into five categories according to the directions of arteries 
that surrounds the stomach as follows: the left gastric area, the right gastric area, the right 
gastroepiploic area, the left gastropeiploic are and the posterior gastric artery area.  
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Gastrectomy Range of Resection Dissection Option 
Modified A < 2/3 D1 + No.7* Vagus preserving 
Modified B < 2/3 D1 + No.7,8a,9 Pylorus preserving 
   Laparoscopic 
Standard 2/3 D2  
Extended 2/3 D2 D3 
Combined resection    
*In case of lower third cancer, No.8a nodes should be dissected. 
Standard gastrectomy includes proximal, distal or total gastrectomy associated with D2 dissection 
according to the size and location of the tumor.  
The differentiated type: papillary, well and moderately differentiated tubular adenocarcinomas. 
The undifferentiated type: poorly differentiated adenocarcinoma, mucinous adenocarcinoma and 
signet-ring cell  adeno-carcinoma.  
Table 3. Type of gastrectomy 
A preoperative endoscopic injection of dye or radioactive tracer followed by intraoperative 
mapping, intraoperative endoscopic injection, intraoperative subserosal injection of dye are 
the the usual ways of defining the lymphatic basin. The injections are carried out  in four 
quadrants of the tumor either by endoscopy or by open surgery. The dye guided method is 
safe convenient and cost-effective. The radioguided  method is more costly and may 
confront legal issues (Miyashiro et al., 2010). 
The   sentinel node (SN) concept has revolutionized the approach to the surgical staging of 
both melanoma and breast cancer, and these techniques can yield patient benefit by 
avoiding various complications due to unnecessary prophylactic regional lymph node 
dissection in cases with negative SN for cancer metastasis. Clinical application of SN 
mapping for early gastric cancer had been controversial for years. However, single 
institutional results of SN mapping for early gastric cancer are almost acceptable results in 
terms of detection rate and accuracy to determine lymph node status. Hypothesizing  that 
SN mapping plays a key role to obtain individual information and allows modification of 
the surgical procedure for early gastric cancer, The Japan Society of Sentinel Node 
Navigation Surgery (JSNNS) has conducted a prospective multicenter trial of SN mapping 
by a dual tracer method with radioactive colloid and blue dye. Between September 2004 and 
March 2008, 433 patients with early gastric cancer were accrued at 12 comprehensive hospitals. 
Patients were enrolled under JSNNS and each institutional review board-approved protocols. 
Eligibility criteria were that patients had clinically T1N0M0 or T2N0M0 single tumor with 
diameter of primary lesion less than 4cm without any previous treatments. Technetium-99m 
tin colloid and isosulfan blue were utilized as dual tracers for SN mapping.  SN mapping was  
performed for 397 patients with early gastric cancer. Detection rate of hot and/or blue node 
using their procedure was 97.5% (387/397). The mean number of sentinel nodes per case was 
5.6. Fifty-three of 57 cases with lymph node metastasis showed positive sentinel nodes. The 
sensitivity to detect metastasis based on SN status was therefore 93% in their experience. 
Accuracy of metastatic status based on SN was 99% (383/387). In two of the four SN false-
negative cases, the tumor involved to pT2, and only one case showed the metastatic lymph 
node beyond the SN basin (Kitagawa et al., 2009). Reviewing the relevant data, it becomes 
evident that the success rate of SLN mapping varies from as high as 99% in the Hiratsuka et al.  
series or 95% in the Aikou et al. series  to as low as 74% in other series. 
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4.1 Pertinent issues 
Skip metastasis is defined as the detection of metastatically infiltrated extragastric lymph 
nodes (level 2) in the absence of perigatric lymph node (level 1) involvement (Lee et al., 
2009).  However, the existence of skip metastases maybe as high as 17% and because of the 
complex and multi directional status of the gastric lymphatic drainage and the alteration of 
lymphatic pathways in advanced tumors because of the obstruction caused by tumor 
deposits  (Griniatsos et al., 2009).  There are also concerns about the negative predictivity of 
the technique. In patients with histologically classified as level one lymph node negative 
early gastric cancer, micrometastatically infiltrated level 2 lyph nodes are detected in 10 % 
(Morgagni et al., 2003). The lymphatic drainage route is patient-specific and lesion-specific 
in gastric cancer due to complicated lymphatic streams from the stomach. The most 
common channel for metastasis has been analyzed by subdividing the location of the tumor. 
For upper-thirds, the left gastric artery channel (Nos. 1, 3, 7) is the most common route. For 
the lower- and middle-third tumors, the left gastric artery channel and right gastroepiploic 
artery channel (No. 4and No. 6) are equally frequent routes. The following factors could 
play some role in the pathogenesis of skip metastasis: (1) Occult metastasis or 
micrometastasis to N1 nodes may have been missed during the dissection or routine 
histopathologic examination; (2) There may have been some aberrant lymphatic drainage 
patterns in patients with gastric cancer through which metastasis bypassed the lymphatic 
vessels; (3) Lymphatic flows to the N1 nodes may have been blocked by cancer tissue; (4) 
Free cancer cells may diffuse through regional nodes to distant nodes because the 
microenvironment in N1 nodes is unfit for the development of metastasis (Li et al., 2008) 
In overweight patients when the cancer is located in the upper third of the stomach dense 
fat can conceal the visualization of SNL. When harvested lymph nodes are smaller than 3 
false negativity increases. So maybe instead of lymph node biopsy, limited 
lymphadenectomy or lymphatic basin dissection may  lead to better results. This is not 
actually a sentinel node biopsy because it is not a single pick biopsy but a limited resection. 
However if there are too many lymph nodes in the sentinel piece it will be hard to examine 
by frozen section. 
When a lymph node micrometastasis is identified, routine extended resection is indicated 
but currently it is hard to detect micrometastasis in a short time during the 
operation.Another shortcoming is that in cases where SNs dont contain metastasis how to 
determine the extent of dissection.  
The presence of micrometastasis in a  lymph node is a critical issue for the clinical 
application of sentinel node biopsy for gastric cancer. There has been found micrometastases 
among patients who had been classified as tumor-free in routine histological examination. 
Micrometastases may be found by using step sectioning, immunohistochemical (IHC) 
staining and reverse transcriptase-polimerase chain reaction.  Matsumoto et al. (2002) 
demonstrated that the reverse transcriptase chain reaction is more sensitive than IHC for 
detection of micrometastases.  However Yamamoto et al. (2001) suggested that positive 
results with a molecular array may not be indicative of the presence of viable tumor cells but 
rather the presence of tumor dna thus may be associated with an increase rate of false 
positivity. The serial sectioning with IHC is thought to be the  most accurate method for 
detection of lymph node micrometastases. In  a study by Ishii et al. (2008) they 
demonstrated that the the sentinel nodes were the first to receive micrometastases and they 
found no micrometastasis without the sentinel lymph node metastasis. They also suggested 
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that it is sufficient to examine the sentinel lymph node for micrometastasis to determine 
whether or not there are lymph node micrometastases in patients with gastric cancer. 
Ajisaka et al. have proposed that dissection of the lymph nodes in the same lymphatic basin 
with the SN maybe mandatory even if the SN does  not contain metastasis. Afer they found 
out that mestastatic nonsentinel nodes lie within th same basin with micrometastatic SNs, 
they proposed that the dissection of lymphatic basin containing SNs is minimal requirement 
for early stage gastric cancer even for patients without histologically detectable metastases 
in SNs (Ajisaka et al., 2003).  
Another issue is that the reports from far Asia yields and accuracy rate of 98%, whereas in 
Europe the false  negativity increases as well as accuracy to drops to 80%. In a study from 
Tel Aviv University they concluded that while in T1 And T2  tumors sentinel node mapping 
may be of assistance in decision making process regarding the extent of lymphadenectomy, 
SLN mapping in patients with T3 tumors maybe misleading in a third of the patients and 
therefore is not advised (Rabin et al., 2010).  
5. Micrometastases and early gastric cancer  
While the presence of lymph node metastases in early gastric cancer (EGC) is the most 
significant prognostic factor, the relevance of lymph node micrometastases (MM)  remains 
uncertain. In 1996 Maehara noticed that even after curative resection of an early gastric 
cancer, some patients die of a recurrence. It is thought that patients with early gastric cancer 
who died of their disease had occult micrometastases in perigastric lymph nodes at the time 
of the original diagnosis.  
Saito et  al. (2007) studied seven hundred and sixty-five patients with early gastric cancer 
who underwent curative gastrectomy  and analyzed them to identify the prognostic factor. 
The recurrence was observed in 17 patients. Hematogenous recurrence was observed most 
frequently (47.1%), followed by peritoneal recurrence (23.5%). Of 17 patients with 
recurrence, 6 (35.3%) patients died more than 5 years after operation. The prognosis was 
poorer when the patients were older, and the depth of invasion was greater, lymph node 
metastasis, lymphatic involvement, and vascular involvement were present, and lymph 
node dissection was limited. The independent prognostic factors were lymph node 
metastasis, lymph node dissection, and age by multivariate analysis using Cox proportional 
hazards. Micrometastases within lymph nodes were confirmed in 3 of 6 node-negative 
patients with recurrence (Saito et al., 2007). Several other studies have also supported the 
poorer prognosis of occult metastasis in early gastric cancer patients. In retrospective studies 
the  frequency of micrometastasis in early gastric cancer can be as high as 20% and in most 
studies they are associated with poorer survival and more recurrence.  
In a study by Liang Cao et al.  MM was significantly associated with tumor size  and 
lymphatic invasion . The statistically significant prognostic factors affecting 5-year survival 
rates were depth of tumor invasion, tumor size, lymphatic invasion, MM, and type of MM. 
The presence of MM, and particularly the cluster-type MM (P<0.001), were independent 
prognostic factors in pN0 early gastric cancer patients : The incidence of lymph node MM in 
patients with node negative early gastric cancer was 21.3%, and cancer cell cluster type of 
MM proved a primary independent prognostic factor for pN0 early gastric cancer patients 
(Cao et al.,2011) 
Many studies have proved that there are two types micrometastases in lymph nodes: single-
cell type and clustered-cell type.  This can be explained by invoking the concept of tumor 
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4.1 Pertinent issues 
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The presence of micrometastasis in a  lymph node is a critical issue for the clinical 
application of sentinel node biopsy for gastric cancer. There has been found micrometastases 
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found no micrometastasis without the sentinel lymph node metastasis. They also suggested 
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metastasis, lymph node dissection, and age by multivariate analysis using Cox proportional 
hazards. Micrometastases within lymph nodes were confirmed in 3 of 6 node-negative 
patients with recurrence (Saito et al., 2007). Several other studies have also supported the 
poorer prognosis of occult metastasis in early gastric cancer patients. In retrospective studies 
the  frequency of micrometastasis in early gastric cancer can be as high as 20% and in most 
studies they are associated with poorer survival and more recurrence.  
In a study by Liang Cao et al.  MM was significantly associated with tumor size  and 
lymphatic invasion . The statistically significant prognostic factors affecting 5-year survival 
rates were depth of tumor invasion, tumor size, lymphatic invasion, MM, and type of MM. 
The presence of MM, and particularly the cluster-type MM (P<0.001), were independent 
prognostic factors in pN0 early gastric cancer patients : The incidence of lymph node MM in 
patients with node negative early gastric cancer was 21.3%, and cancer cell cluster type of 
MM proved a primary independent prognostic factor for pN0 early gastric cancer patients 
(Cao et al.,2011) 
Many studies have proved that there are two types micrometastases in lymph nodes: single-
cell type and clustered-cell type.  This can be explained by invoking the concept of tumor 
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cell dormancy. Studies report that single cancer cells in lymph nodes may be associated with 
cells either under cell-cycle arrest or approaching apoptosis. According to cancer stem cell 
theory, an alternative explanation is that the disseminated cancer cells in some of the 
patients arose from the spread of nontumorigenic cells and only when cancer stems cells 
disseminate, and subsequently self-renew, will metastatic tumors form.  Cancer stem cell 
can proliferate and form clusters of tumor cells, and nontumorigenic cells form single cells 
lymph node MM. Only when cancer stem cells disseminate and self-renew will the cluster 
type of MM form. Cancer stem cell theory predicts that the prognosis of clustered-cell MM 
should be worse compared to single-cell MM.. The 5-year survival rate for the group of 
patients with cluster-type MM (45.8%) was significantly lower than that for the group with 
negative (92.9%) or single-cell MM (80%). Cluster type of MM was proved a major 
independent prognostic factor for histologically node negative gastric cancer patients. This 
phenomenon can be explained by the association of clustering with the presence true cancer 
stem cells (Cao et al., 2011). Cai describes that a high incidence of nodal involvement is 
found in submucosal cancers of large size (>2 cm; 43%), a depressed type (48%) and 
lymphatic invasion. A higher incidence of microinvasion is found with the diffuse-type 
carcinoma (33%) (Cai et al., 2000). 
Morgagni et al. studied 5400 lymph nodes dissected from 300 patients treated surgically for 
EGC between 1976 and 1999, all of whom were histologically pN0. Micrometastases were 
defined as single or small clusters of neoplastic cells identifiable only by 
immunohistochemical methods. Lymph node micrometastases were observed in 30 of the 
300 patients (10%). No significant correlation was observed between micrometastases and 
other clinicopathological characteristics. Analysis of overall survival showed no significant 
difference between positive or negative micrometastasis groups. The results of their study 
show that the presence of lymph node micrometastases in EGC does not influence patient 
prognosis (Morgagni et al., 2003). 
6. Micrometastasis in locally advanced and advanced tumors 
Giuli reviewed micrometastasis in gastric cancer in 2003. Nakajo et al. (2001)  reported that 
lymph node micrometastasis was correlated with a significantly worse survival rate in 
patients with T1 or T2  tumors . Cai et al. (1999) also found a significant relationship 
between lymph node micrometastasis and poor prognosis in patients with T3 gastric cancer. 
However, Fukagawa et al.  found that the presence of lymph node micrometastasis did not 
affect the survival in large numbers of  patiens with T2 cancer (Fukagawa et al., 2001). To 
clarify the prognostic importance of lymph node micrometastasis in patients with gastric 
cancer, histologically node-negative gastric cancers invading the muscularis propria or 
deeper (T2 and T3) were selected by Yasuda. The author's results indicate that lymph node 
micrometastasis is an independent prognostic indicator for patients with histologically 
node-negative gastric cancer invading the muscularis propria or deeper (T2 or T3). 
Micrometastasis of four or more lymph nodes or micrometastasis of level 2 nodes was 
significantly associated with a poor outcome. Lymph node metastasis is linked to tumor 
progression. Lymph node micrometastasis in gastric cancer is also associated with deep 
invasion through the gastric wall, large tumor size, and positive lymphatic or venous 
invasion. In this study, although no relationship was found between the presence of lymph 
node micrometastasis and clinico-pathologic characteristics, a weak association was found 
between lymph node micrometastasis and depth of wall invasion. In this series, the most 
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common pattern of recurrence was peritoneal and lung metastasis. Similar to these results, 
previous studies reported that lymph node micrometastasis was strongly associated with 
subsequent development of hematogenous and peritoneal metastases, but not locoregional 
lymph node recurrence (Yasuda et al., 2002).  Cai et al. studied  cases of pT3 gastric cancer 
and found out even when standard histological staining reveals no evidence of metastases 
in the regional lymph nodes, patients still may die of postoperative recurrence of the tumor. 
Evidence of occult involvement was found in 299 of 2310 (13%) lymph nodes and in 54 of 83 
(65%) patients with pT3 gastric cancer. An analysis of survival demonstrated the limited 5-
year survival of patients with occult involvement in their resected lymph nodes, as 
compared with that of patients without involvement. Moreover, the patients in whom group 
2 lymph nodes had occult cancer cells had a significantly poorer prognosis than those in 
whom occult involvement was limited to group 1 lymph nodes (Cai et al., 1999) . 
Lee et al. studied the overall 5-year survival rate of patients in the MM negative group (76%) 
was higher compared with the rate of patients in the MM positive group (49%) for both 
patients with EGC and patients with AGC (Table 4). The effect of MM was most pronounced 
among patients in the Stage I and LNM negative group . There was a significant correlation 
between MM and depth of tumor invasion. Patients with MM had a decreased 5-year 
survival rate (49%) compared with patients without MM  (76%) for both early and advanced 
gastric carcinoma. The effect of MM on survival was most pronounced for patients in the 
Stage I and LNM negative group (Lee et al., 2002). 
7. Early gastric cancer and lymphadenectomy 
Early gastric cancer is a more common entity in the east where screening programs are 
active, In the west most of the cancers are locally advanced or advanced at the time of 
diagnosis at present. The outcome of surgical treatment for early gastric cancer is 
satisfactory. Early gastric cancer is limited to mucosa or submucosa with or without lymph 
node metastasis. Even though the surgical treatment has excellent results in the 
management of early gastric cancer, the presence of lymph node metastasis is the most 
important prognostic factor.  
For intramucosal cancer lesions with a differentiated histological type and without 
lymphatic-vascular involvement or ulcerative findings within the cancerous lesion there is a 
minimal risk for lymph node invasion. The surgical treatment is excellent even in lymph 
node positive diease. In a study by Sano et al. in which they summarized their findings in 
1475 patients and reviewed 20 other articles in Japan about early gastric cancer, they pointed 
out that recurrence was higher in submucosal group (2,6%) than in mucosal grup (0,4%) and 
in lymph node positive group (7,3%) than the node free group (0,7%). In addition to this, 
histologically well differentiated tumors tended to recur more. The modes of recurrence 
were lymphatic, hematogenous, local peritoneal or a combination of these (Sano et al., 1993)  
In their literature review they found out the overall recurrence rate was between 0,25% and 
4,18% with a mean of 1,9%. The principal route of recurrence which led to death was 
hematogenous route in 59,3% of the patients and 68% of these recurrent tumors were well 
differentiated. Nevertheless, all the papillary carcinomas and  five out of six poorly 
differentiated adenocarcionomas that recurred had positive lymph nodes at the time of 
diagnosis. The recurrence modes were almost similar for both nodal and node-free diseases, 
hematogenous recurrence being the most prominent one. As a conclusion, submucosal 
invasion, node positivity, histologically differentiated tumors and type 2a and 2c are high 
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cell dormancy. Studies report that single cancer cells in lymph nodes may be associated with 
cells either under cell-cycle arrest or approaching apoptosis. According to cancer stem cell 
theory, an alternative explanation is that the disseminated cancer cells in some of the 
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patients with cluster-type MM (45.8%) was significantly lower than that for the group with 
negative (92.9%) or single-cell MM (80%). Cluster type of MM was proved a major 
independent prognostic factor for histologically node negative gastric cancer patients. This 
phenomenon can be explained by the association of clustering with the presence true cancer 
stem cells (Cao et al., 2011). Cai describes that a high incidence of nodal involvement is 
found in submucosal cancers of large size (>2 cm; 43%), a depressed type (48%) and 
lymphatic invasion. A higher incidence of microinvasion is found with the diffuse-type 
carcinoma (33%) (Cai et al., 2000). 
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defined as single or small clusters of neoplastic cells identifiable only by 
immunohistochemical methods. Lymph node micrometastases were observed in 30 of the 
300 patients (10%). No significant correlation was observed between micrometastases and 
other clinicopathological characteristics. Analysis of overall survival showed no significant 
difference between positive or negative micrometastasis groups. The results of their study 
show that the presence of lymph node micrometastases in EGC does not influence patient 
prognosis (Morgagni et al., 2003). 
6. Micrometastasis in locally advanced and advanced tumors 
Giuli reviewed micrometastasis in gastric cancer in 2003. Nakajo et al. (2001)  reported that 
lymph node micrometastasis was correlated with a significantly worse survival rate in 
patients with T1 or T2  tumors . Cai et al. (1999) also found a significant relationship 
between lymph node micrometastasis and poor prognosis in patients with T3 gastric cancer. 
However, Fukagawa et al.  found that the presence of lymph node micrometastasis did not 
affect the survival in large numbers of  patiens with T2 cancer (Fukagawa et al., 2001). To 
clarify the prognostic importance of lymph node micrometastasis in patients with gastric 
cancer, histologically node-negative gastric cancers invading the muscularis propria or 
deeper (T2 and T3) were selected by Yasuda. The author's results indicate that lymph node 
micrometastasis is an independent prognostic indicator for patients with histologically 
node-negative gastric cancer invading the muscularis propria or deeper (T2 or T3). 
Micrometastasis of four or more lymph nodes or micrometastasis of level 2 nodes was 
significantly associated with a poor outcome. Lymph node metastasis is linked to tumor 
progression. Lymph node micrometastasis in gastric cancer is also associated with deep 
invasion through the gastric wall, large tumor size, and positive lymphatic or venous 
invasion. In this study, although no relationship was found between the presence of lymph 
node micrometastasis and clinico-pathologic characteristics, a weak association was found 
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common pattern of recurrence was peritoneal and lung metastasis. Similar to these results, 
previous studies reported that lymph node micrometastasis was strongly associated with 
subsequent development of hematogenous and peritoneal metastases, but not locoregional 
lymph node recurrence (Yasuda et al., 2002).  Cai et al. studied  cases of pT3 gastric cancer 
and found out even when standard histological staining reveals no evidence of metastases 
in the regional lymph nodes, patients still may die of postoperative recurrence of the tumor. 
Evidence of occult involvement was found in 299 of 2310 (13%) lymph nodes and in 54 of 83 
(65%) patients with pT3 gastric cancer. An analysis of survival demonstrated the limited 5-
year survival of patients with occult involvement in their resected lymph nodes, as 
compared with that of patients without involvement. Moreover, the patients in whom group 
2 lymph nodes had occult cancer cells had a significantly poorer prognosis than those in 
whom occult involvement was limited to group 1 lymph nodes (Cai et al., 1999) . 
Lee et al. studied the overall 5-year survival rate of patients in the MM negative group (76%) 
was higher compared with the rate of patients in the MM positive group (49%) for both 
patients with EGC and patients with AGC (Table 4). The effect of MM was most pronounced 
among patients in the Stage I and LNM negative group . There was a significant correlation 
between MM and depth of tumor invasion. Patients with MM had a decreased 5-year 
survival rate (49%) compared with patients without MM  (76%) for both early and advanced 
gastric carcinoma. The effect of MM on survival was most pronounced for patients in the 
Stage I and LNM negative group (Lee et al., 2002). 
7. Early gastric cancer and lymphadenectomy 
Early gastric cancer is a more common entity in the east where screening programs are 
active, In the west most of the cancers are locally advanced or advanced at the time of 
diagnosis at present. The outcome of surgical treatment for early gastric cancer is 
satisfactory. Early gastric cancer is limited to mucosa or submucosa with or without lymph 
node metastasis. Even though the surgical treatment has excellent results in the 
management of early gastric cancer, the presence of lymph node metastasis is the most 
important prognostic factor.  
For intramucosal cancer lesions with a differentiated histological type and without 
lymphatic-vascular involvement or ulcerative findings within the cancerous lesion there is a 
minimal risk for lymph node invasion. The surgical treatment is excellent even in lymph 
node positive diease. In a study by Sano et al. in which they summarized their findings in 
1475 patients and reviewed 20 other articles in Japan about early gastric cancer, they pointed 
out that recurrence was higher in submucosal group (2,6%) than in mucosal grup (0,4%) and 
in lymph node positive group (7,3%) than the node free group (0,7%). In addition to this, 
histologically well differentiated tumors tended to recur more. The modes of recurrence 
were lymphatic, hematogenous, local peritoneal or a combination of these (Sano et al., 1993)  
In their literature review they found out the overall recurrence rate was between 0,25% and 
4,18% with a mean of 1,9%. The principal route of recurrence which led to death was 
hematogenous route in 59,3% of the patients and 68% of these recurrent tumors were well 
differentiated. Nevertheless, all the papillary carcinomas and  five out of six poorly 
differentiated adenocarcionomas that recurred had positive lymph nodes at the time of 
diagnosis. The recurrence modes were almost similar for both nodal and node-free diseases, 
hematogenous recurrence being the most prominent one. As a conclusion, submucosal 
invasion, node positivity, histologically differentiated tumors and type 2a and 2c are high 
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risk group. Traditional surgical resection is associated with 90% survival over 10 years (Sano 
et al., 1993).  
Although there was a controversy on the extent of lymph node dissection in the past,  today 
there is a concensus that limited D1 dissection is suitable  for most of the cases. The reason 
for a minimally invasive treatment is the low incience of lymp node metastasis. Only 2% 
(range 0-4,8%) of patients with mucosal cancer will have positive lymph nodes. However 
when the tumor invades the submucosa this rate is about %20 (range15-25%) and this 
metastasis is not confined to the first lympatic echelon, especially when the submucosal 
lesion is bigger than 2 cms in diameter (Roukos et al., 2002). 
For tumors which have exceeded the mucosa the risk factors for lymph node metastasis are 
tumor size larger than 30 mm, undifferentiated histologial type, lymphatic vascular 
involvement and submucosal  invasion more than 0,5 mm. Additional surgery with lymph 
node dissection is of little benefit for tumors that satisfy the following conditions. No 
lymphovascular involvement, tumor size smaller than 2 cm, differentiated histological tpe 
and depth of submucosal penetrations smaller than 0,5mm.  
According to the Japanese guideline 2004 for macroscopic mucosal cancer  of differentiated 
type (papilary, tubuler carcinoma grade1, tubullary carcinoa gade 2) less than 2 cm in 
diameter with no ulceration or scar in cases of depressed type, irrespective of macroscopic 
type, no lymph node dissection is recommended. In such cases local excision of tumor with 
endoscopic procedures are considered sufficient if the procedure is carried out in a 
specialized center. For T1 cancers which are  not indicated for EMR and which are with little 
possibility of lymph node metastasis, are  expected to be cured with  D1+α dissection. Such 
conditions are macroscopic mucosal cancer (more than 21 mms )  without lymph node 
metastasis and macroscopic submucosal cancer  of differentiated type less than 1.5 cm in 
diameter without lymph node metastasis . An  α dissection refers to dissection of first 
echelon lymph nodes and the 7th  lymp node station in the second tier with addition  of the 
8th nodal station in cancers of the lower third with standard gastrectomy that is removal of 
two thirds of stomach. If that the cancer is differentiated type, ≤ 2.0 cm in diameter, no 
ulceration in cases of depressed-type and there is involvement of the first tier of lymph 
nodes modified or if the submucosal cancer is differentiated type but more than 1,5 cms 
without lymph node involvement surgery-B  (subtotal gastrectomy with the removal of first 
tier lymph nodes as well as lymph node stations  7, 8a, 9) is recommended. For other T1 
tumors up to N2 nodal involvement standard surgery that is subtotal gastrectomy with the 
removal of second tiers of nodes is recommended. A very careful pre and intraoperative 
assesment of lymph nodes are mandatory and  in case of any suspicion standard 
gastrectomy should be carried out. 
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risk group. Traditional surgical resection is associated with 90% survival over 10 years (Sano 
et al., 1993).  
Although there was a controversy on the extent of lymph node dissection in the past,  today 
there is a concensus that limited D1 dissection is suitable  for most of the cases. The reason 
for a minimally invasive treatment is the low incience of lymp node metastasis. Only 2% 
(range 0-4,8%) of patients with mucosal cancer will have positive lymph nodes. However 
when the tumor invades the submucosa this rate is about %20 (range15-25%) and this 
metastasis is not confined to the first lympatic echelon, especially when the submucosal 
lesion is bigger than 2 cms in diameter (Roukos et al., 2002). 
For tumors which have exceeded the mucosa the risk factors for lymph node metastasis are 
tumor size larger than 30 mm, undifferentiated histologial type, lymphatic vascular 
involvement and submucosal  invasion more than 0,5 mm. Additional surgery with lymph 
node dissection is of little benefit for tumors that satisfy the following conditions. No 
lymphovascular involvement, tumor size smaller than 2 cm, differentiated histological tpe 
and depth of submucosal penetrations smaller than 0,5mm.  
According to the Japanese guideline 2004 for macroscopic mucosal cancer  of differentiated 
type (papilary, tubuler carcinoma grade1, tubullary carcinoa gade 2) less than 2 cm in 
diameter with no ulceration or scar in cases of depressed type, irrespective of macroscopic 
type, no lymph node dissection is recommended. In such cases local excision of tumor with 
endoscopic procedures are considered sufficient if the procedure is carried out in a 
specialized center. For T1 cancers which are  not indicated for EMR and which are with little 
possibility of lymph node metastasis, are  expected to be cured with  D1+α dissection. Such 
conditions are macroscopic mucosal cancer (more than 21 mms )  without lymph node 
metastasis and macroscopic submucosal cancer  of differentiated type less than 1.5 cm in 
diameter without lymph node metastasis . An  α dissection refers to dissection of first 
echelon lymph nodes and the 7th  lymp node station in the second tier with addition  of the 
8th nodal station in cancers of the lower third with standard gastrectomy that is removal of 
two thirds of stomach. If that the cancer is differentiated type, ≤ 2.0 cm in diameter, no 
ulceration in cases of depressed-type and there is involvement of the first tier of lymph 
nodes modified or if the submucosal cancer is differentiated type but more than 1,5 cms 
without lymph node involvement surgery-B  (subtotal gastrectomy with the removal of first 
tier lymph nodes as well as lymph node stations  7, 8a, 9) is recommended. For other T1 
tumors up to N2 nodal involvement standard surgery that is subtotal gastrectomy with the 
removal of second tiers of nodes is recommended. A very careful pre and intraoperative 
assesment of lymph nodes are mandatory and  in case of any suspicion standard 
gastrectomy should be carried out. 
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Although the prognosis of unresectable gastric cancer remains poor (Hohenberger & 
Gretshel, 2003), recent advances in chemotherapy for this cancer have considerably 
improved the therapeutic effects.  An oral fluoropyrimidine anticancer agent, S-1, developed 
in Japan, was designed to enhance the anticancer activity of 5-FU via combination with two 
modulating substances: gimeracil to inhibit dihydropyrimidine dehydrogenase and 
potassium oxonate to reduce gastrointestinal toxicities (Shirasaka, et al, 1996).  The 
antitumor effects of fluoropyrimidine are known to be enhanced through biochemical 
modulation of folate metabolism modified by cisplatin (Scanlon, et al, 1986), and 
combination therapy using S-1 and cisplatin reportedly achieves high response rates 
(Koizumi, et al, 2008 ; Lenz, et al, 2007).  Therefore, in Japan, S-1 with cisplatin is the 
standard therapy for advanced gastric cancer.  However, disease progression is still 
observed in up to 40% of cases (Iwase, et al, 2005; Koizumi, et al, 2008) and further 
improvement of treatment is thus necessary.   
Taxanes have shown encouraging anti-tumor activities against various malignancies, 
including gastric cancer (Ohtsu, et al, 1998; Sulkes, et al, 1994).  Taxane derivatives, 
docetaxel and paclitaxel, have a unique mechanism of action that differs from those of 
fluoropyrimidines and platinum compounds.  The docetaxel containing combination 
regimens are associated with severe neutropenia (Yamaguchi, et al, 2006).  Just recently, a 
phase I/ II study of docetaxel combined with S-1 plus cisplatin (DSC triple therapy) was 
conducted for advanced gastric cancer, and a very high tumor response rate was achieved 
with febrile neutropenia developing in approximately 20 % of patients (Nakayama, et al, 
2008; Sato, et al, 2010).  Paclitaxel combined with other drugs reportedly has tolerable 
toxicity (Kang, et al, 2008).  In addition, continuous infusion of cisplatin for 24 hours has 
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been used to minimize side effects including renal and hematological toxicity (Ina, et al, 
2008; Iwase, et al, 2005) with anti-tumor effects the same as in previous reports (Koizumi, et 
al, 2008 ; Lenz, et al, 2007).  Therefore, with the aim of improving the tumor response to S-1 
plus cisplatin therapy, we combined paclitaxel with S-1 plus cisplatin (PSC triple therapy) 
for the treatment of advanced gastric cancer.  
2. Patients and methods 
Patients were eligible if they signed an informed consent document and met all of the 
following criteria; (1) pathologically proven inoperable gastric cancer and at least one 
measurable lesion; (2) age 20 to 75 years; (3) Eastern Cooperative Oncology Group 
performance status of 0 to 2; (4) white blood cell count between 4000 and 12,000 /mm3, 
platelet count > 100,000/mm3, haemoglobin > 8 g/ dl; serum bilirubin < 1.5 mg/ dl, 
aspartate aminotransferase and alanine aminotransferase < 3 times the upper limit of 
normal (ULN); and serum creatinin less than or equal to ULN; (5) no prior chemotherapy or 
one regimen that was completed > 4 weeks before entry.  S-1 at a dose of 70 mg/m2 was 
given orally twice daily for 2 weeks followed by 2 weeks rest.  Paclitaxel at a dose of 120 
mg/m2 was administered by 2-hour infusion on day 1,  cisplatin at a dose of 60 mg/m2 by 
continuous infusion for 24 hours on day 14 (Figure 1).  Patients received a maximum of 6 
cycles.  The objective response to chemotherapy was evaluated employing the criteria 
proposed by the Japanese Research Society for Gastric Cancer (Japanese Research Society for 
Gastric Cancer, 1995) for the primary lesion and according to RECIST (Response Evaluation 
Criteria in Solid Tumors) for metastatic lesions.  A complete response (CR) was defined as 
the disappearance of all evidence of cancer for at least 4 weeks. According to RECIST, a 
partial response (PR) was defined as a greater than 50% tumor volume reduction. A new 
lesion or enlargement exceeding the original tumor size by 25% was defined as progressive 
disease (PD). All patients not in these categories were considered to have stable disease 
(SD).  Progression–free survival (PFS) and overall survival (OS) were calculated from the 
start of PSC triple therapy until death or the most recent follow-up day.  The Kaplan-Meier 
method was used to plot PFS and OS curves. The National Cancer Institute common toxicity 
criteria version 4.0 was applied to evaluate adverse effects  Doses were adjusted at the 
initiation of subsequent cycles, if severe toxicity (grade 3 – 4) was present; S-1 was 
discontinued and then resumed at a reduced dose (10 mg/m2/ day) and paclitaxel was 
reduced by 25% in the next cycle when toxicity resolved. Cisplatin was postponed until 
toxicity resolved; the maximum duration of postponement was no more than 2 weeks.  
 
 
Fig. 1. PSC triple combination therapy 
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S-1 at a dose of 70 mg/m2 was given orally twice daily for two weeks followed by two 
weeks rest.  Paclitaxel at a dose of 120 mg/m2 was administered by 2-hour infusion on day 
1, cisplatin at a dose of 60 mg/m2 by continuous infusion for 24 hours on day 15.  Patients 
received a maximum of 6 cycles.  Doses were adjusted at the initiation of subsequent cycles, 
if severe toxicity (grade 3–4) was present; S-1 was discontinued and then resumed at a 
reduced dose (10 mg/m2/day) and paclitaxel was reduced by 25% in the next cycle when 
toxicity resolved.  Cisplatin was postponed until toxicity resolved; the maximum duration of 
postponement was no more than 2 weeks. 
3. Results 
3.1 Study population 
Ten patients with metastatic or recurrent gastric cancer were enrolled from November, 2005 
to October, 2010 in our hospital.  Patient characteristics are summarized in Table 1.  There 
were 8 men and 2 women, with a median age of 65 (range, 57–73) years.  Performance status 
was 0 in 4 patients, 1 in 2, and 2 in 4.  Metastases were identified in the liver in 3 patients, 
the lung in 2, lymph nodes in 6, and the peritoneum in 7. Prior chemotherapy was 
conducted in 4 patients (S-1/ paclitaxel in 3; S-1 alone in 1), while the other 6 were chemo–
naïve.  These patients were administered a total of 40 cycles, with the median being 5 cycles 
(range, 3–6). 
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Total cycles 3 - 6 
Median 5 
Table 1. Patient backgrounds 
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The response rates according to site are shown in Table 2: primary lesion, 67% (4 of 6); 
lymph node metastases, 83% (5 of 6); liver metastases, 67% (2 of 3); and lung metastases, 
100% (2 of 2).  The overall response rate was 70% (7/10; CR 1, PR 6) and the disease control 
rate was 100%.  Seven patients received subsequent chemotherapy: 3 S-1 alone, 3 S-1/ 
irinotecan and, 1 paclitaxel alone.  The median PFS was 373 days (95% CI: 160–573 days) 
(Figure 2).  In this series, no patients underwent surgery after PSC, but the median OS was 
747 days (95% CI: 488–1714 days) as shown in Figure 3.  
 
 
 CR PR SD PD Response rate CR rate 
Overall 1 6 3 0 70 % 10 % 
Primary lesion 1 3 2 0 67 % 10 % 
Lymph node 1 4 1 0 83 % 10 % 
Liver 0 2 1 0 67 % 0 % 
Lung 1 1 0 0 100 % 50 % 
Ascites 0 3 0 0 100 % 0 % 






Fig. 2. Progression-free survival (PFS) in patients receiving PSC therapy 
Kaplan–Meier analysis of PFS in 10 patients showed PFS to be 373 days (95% CI: 160–573 days). 
Prospective Study of Triple Combination Chemotherapy Consisting of Paclitaxel, 






Fig. 3. Overall survival (OS) in patients receiving PSC therapy 
Kaplan–Meier analysis of OS in 10 patients showed OS to be 747 days (95% CI: 488–1714 days). 
3.3 Adverse effects 
Adverse effects during PSC triple therapy were assessed in all 10 patients (Table 3).  The 
most frequently observed severe (grades 3 and 4) toxicity was neutropenia (6 cases, 60%).  
Febrile neutropenia was observed in only one case (10%).  As for non-hematological 
toxicities, severe anorexia and mucositis (grade 3) were observed in one case.  Neither renal 
dysfunction nor hand-foot syndrome occurred in this study.  There were essentially no 
differences in toxicity between patients with versus without prior chemotherapy. 
4. Discussion 
A prospective study of PSC triple therapy was conducted for metastatic or recurrent gastric 
cancer in our hospital.  There have been few studies on the use of these three agents in 
unresectable gastric cancer. Iwase, et al. recommended the following doses: paclitaxel 120 
mg/m2, cisplatin 60 mg/m2, and S-1 70 mg/m2, based on the multicenter phase II study 
(Iwase, et al, 2010).  Our patients were treated according to this regimen.  This triple 
combination therapy yielded a high clinical response rate (70%) and a very high disease 
control rate (100%).  In Japan, S-1/ cisplatin should be regarded as a reference regimen.  In 
terms of survival effects, PSC triple therapy (median OS: 747 days [95% CI, 488–1714 days]) 
was apparently superior to S-1/ cisplatin, for which OS ranged from 10.4 to 13.0 months 
(Koizumi, et al, 2008 ; Lenz, et al, 2007).  PSC appears to be more beneficial than other triple 
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Toxicity (n = 10) Grade 
 2 3 4 
Hematological toxicity    
Leucopenia 5 3 1 
Neutropenia 3 4 2 
Thrombocytopenia 3 1 0 
Anemia 4 2 0 
Non-hematological toxicity    
Skin rash 1 0 0 
Mucositis 0 1 0 
Diarrhea 0 1 0 
Anorexia 3 1 0 
Nausea 1 1 0 
Vomiting 1 0 0 
Liver dysfunction 1 0 0 
Table 3. Toxicity incidence 
Grade is based on the National Cancer Institute common toxicity criteria, version 4.0. 
combination therapies (OS; DCF therapy 9.2 months, DSC therapy 687 days) (Sato, et. al, 
2010; van Custem, et al, 2006). 
In this trial, all toxicities were manageable and no patients died due to adverse effects.  
Neutropenia was the most common toxicity, but febrile neutropenia occurred in only one 
patient, who also had severe mucositis and diarrhea during the same (5th) course of PSC 
therapy.  Continuous infusion of cisplatin for 24 hours induces nausea and vomiting, but the 
toxicity was milder than that associated with bolus injection of cisplatin.  In addition, since 
June, 2010 we have routinely used aprepitant (Warr, et. al, 2005) to prevent gastrointestinal 
symptoms induced by cisplatin. Aprepitant remarkably reduces both the incidence and 
degree of vomiting, nausea, and anorexia.  
Our prospective study further support the results of a phase II study (Iwase, et al, 2010) 
indicating that triple combination chemotherapy consisting of paclitaxel, S-1, and cisplatin 
had a favorable safety profile with encouraging efficacy against inoperable advanced gastric 
cancer.  This PSC regimen is the major candidates for becoming the standard treatment for 
advanced gastric cancer.  The results of controlled studies comparing PSC triple therapy 
with S-1/ cisplatin therapy are eagerly anticipated. 
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Neuroendocrine tumors, or more properly gastro-entero-pancreatic tumors (GEP-NETs), are 
cancers of the interface between the endocrine (hormonal) system and the nervous system. 
A neuroendocrine tumor begins in the hormone-producing cells of the body’s 
neuroendocrine system, which is made up of cells that are a cross between traditional 
endocrine cells (or hormone-producing cells) and nerve cells. Neuroendocrine cells are 
found throughout the body in organs, such as the lungs and gastrointestinal tract (such as 
the stomach and intestines), and perform specific functions, such as regulating the air and 
blood flow through the lungs and controlling the speed at which food is moved through the 
gastrointestinal tract (1). 
2. NETs epidemiology and characteristics 
Neuroendocrine tumors (NETs) are rare, slow-growing neoplasms characterized by their 
ability to store and secrete different peptides and neuroamines. Some of these substances 
cause specific clinical syndromes, whereas other may have elevated plasma or urine levels 
that are not associated with specific syndromes or symptom complexes. The biochemical 
markers are those hormones or amines secreted by the neuroendocrine cells from which 
these tumors are derived. Some of these are not specific to any tumor, but are produced and 
secreted by most NETs, whereas other biochemical markers are more specific to the type of 
tumor and where their quantification can lead to the suspicion or confirmation of the 
presence of such a tumor (2). There are many types of neuroendocrine tumors, such as: 
pheochromocytoma, Merkel cell cancer, and neuroendocrine carcinoma, and also other 
types of cancer that begin in hormone-producing cells, including endocrine tumors, 
carcinoid tumors, thymoma, thyroid cancer, and islet cell tumors. Approximately 60% of 
neuroendocrine tumors are not able to be described as a specific type of cancer other than 
neuroendocrine carcinoma. Neuroendocrine carcinoma can be found in a number of places 
in the body, including the lungs, brain, and gastrointestinal tract. The annual incidence of 
NETs has risen to 40 to 50 cases per million, perhaps because of better diagnosis and the 
availability of highly specific and sensitive ways to measure these tumors products, improved 
immunohistochemistry, and enhanced techniques for tumor detection (3). There are a number 
of impediments to the diagnosis of these tumors. They are rare, comprising less than 2% of 
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gastrointestinal (GI) malignancies, and are therefore not high on the list of causes of specific 
symptom complexes. Symptoms themselves are often nonspecific and do not lend themselves 
readily to identifying the specific underlying tumor. In addition, the manifestations are 
protean and mimic a variety of disorders. Tumors may be found incidentally on laparoscopy 
for abdominal pain or during the surgical removal of an appendix or even during a 
computerized tomographic scan of the abdomen for unexplained symptoms (3,4). 
3. Classification of GEP-NETs by site of origin and by symptoms 
The clinical behavior of NETs is extremely variable; they may be functioning or not 
functioning, ranging from very slow-growing tumors (well-differentiated NETs), which are 
the majority, to highly aggressive and very malignant tumors (poorly differentiated NETs) (5).  
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malignancy + >30 Poor + Any size 
†Identical to MIB1. 
‡Gastrointestinal neuroendocrine tumor. 
§Pancreatic neuroendocrine tumor. 
NET: Neuroendocrine tumor. 
Table 1. WHO classification of neuroendocrine tumors. 
3.1 Nonfunctioning NETs 
Nonfunctioning NETs are not associated with a distinct hormonal syndrome so are more 
difficult to detect than functioning NETs; owing to this, patients generally present late with 
large primary tumors and advanced disease. However, nonfunctioning NETs may secrete 
bioactive hormones or amines at subclinical levels, or secrete compounds that lead to other, 
still under-recognized hormonal syndromes. They can also cause nonspecific symptoms 
related to increased tumor mass and/or metastases such as weight loss, bleeding or 
abdominal pain. 
3.2 Functioning NETs 
NETs can arise in different organs and from different cell types and so present a clinical 
challenge to physicians owing to their diversity and the variety of symptoms they cause. 
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Functioning NETs are characterized by the hormones they produce and/or the symptoms 
they cause; clinical symptoms are typically observed following metastasis to the liver. 
3.3 GEP-NETs classification 
The vast majority of GEP-NETs fall into two nearly distinct categories: carcinoids, and 
pancreatic endocrine tumors (PETs). Despite great behavioral differences between the two, 
they are grouped together as GEP-NETs because of similarities in cell structure. PETs (1-2% 
of all pancreatic tumors) may secrete hormones (as a result, perhaps, of impaired storage 
ability), and those hormones can wreak symptomatic havoc on the body. Those PETs that do 
not secrete hormones are called nonfunctioning tumors. Secretory (functioning) tumors  are 
classified by the hormone most strongly secreted – for example, insulinoma, which produces 
excessive insulin, and gastrinoma, which produces excessive gastrin. Carcinoid tumors are 
further classified, depending on the point of origin, as foregut (lung, thymus, stomach, and 
duodenum) or midgut (distal ileum and proximal colon) or hindgut (distal colon and 
rectum). Less than one percent of carcinoid tumors originate in the pancreas. But for many 
tumors, the point of origin is unknown. Carcinoid tumors tend to grow much more slowly 
than PETs (2,6).  
3.4 Carcinoid syndrome  
A carcinoid tumor may produce serotonin (5-HT), a biogenic amine that causes a specific set 
of symptoms including 
 flushing 
 diarrhea or increase in number of bowel movements 
 weight loss 
 weight gain 
 heart palpitations 
 congestive heart failure (CHF) 
 asthma 
 acromegaly 
 Cushing's syndrome 
This set of symptoms is called carcinoid syndrome which occurs in approximately 10% of 
patients with metastatic NETs. It is characterized by flushing (63–94% of patients), diarrhea 
(68–84%), abdominal pain (10–55%), telangiectasia (25%) and bronchoconstriction (3–19%). 
Carcinoid crisis is the most immediate life-threatening complication of carcinoid syndrome 
and is thought to result from a massive release of bioactive products from the tumor. Crises 
can occur spontaneously, but often arise in response to stress, anesthesia, chemotherapy or 
surgery. Symptoms are an exacerbation of the usual clinical symptoms of carcinoid 
syndrome, including severe flushing with or without bronchospasm, tachycardia and 
hypo/hypertension. Failure to effectively manage carcinoid syndrome can lead to exposure 
of the heart to high levels of vasoactive substances released from hepatic metastases, which 
causes carcinoid heart disease; between 10–20% of patients with carcinoid syndrome have 
heart disease at diagnosis. Carcinoid heart disease is characterized by plaque-like, fibrous 
thickening of the endocardium (classically on the right side of the heart); tricuspid and 
pulmonary valves; right-sided carcinoid heart disease is associated with substantial 
morbidity and mortality (7-10).  
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3.5 Summary of GEP - NETs classification (2,11,12) 
 carcinoids (about two thirds of GEP-NETs)  
 with carcinoid syndrome (about 10 percent of carcinoids) 
 without carcinoid syndrome (about 90 percent of carcinoids) 
 PET s (about one third of GEP-NETs)  
 nonfunctioning (15 to 30 percent of PETs) 
 functioning (70 to 85 percent of PETs)  
 gastrinoma, producing excessive gastrin and causing Zollinger-Ellison 
Syndrome (ZES) 
 insulinoma, producing excessive insulin 
 glucagonoma, producing excessive glucagon 
 vasoactive intestinal peptideoma (VIPoma), producing excessive vasoactive 
intestinal peptide (VIP) 
 PPoma, producing excessive pancreatic polypeptide (often classed with 
nonfunctioning PETs) 
 somatostatinoma, producing excessive somatostatin 
 watery diarrhea, hypokalemia-achlorhydria (WDHA) 
 CRHoma, producing excessive corticotropin-releasing hormonse (CRH) 
 calcitoninoma, producing excessive calcitonin 
 GHRHoma, producing excessive growth-hormone-releasing hormone (GHRH) 
 neurotensinoma, producing excessive neurotensin 
 ACTHoma, producing excessive adrenocorticotropic hormone (ACTH) 
 GRFoma, producing excessive Growth hormone-releasing factor (GRF) 
 parathyroid hormone–related peptide tumor 
 Other NETs  
 medullary carcinoma of the thyroid 
 Merkel cell cancer (trabecular cancer) 
 small-cell lung cancer (SCLC) 
 large-cell neuroendocrine carcinoma (of the lung) 
 extrapulmonary small cell carcinomas (ESCC or EPSCC)in general 
 neuroendocrine carcinoma of the cervix 
 Multiple Endocrine Neoplasia type 1 (MEN-1 or MEN1) (usually nonfunctioning) 
(also causing ZES) 
 Multiple Endocrine Neoplasia type 2 (MEN-2 or MEN2) 
 neurofibromatosis type 1 
 tuberous sclerosis 
 von Hippel-Lindau (VHL) disease 
 neuroblastoma 
 pheochromocytoma (phaeochromocytoma) 
 paraganglioma 
 neuroendocrine tumor of the anterior pituitary 
 Carney's complex 
4. Metastases and malignancy 
GEP-NETs are often malignant, since the primary site often eludes detection for years, 
sometimes decades – during which time the tumor has the opportunity to metastasize. The 
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most common metastatic sites are the liver, the lymph nodes, and the bones. Liver 
metastases are so frequent and have such prominent blood supply that for many patients, 
they dominate the course of the cancer (13).   
5. Well-differentiated neuroendocrine (carcinoid) tumors of the stomach 
Neuroendocrine tumors (NETs) of the stomach comprise less than 1% of gastric neoplasms. 
In the pre-endoscopy era,they comprised 1.9% of all carcinoids, but in more recent studies, 
10% to 30% of all carcinoids are reported in the stomach. They can be subclassified into 3 
distinct groups: those associated with chronic atrophic gastritis/pernicious anemia (type 1; 
70%-80%), those associated with Zollinger-Ellison syndrome (ZES) with multiple endocrine 
neoplasia type I (MEN I) (type 2; 5%), and sporadic NETs of the stomach (type 3; 15%-20%) 
(13-15).  
5.1 Etiology 
Both types 1 and 2 NETs of the stomach are associated with hypergastrinemia (Table 2). 
High levels of gastrin are thought to result in hyperplasia of the enterochromaffin-like cells 
in the stomach, ultimately leading to hyperplastic lesions and small, often multiple carcinoid 
tumors. In contrast to types 1 and 2 carcinoids, type 3 carcinoids develop in the absence of 
hypergastrinemia and tend to pursue an aggressive clinical course. Type 1 carcinoids are 
generally small and frequently multiple; limited to the mucosa-submucosa, and metastases 
occur in less than 2.5% to lymph nodes and less than 2.5%% to the liver. Type 2 carcinoids 
are almost always multiple and generally small (<1 cm) and are usually limited to the 
mucosa-submucosa, but are slightly more aggressive than type 1 carcinoids, with up to 30% 
showing lymph node metastases, and up to 10% may show liver metastases.Type 3 
carcinoids are usually single, generally larger (>1 cm in 70%), and invasive through the 
submucosa and deeper in most cases (>75%); 70% had accompanying lymph node 







Size, cm No. tumors Clinical Features 
Type 1 (in 
setting of chronic 
atrophic gastritis 
type A) 
Yes (as a result of 
achlorhydria) Low < 1 Multifocal 
Rarely invasive; 
endoscopic removal often 
adequate 
Type 2 (in 
setting of ZES) 
Yes (as a result of 
ectopic gastrin 
secretion) 
High < 1 Multifocal 
Rarely invasive; may 
respond to somatostatin 
analogs 
Type 3 
(sporadic) No Normal > 1 Solitary 
Frequently invasive and 
metastatic 
Table 2. Types of gastric NETs 
5.2 Pathological classification 
In general, NETs of the stomach and other NETs are divided into well-differentiated and 
poorly differentiated categories. The concept of differentiation is linked to the grade of the 
 
Management of Gastric Cancer 
 
132 
3.5 Summary of GEP - NETs classification (2,11,12) 
 carcinoids (about two thirds of GEP-NETs)  
 with carcinoid syndrome (about 10 percent of carcinoids) 
 without carcinoid syndrome (about 90 percent of carcinoids) 
 PET s (about one third of GEP-NETs)  
 nonfunctioning (15 to 30 percent of PETs) 
 functioning (70 to 85 percent of PETs)  
 gastrinoma, producing excessive gastrin and causing Zollinger-Ellison 
Syndrome (ZES) 
 insulinoma, producing excessive insulin 
 glucagonoma, producing excessive glucagon 
 vasoactive intestinal peptideoma (VIPoma), producing excessive vasoactive 
intestinal peptide (VIP) 
 PPoma, producing excessive pancreatic polypeptide (often classed with 
nonfunctioning PETs) 
 somatostatinoma, producing excessive somatostatin 
 watery diarrhea, hypokalemia-achlorhydria (WDHA) 
 CRHoma, producing excessive corticotropin-releasing hormonse (CRH) 
 calcitoninoma, producing excessive calcitonin 
 GHRHoma, producing excessive growth-hormone-releasing hormone (GHRH) 
 neurotensinoma, producing excessive neurotensin 
 ACTHoma, producing excessive adrenocorticotropic hormone (ACTH) 
 GRFoma, producing excessive Growth hormone-releasing factor (GRF) 
 parathyroid hormone–related peptide tumor 
 Other NETs  
 medullary carcinoma of the thyroid 
 Merkel cell cancer (trabecular cancer) 
 small-cell lung cancer (SCLC) 
 large-cell neuroendocrine carcinoma (of the lung) 
 extrapulmonary small cell carcinomas (ESCC or EPSCC)in general 
 neuroendocrine carcinoma of the cervix 
 Multiple Endocrine Neoplasia type 1 (MEN-1 or MEN1) (usually nonfunctioning) 
(also causing ZES) 
 Multiple Endocrine Neoplasia type 2 (MEN-2 or MEN2) 
 neurofibromatosis type 1 
 tuberous sclerosis 
 von Hippel-Lindau (VHL) disease 
 neuroblastoma 
 pheochromocytoma (phaeochromocytoma) 
 paraganglioma 
 neuroendocrine tumor of the anterior pituitary 
 Carney's complex 
4. Metastases and malignancy 
GEP-NETs are often malignant, since the primary site often eludes detection for years, 
sometimes decades – during which time the tumor has the opportunity to metastasize. The 
 
A Rare Gastric Carcinoma - Neuroendocrine Tumors 
 
133 
most common metastatic sites are the liver, the lymph nodes, and the bones. Liver 
metastases are so frequent and have such prominent blood supply that for many patients, 
they dominate the course of the cancer (13).   
5. Well-differentiated neuroendocrine (carcinoid) tumors of the stomach 
Neuroendocrine tumors (NETs) of the stomach comprise less than 1% of gastric neoplasms. 
In the pre-endoscopy era,they comprised 1.9% of all carcinoids, but in more recent studies, 
10% to 30% of all carcinoids are reported in the stomach. They can be subclassified into 3 
distinct groups: those associated with chronic atrophic gastritis/pernicious anemia (type 1; 
70%-80%), those associated with Zollinger-Ellison syndrome (ZES) with multiple endocrine 
neoplasia type I (MEN I) (type 2; 5%), and sporadic NETs of the stomach (type 3; 15%-20%) 
(13-15).  
5.1 Etiology 
Both types 1 and 2 NETs of the stomach are associated with hypergastrinemia (Table 2). 
High levels of gastrin are thought to result in hyperplasia of the enterochromaffin-like cells 
in the stomach, ultimately leading to hyperplastic lesions and small, often multiple carcinoid 
tumors. In contrast to types 1 and 2 carcinoids, type 3 carcinoids develop in the absence of 
hypergastrinemia and tend to pursue an aggressive clinical course. Type 1 carcinoids are 
generally small and frequently multiple; limited to the mucosa-submucosa, and metastases 
occur in less than 2.5% to lymph nodes and less than 2.5%% to the liver. Type 2 carcinoids 
are almost always multiple and generally small (<1 cm) and are usually limited to the 
mucosa-submucosa, but are slightly more aggressive than type 1 carcinoids, with up to 30% 
showing lymph node metastases, and up to 10% may show liver metastases.Type 3 
carcinoids are usually single, generally larger (>1 cm in 70%), and invasive through the 
submucosa and deeper in most cases (>75%); 70% had accompanying lymph node 







Size, cm No. tumors Clinical Features 
Type 1 (in 
setting of chronic 
atrophic gastritis 
type A) 
Yes (as a result of 
achlorhydria) Low < 1 Multifocal 
Rarely invasive; 
endoscopic removal often 
adequate 
Type 2 (in 
setting of ZES) 
Yes (as a result of 
ectopic gastrin 
secretion) 
High < 1 Multifocal 
Rarely invasive; may 
respond to somatostatin 
analogs 
Type 3 
(sporadic) No Normal > 1 Solitary 
Frequently invasive and 
metastatic 
Table 2. Types of gastric NETs 
5.2 Pathological classification 
In general, NETs of the stomach and other NETs are divided into well-differentiated and 
poorly differentiated categories. The concept of differentiation is linked to the grade of the 
 
Management of Gastric Cancer 
 
134 
tumors (see below), but there are subtle differences between differentiation and grade. 
Differentiation refers to the extent to which the neoplastic cells resemble their nonneoplastic 
counterparts. In NETs, well-differentiated examples have characteristic "organoid" 
arrangements of the tumor cells, with nesting, trabecular, or gyriform patterns. The cells are 
relatively uniform and produce abundant neurosecretory granules, reflected in the strong 
and diffuse immunoexpression of neuroendocrine markers such as chromogranin A (CGA) 
and synaptophysin. Poorly differentiated NETs less closely resemble nonneoplastic 
neuroendocrine cells and have a more sheet-like or diffuse architecture, irregular nuclei, and 
less cytoplasmic granularity. Immunoexpression of neuroendocrine markers is usually more 
limited. Grade, on the other hand, refers to the inherent biologic aggressiveness of the 
tumor. Low-grade NETs are relatively indolent, high-grade tumors are extremely 
aggressive, and intermediate-grade examples have a less predictable, moderately aggressive 
course. In general, well-differentiated NETs are either low or intermediate grade, and poorly 
differentiated NETs are considered high grade in all cases (Table 3 ) (18-22).  
 
Differentiation Grade 
Well differentiated Low grade (ENETS G1) Intermediate grade (ENETS G2) 
Poorly differentiated High grade (ENETS G3) 
Table 3. Differentiation of gastric NETs  
 
Grade Lung, Thymus (WHO) 
GEP NETs 
(ENETS) GEP NETs (WHO 2010) 




tumor NET grade 2 (G2) 
Neuroendocrine 





carcinoma grade 3 
(G3), small cell 
carcinoma 
Neuroendocrine 
carcinoma grade 3, 





carcinoma grade 3 
(G3), large cell 
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The grade of the tumor must be included in the pathology report, along with a reference 
to the specific grading system being used. Unqualified terms such as neuroendocrine 
tumor or neuroendocrine carcinoma without reference to grade do not provide adequate 
pathology information. 
Table 4. Differentiation of gastric Nets (2)  
 
A Rare Gastric Carcinoma - Neuroendocrine Tumors 
 
135 
Table 4 displays a comparison of the various systems of nomenclature currently in use for 
NETs, along with for which organ systems each system is most commonly used. 
Figures 1-3 are presenting histology evaluation of neuroendocrine gastric carcinoma-large 
cell type, that demonstrates trabecula and islet of round cells with rare eosinophilic 
cytoplasm. The nuclei are atypical, hyperchromatic, moderately pleomorphic, without 
prominent nucleolus. The stroma is edematous. Vascular invasion in mucosa and 
submucosa is also detected ( Stained H&E - Figure 1). Cytological immunophenotypes 
includes: marked and diffuse immunoreactivity in the majority of the cells to neuron 
specific-enolase (NSE) – ( Figure 2), chromogranin A( Figure 3 ) and synaptophysin.  
 
 
Fig. 1. Neuroendocrine gastric carcinoma-large cell type, Stained H&E, x400. Courtesy by 
Prof S.Usaj 
The American Joint Committee on Cancer (AJCC) has recently published a new TNM 
staging manual that includes NETs of all anatomical sites, and the ENETS has previously 
published recommendations for TNM staging of GEP NETs. dditionally, the staging criteria 
for both systems rely predominantly on the size of the tumor and the extent of invasion into 
similar landmarks as used for the staging of nonneuroendocrine carcinomas of the same 
sites. It is recommended that the extent of involvement of these structures be specifically 
indicated in the pathology reports, in addition to providing a TNM stage based on a system 
that is specifically referenced (Table 5) (23-26). Figures 4 and 5 represent T2 and M1 GEP 
NET thru the EUS image. 
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Fig. 2. Neuroendocrine tumor cells of the stomach wall -Immunostaining - NSE (LSAB+ , 
x200). Courtesy by Prof S.Usaj 
 
 
Fig. 3. Neuroendocrine tumor cells of the stomach wall- Immunostaining - chromogranin A  
(LSAB+ , x200). Courtesy by Prof S.Usaj 
 




Primary tumor (T) 
ENETS 
T-Primary Tumor 
TX Primary tumor cannot 
be assessed 
TX Primary tumor cannot be 
assessed 
T0 No evidence of primary 
tumor 
T0 No evidence of primary 
tumor 
Tis Carcinoma in 
situ/dysplasia (tumor 
size <0.5mm), confined 
to mucosa 
__  
T1 Tumor invades lamina 
propria or submucosa 
and ≤ 1 cm 
T1 Tumor invades lamina 
propria or submucosa 
and ≤ 1 cm 
T2 Tumor invades 
muscularis propria or > 
1 cm 
T2 Tumor invades 
muscularis propria or > 1 
cm 
T3 Tumor penetrates 
subserosa 
T3 Tumor invades pancreas 
or retroperitoneum 
T4 Tumor invades serosa 
(visceral peritoneum) or 
other organs or adjacent 
structures 
T4 Tumor invades 
peritoneum or other 
organs 
Regional Lymph nodes 
(N) 
 N-Regional Lymph 
Nodes 
 
NX Regional lymph node(s) 
cannot be assessed 
NX Regional lymph node(s) 
cannot be assessed 
N0 No regional lymph 
node metastasis 
N0 No regional lymph node 
metastasis 
N1 Regional lymph node 
metastasis 
N1 Regional lymph node 
metastasis 
Distant metastasis (M)  M-distant metastasis  
__  MX Distant metastasis cannot 
be assessed 
M0 No distant metastasis M0 No distant metastasis 
M1 Distant metastasis M1 Distant metastasis 
Stage T N M Stage T N M 
0 Tis N0 M0 0 Tis N0 M0 
I T1 N0 M0 I T1 N0 M0 
IIA T2 N0 M0 IIa T2 N0 M0 
IIB T3 N0 M0 IIb T3 N0 M0 
IIIA T4 N0 M0 IIIa T4 N0 M0 
IIIB Any T N1 M0 IIIb Any T N1 M0 
IV Any T Any N M1 IV Any T Any N M1 
Table 5. The TNM NETs classification 
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Fig. 4. EUS image: T2 tumor of the stomach wall. Courtesy by Prof M.Krstic 
 
 
Fig. 5. EUS image of enlarged lymph nodes around the tumor (see white arrows). Courtesy 
by Prof M.Krstic 
 




Most NETs of the stomach are directly imaged and diagnosed during endoscopy. For larger 
lesions, endoscopic ultrasound (EUS) may be performed to assess whether the NETs of the 
stomach is invasive. Cross-sectional imaging with computed tomography (CT) or magnetic 
resonance imaging (MRI) is recommended to assess for metastases in patients with type 1 or 
2 NETs of the stomach more than 2 cm in diameter, or for patients with type 3 NETs of the 
stomach in whom metastatic risk is a concern. Neuroendocrine tumors are generally 
vascular tumors that enhance intensely with intravenous contrast during early arterial 
phases of imaging with washout during the delayed portal venous phase. The key to 
detecting small NETs on CT is to maximize the contrast between the tumor and the adjacent 
normal parenchyma. For abdominal and pelvic imaging, recommendation is multiphasic CT 
that includes the arterial phase and the portal venous phase. Rapid intravenous bolus of 
intravenous contrast is also recommended. Thin sectioning and the use of a negative oral 
contrast agent also may be helpful in detecting small primary tumor in the small bowel that 
may not otherwise be seen. Magnetic resonance imaging is preferred over CT for patients 
with a history of allergy to iodine contrast material or for those with renal insufficiency. 
Somatostatin receptor scintigraphy (SRS) provides a second useful imaging modality for the 
detection of metastatic disease in patients with malignant NETs of the stomach. Indium In 
111-labeled somatostatin analog [111In-DTPA0]octreotide was developed for scintigraphy of 
NETs. It shares the receptor-binding profile of octreotide, which makes it a good 
radiopharmaceutical for imaging of somatostatin receptor 2- and receptor 5-positive tumors. 
The overall sensitivity of [111In-DTPA0]octreotide scintigraphy seems to be about 80% to 
90%. Unlike cross-sectional imaging, which is generally site directed, [111In-
DTPA0]octreotide scintigraphy is done as whole-body imaging and thus can detect disease 
at unsuspected sites. Chest x-ray can be used as a screening examination for patients 
without evidence of thoracic disease (27,29). 
7. Biochemical monitoring 
Fasting serum gastrin levels are important to differentiate types 1 and 2 NETs of the 
stomach from type 3. 5-Hydroxyindoleacetic acid (5-HIAA) levels are generally not useful in 
patients with NETs of the stomach, because development of the carcinoid syndrome is 
uncommon. Furthermore, carcinoid syndrome, if it occurs in these patients, is reported to be 
characteristically atypical with normal serotonin and 5-HIAA levels, although a recent study 
reports the typical carcinoid syndrome can occur in rare patients with NETs of the stomach. 
Plasma CGA levels are recommended because CGA is frequently elevated in both patients 
with types 1 and 2 as well as type 3 NETs of the stomach, and changes in CGA levels may be 
helpful in the follow-up. Chromogranin A should be used with caution as a marker of 
disease activity in patients treated with somatostatin analogs, because these agents 
significantly reduce plasma CGA levels, a change that may be more reflective of changes in 
hormonal synthesis and release from tumor cells than an actual reduction in tumor mass.  In 
patients on stable doses of somatostatin analogs, consistent increases in plasma CGA levels 
over time may reflect loss of secretory control and/or tumor growth. Plasma CGA levels 
have also been shown to have a prognostic value in patients with metastatic disease 
(16,17,30,31).  
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8. Management of localized NETs of the stomach 
Because types 1 and 2 NETs of the stomach generally pursue an indolent course, tumors less 
than 2 cm (up to 6) should be resected endoscopically, with subsequent interval follow-up 
(15,27,32). Patients with tumors measuring more than 2 cm, with recurrent tumors or with 
more than 6 polyps, generally require more aggressive management, and local surgical 
resection is recommended. In patients with type 1 NETs of the stomach arising in the setting 
of chronic atrophic gastritis, antrectomy may be performed to eliminate the source of gastric 
production. Antrectomy has been reported to result in tumor regression in such cases. In 
patients with type 2 NETs of the stomach secondary to ZES/MEN I syndrome, treatment 
with somatostatin analogs may be initiated and has resulted in tumor regression.(33-35) The 
surgical management of type 3 isolated sporadic NETs of the stomach requires more 
aggressive surgery, generally with partial gastrectomy and lymph node dissection (Table 6). 
Surgery is the only therapy that can cure GEP-NETs. However, the typical delay in 
diagnosis, giving the tumor the opportunity to metastasize, makes most GEP-NETs 
ineligible for surgery (non-resectable). The most common nonsurgical therapy for all GEP-
NETs is chemotherapy, although chemotherapy is reported to be largely ineffective for 
carcinoids, not particularly durable (long-lasting) for PETs, and inappropriate for PETs of 
nonpancreatic origin. When chemotherapy fails, the most common therapy, in the United 
States, is more chemotherapy, with a different set of agents. Some studies have shown that 
the benefit from one agent is not highly predictive of the benefit from another agent, except 
that the long-term benefit of any agent is likely to be low. Strong uptake of somatostatin 
analogs is a negative indication for chemo. There are two major somatostatin-analog-based 
targeted therapies. The first of the two therapies provides symptomatic relief for patients 
with secretory tumors. In effect, somatostatin given subcutaneously or intramuscularly 
 
 
 Size, cm No. tumors Therapy Clinical Features 




< 2 < 6 Resected endoscopically Rarely invasive; endoscopic 
removal often adequate 
> 2 > 6 Local surgical resection/antrectomy
Type 2 (in setting 
of ZES) 
< 2 < 6 Resected endoscopically Rarely invasive; may 
respond to somatostatin 
analogs > 2 > 6 Local surgical resection/antrectomy
Type 3 (sporadic) > 1 Solitary 
Partial gastrectomy 
and lymph nodes 
resection 
Frequently invasive and 
metastatic-Chemotherapy, 
chemotherapy with 
different agents  
Table 6. Management of localized NETs of the stomach 
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"clogs up" the receptors, blocking the secretion of hormones from the tumor cells. The 
second of the two major somatostatin-analog-based targeted therapies is called peptide 
receptor radionuclide therapy (PRRT), though we might simply call it hormone-delivered 
radiotherapy. In this form of radioisotope therapy (RIT), radioactive substances (called 
radionuclides or radioligands) are chemically conjugated with hormones (peptides or 
neuroamines); the combination is given intravenously to a patient who has good uptake of 
the chosen hormone. The radioactive labelled hormones enter the tumor cells, and the 
attached radiation damages the tumor- and nearby cells. Not all cells are immediately killed 
this way. The process of tumor cells dying as result of this therapy can go on for several 
months, even up to two years. In patients with strongly overexpressing tumor cells, nearly 
all the radiation either gets into the tumors or is excreted in urine (10). 
9. Management of metastatic NETs of the stomach 
In general, metastatic NETs of the stomach, which are infrequent and therefore usually 
included in general studies including other more frequent malignant carcinoids (especially 
midgut), are treated in a similar fashion as these other malignant carcinoids. It has been 
proposed for the occasional, younger patient without any of these risk factors with a 
metastatic carcinoid tumor that is unresectable and limited to the liver that liver 
transplantation remains an option that should be considered (Table 7). 
10. Hepatic resection and transplantation 
A small percentage of patients (5%-15%) with metastatic liver disease with a limited number 
of hepatic metastases localized preferable to one lobe may be successfully treated with 
hepatic resection, providing both long-term symptomatic relief and likely increasing 
survival times. The number of patients with liver-isolated metastatic NETs in whom 
orthotopic liver transplantation (OLT) has been attempted remains small, resulting in the 
role of OLT in such patients being controversial and cannot, at this time, be routinely 
recommended (36-38). 
11. Hepatic artery embolization 
Hepatic arterial embolization is recommended as a palliative option in patients with 
hepatic metastases who are not candidates for surgical resection, have an otherwise 
preserved performance status, have disease primarily confined to the liver, and have a 
patent portal vein. The response rates associated with embolization, as measured either by 
decrease in hormonal secretion or by radiographic regression, are generally greater than 
50% (39-41).  
12. Cytotoxic chemotherapy 
Because of its rarity, there have not been any specific studies of cytotoxic agents in only 
patients with malignant NETs of the stomach. However, with malignant carcinoids in 
general, cytotoxic chemotherapy plays only a limited role, and therefore, it is probable that 
similar results can be expected with malignant NETs of the stomach. Studies of single-agent 
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therapy with 5-fluorouracil, streptozocin, or doxorubicin in patients with metastatic 
carcinoid tumors have shown that these agents are associated with only modest response 
rates (41,42).  
13. Systemic treatment of metastatic disease 
Patients with metastatic NETs of the stomach may develop an "atypical" carcinoid syndrome 
related to release of histamine and/or 5-HTP or rarely a typical carcinoid syndrome as seen 
in patients with metastatic midgut carcinoids. These patients frequently benefit from 
treatment with somatostatin analogs for symptom control. The addition of α-interferon to 
therapy with somatostatin analogs has been reported to be effective in controlling 
symptoms in patients with carcinoid syndrome who may be resistant to somatostatin 
analogs alone. Treatment with α-interferon may therefore be considered in patients with 
metastatic NETs of the stomach refractory to somatostatin analogs. In clinical trials, doses of 
α-interferon have ranged from 3 to 9 MU subcutaneously, administered from 3 to 7 times 
per week. The direct antineoplastic effects of somatostatin analogs either with or without 
interferon remain uncertain, although recent studies suggest they have a cytostatic effect in 
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14. Radiofrequency ablation and cryoablation 
Other approaches to the treatment of hepatic metastases include the use of radiofrequency 
ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking. 
These approaches can be performed using a percutaneous or laparoscopic approach. 
15. Summary and conclusions 
To conclude, neuroendocrine tumors are small, slow-growing neoplasms, usually with 
episodic expression that makes diagnosis difficult, erroneous, and often late; for these 
reasons, a high index of suspicion is needed, and it is important to understand the 
pathophysiology of each tumor to decide which biochemical markers are more useful and 
when they should be used. It is the purpose of this text to show the importance of 
recognizing, as early as possible, the clinical syndromes that suggest a NET as one of the 
differential diagnoses, and once suspected, look for the appropriate biochemical markers 
and radiological or other means that will confirm the diagnosis or confidently discard it. 
Ultimately, all 3 modalities are important to create a platform for monitoring response to 
therapy, determining prognosis, and choosing the right therapeutic intervention (43).  
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therapy with 5-fluorouracil, streptozocin, or doxorubicin in patients with metastatic 
carcinoid tumors have shown that these agents are associated with only modest response 
rates (41,42).  
13. Systemic treatment of metastatic disease 
Patients with metastatic NETs of the stomach may develop an "atypical" carcinoid syndrome 
related to release of histamine and/or 5-HTP or rarely a typical carcinoid syndrome as seen 
in patients with metastatic midgut carcinoids. These patients frequently benefit from 
treatment with somatostatin analogs for symptom control. The addition of α-interferon to 
therapy with somatostatin analogs has been reported to be effective in controlling 
symptoms in patients with carcinoid syndrome who may be resistant to somatostatin 
analogs alone. Treatment with α-interferon may therefore be considered in patients with 
metastatic NETs of the stomach refractory to somatostatin analogs. In clinical trials, doses of 
α-interferon have ranged from 3 to 9 MU subcutaneously, administered from 3 to 7 times 
per week. The direct antineoplastic effects of somatostatin analogs either with or without 
interferon remain uncertain, although recent studies suggest they have a cytostatic effect in 
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14. Radiofrequency ablation and cryoablation 
Other approaches to the treatment of hepatic metastases include the use of radiofrequency 
ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking. 
These approaches can be performed using a percutaneous or laparoscopic approach. 
15. Summary and conclusions 
To conclude, neuroendocrine tumors are small, slow-growing neoplasms, usually with 
episodic expression that makes diagnosis difficult, erroneous, and often late; for these 
reasons, a high index of suspicion is needed, and it is important to understand the 
pathophysiology of each tumor to decide which biochemical markers are more useful and 
when they should be used. It is the purpose of this text to show the importance of 
recognizing, as early as possible, the clinical syndromes that suggest a NET as one of the 
differential diagnoses, and once suspected, look for the appropriate biochemical markers 
and radiological or other means that will confirm the diagnosis or confidently discard it. 
Ultimately, all 3 modalities are important to create a platform for monitoring response to 
therapy, determining prognosis, and choosing the right therapeutic intervention (43).  
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